KR20160006007A - An electroluminescent compound and an electroluminescent device comprising the same - Google Patents

An electroluminescent compound and an electroluminescent device comprising the same Download PDF

Info

Publication number
KR20160006007A
KR20160006007A KR1020140085277A KR20140085277A KR20160006007A KR 20160006007 A KR20160006007 A KR 20160006007A KR 1020140085277 A KR1020140085277 A KR 1020140085277A KR 20140085277 A KR20140085277 A KR 20140085277A KR 20160006007 A KR20160006007 A KR 20160006007A
Authority
KR
South Korea
Prior art keywords
group
mol
synthesis
substituted
unsubstituted
Prior art date
Application number
KR1020140085277A
Other languages
Korean (ko)
Other versions
KR101913628B1 (en
KR101913628B9 (en
Inventor
현서용
정성욱
박성준
Original Assignee
(주)피엔에이치테크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)피엔에이치테크 filed Critical (주)피엔에이치테크
Priority to KR1020140085277A priority Critical patent/KR101913628B1/en
Publication of KR20160006007A publication Critical patent/KR20160006007A/en
Application granted granted Critical
Publication of KR101913628B1 publication Critical patent/KR101913628B1/en
Publication of KR101913628B9 publication Critical patent/KR101913628B9/en

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/06Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • C07D209/90Benzo [c, d] indoles; Hydrogenated benzo [c, d] indoles
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K50/00Organic light-emitting devices
    • H10K50/10OLEDs or polymer light-emitting diodes [PLED]
    • H10K50/14Carrier transporting layers
    • H10K50/15Hole transporting layers
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K50/00Organic light-emitting devices
    • H10K50/10OLEDs or polymer light-emitting diodes [PLED]
    • H10K50/17Carrier injection layers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02BCLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO BUILDINGS, e.g. HOUSING, HOUSE APPLIANCES OR RELATED END-USER APPLICATIONS
    • Y02B20/00Energy efficient lighting technologies, e.g. halogen lamps or gas discharge lamps
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S428/00Stock material or miscellaneous articles
    • Y10S428/917Electroluminescent

Abstract

The present invention relates to an organic light emitting compound employed in an organic electroluminescent device. The organic light emitting compound is represented by chemical formula 1 or chemical formula 2. In addition, the organic electroluminescent device having excellent light emitting properties such as driving voltage, brightness, long lifespan, and the like is implemented when employing the organic light emitting compound as a phosphorescent host compound inside a hole transport functional layer or a light emitting layer.

Description

유기발광 화합물 및 이를 포함하는 유기전계발광소자{An electroluminescent compound and an electroluminescent device comprising the same}TECHNICAL FIELD The present invention relates to an organic electroluminescent compound and an electroluminescent device comprising the same,

본 발명은 유기발광 화합물에 관한 것으로서, 보다 구체적으로는 유기전계발광소자의 발광층 호스트 화합물 또는 정공수송 재료로 채용되는 유기발광 화합물 및 이를 채용하여 장수명 및 발광 효율이 현저히 향상된 유기전계발광소자에 관한 것이다.BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an organic light emitting compound, and more particularly, to an organic light emitting compound which is employed as a host compound or a hole transport material in an organic electroluminescent device, and an organic electroluminescent device .

유기전계발광소자는 투명 기판 위에도 소자를 형성할 수 있을 뿐 아니라, 플라즈마 디스플레이 패널(Plasma Display Panel)이나 무기 전계 발광(EL) 디스플레이에 비해 10 V 이하의 저전압 구동이 가능하고, 전력 소모가 비교적 적으며, 색감이 뛰어나다는 장점이 있고, 녹색, 청색, 적색의 3가지 색을 나타낼 수가 있어 최근에 차세대 디스플레이 소자로 많은 관심의 대상이 되고 있다.The organic electroluminescent device can not only form an element on a transparent substrate but also can operate at a low voltage of 10 V or less as compared with a plasma display panel (Plasma Display Panel) or an inorganic electroluminescence (EL) display, It has the advantage of excellent color and has three colors of green, blue, and red. It has recently become a subject of interest as a next generation display device.

다만, 이러한 유기전계발광소자가 상기와 같은 특징으로 발휘하기 위해서는 소자 내 유기층을 이루는 물질인 정공주입 물질, 정공수송 물질, 발광 물질, 전자수송 물질, 전자주입 물질 등이 안정하고 효율적인 재료에 의하여 뒷받침되는 것이 선행되어야 하나, 아직까지는 안정하고 효율적인 유기전계발광소자용 유기물층 재료의 개발이 충분히 이루어지지 않은 상태이다. 따라서, 저전압 구동, 고효율 및 장수명을 갖는 새로운 재료의 개발이 계속 요구되고 있는 실정이다.However, in order for such an organic electroluminescent device to exhibit such characteristics, a hole injecting material, a hole transporting material, a light emitting material, an electron transporting material, and an electron injecting material, which are materials forming an organic layer in a device, However, until now, stable and efficient development of an organic material layer material for an organic electroluminescence device has not been sufficiently achieved. Therefore, there is a continuing demand for development of new materials having low-voltage driving, high efficiency and long life.

특히, 종래 정공수송 재료로 구리 프탈로시아닌(CuPc), MTDATA, 4,4'-비스[N-(1-나프틸)-N-페닐아미노]바이페닐(NPB), N,N'-다이페닐-N,N'-비스(3-메틸페닐)-(1,1'-바이페닐)-4,4'-다이아민(TPD) 등이 알려져 있으나, 이를 소자에 채용시 효율 및 수명이 저하되는 문제가 있고, 이를 개량하기 위하여 다양한 치환기를 갖는 아릴아민계 화합물에 대해서 개발되고 있으나, 여전히 효율과 장수명을 동시에 충족시키기에는 충분하지 않은 문제점을 갖고 있다.In particular, conventional hole transport materials include copper phthalocyanine (CuPc), MTDATA, 4,4'-bis [N- (1-naphthyl) -N- phenylamino] biphenyl (NPB), N, N, N'-bis (3-methylphenyl) - (1,1'-biphenyl) -4,4'-diamine (TPD) has been known. However, Based compound having various substituents in order to improve it, but it still has a problem that it is not enough to satisfy efficiency and long life at the same time.

또한, 유기 발광 소자에서 발광효율을 결정하는 가장 중요한 요인은 발광 재료이다. 발광 재료로는 현재 형광 재료가 널리 사용되고 있으나, 발광 메커니즘 상 인광 재료의 개발이 이론적으로 발광 효율을 보다 개선시킬 수 있는 방법 중의 하나이고, 이에 따라 현재까지 다양한 인광 재료에 대해서 개발이 이루어지고 있으며, 특히 인광 발광 호스트 재료로는 현재까지 CBP가 가장 널리 알려져 있고, BALq 유도체를 호스트로 이용한 유기 발광 소자가 공지되어 있다.Further, the most important factor for determining the luminous efficiency in an organic light emitting device is a light emitting material. However, the development of a phosphorescent material on a light-emitting mechanism is one of the ways that the luminous efficiency can be improved more theoretically. Accordingly, a variety of phosphorescent materials have been developed to date, In particular, CBP is the most widely known phosphorescent host material, and an organic light emitting device using a BALq derivative as a host is known.

그러나, 인광 발광 재료를 사용한 유기 발광 소자는 형광 발광 재료를 사용한 소자에 비해 전류 효율이 상당히 높으나, 인광 발광 재료의 호스트로 BAlq, CBP 등의 재료를 사용할 경우, 형광재료를 사용한 소자에 비해 구동 전압이 높아서 전력 효율면에서 큰 이점이 없고, 또한, 소자의 수명 측면에서도 만족할만한 수준이 되질 못하여 더욱 안정적이고, 고성능의 호스트 재료의 개발이 요구되고 있다.However, in the case of using a material such as BAlq or CBP as a host of a phosphorescent material, the organic electroluminescent device using the phosphorescent material has a higher current efficiency than the device using the fluorescent material, There is no great advantage in terms of power efficiency, and the life of the device can not be satisfactory. Thus, development of a more stable and high-performance host material is required.

본 발명은 유기전계발광소자의 발광층 또는 정공주입층 내지 정공수송층에 채용되어 우수한 발광 특성을 구현할 수 있는 신규한 유기발광 화합물 및 이를 포함하는 유기전계발광 소자를 제공하고자 한다.The present invention provides a novel organic electroluminescent compound which can be used for a light emitting layer, a hole injecting layer, and a hole transporting layer of an organic electroluminescent device to realize excellent luminescent characteristics, and an organic electroluminescent device including the same.

본 발명은 상기 과제를 해결하기 위하여, 하기 [화학식 1] 또는 [화학식 2]로 표시되는 유기발광 화합물 및 이를 포함하는 유기전계발광소자를 제공한다.The present invention provides an organic electroluminescent compound represented by the following general formula (1) or (2) and an organic electroluminescent device including the same.

[화학식 1] [화학식 2][Chemical Formula 1] (2)

Figure pat00001
Figure pat00001

상기 [화학식 1] 또는 [화학식 2]에 따른 유기발광 화합물의 구체적인 구조 및 치환기에 대해서는 후술한다.The specific structures and substituents of the organic luminescent compound according to the above formula (1) or (2) will be described later.

본 발명에 따른 유기발광 화합물은 구조 평판도가 우수하고, 높은 삼중항(triplet) 상태를 가져서 종래 인광 호스트 화합물이나 정공수송 화합물에 비하여 보다 향상된 발광 효율과 장수명 특성의 구현이 가능하여 이를 채용한 유기전계발광소자는 다양한 디스플레이 소자에 유용하여 사용될 수 있다.The organic luminescent compound according to the present invention has an excellent structure flatness and a high triplet state, which enables to realize a luminescent efficiency and a longevity characteristic which are higher than those of conventional phosphorescent host compounds and hole transport compounds, The light emitting device can be used for various display devices.

도 1 내지 5는 본 발명의 일 실시예에 따른 유기전계발광소자의 구조를 예시한 단면도이다.1 to 5 are cross-sectional views illustrating the structure of an organic electroluminescent device according to an embodiment of the present invention.

이하, 본 발명을 보다 구체적으로 설명한다.Hereinafter, the present invention will be described more specifically.

본 발명은 하기 [화학식 1] 또는 [화학식 2]로 표시되는 신규한 유기발광 화합물에 관한 것이다.The present invention relates to a novel organic luminescent compound represented by the following formula (1) or (2).

[화학식 1] [화학식 2][Chemical Formula 1] (2)

Figure pat00002
Figure pat00002

상기 [화학식 1] 또는 [화학식 2]에서,In the above Chemical Formula 1 or Chemical Formula 2,

X1 내지 X11은 서로 동일하거나 상이하고, 각각 독립적으로 N, O, S, Te, CR1, NR2, CR3R4, SiR5R6, GeR7R8, PR9 및 BR10 중에서 선택되고, 상기 R3와 R4, R5와 R6, R7와 R8은 각각 서로 연결되어 고리를 형성할 수 있다.X 1 to X 11 are the same or different from each other, each independently from N, O, S, Te, CR 1, NR 2, CR 3 R 4, SiR 5 R 6, GeR 7 R 8, PR 9 and BR 10 And R 3 and R 4 , R 5 and R 6 , R 7 and R 8 may be connected to each other to form a ring.

상기 R1 내지 R10은 서로 동일하거나 상이하고, 각각 독립적으로 수소, 중수소, 치환 또는 비치환된 탄소수 1 내지 30의 알킬기, 치환 또는 비치환된 탄소수 2 내지 30의 알케닐기, 치환 또는 비치환된 탄소수 2 내지 30의 알키닐기, 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬기, 치환 또는 비치환된 탄소수 2 내지 30의 헤테로시클로알킬기, 치환 또는 비치환된 탄소수 5 내지 30의 시클로알케닐기, 치환 또는 비치환된 탄소수 1 내지 30의 알콕시기, 치환 또는 비치환된 탄소수 6 내지 30의 아릴옥시기, 치환 또는 비치환된 탄소수 1 내지 30의 알킬티옥시기, 치환 또는 비치환된 탄소수 5 내지 30의 아릴티옥시기, 치환 또는 비치환된 탄소수 1 내지 30의 알킬아민기, 치환 또는 비치환된 탄소수 5 내지 30의 아릴아민기, 치환 또는 비치환된 탄소수 5 내지 50의 아릴기, 치환 또는 비치환된 탄소수 3 내지 50의 헤테로아릴기, 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬이 하나 이상 융합된 치환 또는 비치환된 탄소수 5 내지 50의 아릴기, 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬이 하나 이상 융합된 치환 또는 비치환된 탄소수 2 내지 50의 헤테로아릴기, 치환 또는 비치환된 실릴기, 치환 또는 비치환된 게르마늄기, 치환 또는 비치환된 붕소기, 카르보닐기, 포스포릴기, 아미노기, 싸이올기, 시아노기, 히드록시기, 니트로기, 할로겐기 및 아미드기 중에서 선택된다.Wherein R 1 to R 10 are the same or different from each other and each independently represents hydrogen, deuterium, a substituted or unsubstituted alkyl group having 1 to 30 carbon atoms, a substituted or unsubstituted alkenyl group having 2 to 30 carbon atoms, A substituted or unsubstituted cycloalkyl group having 3 to 30 carbon atoms, a substituted or unsubstituted heterocycloalkyl group having 2 to 30 carbon atoms, a substituted or unsubstituted cycloalkenyl group having 5 to 30 carbon atoms, a substituted or unsubstituted cycloalkyl group having 3 to 30 carbon atoms, Or an unsubstituted or substituted C 1 -C 30 alkoxy group, a substituted or unsubstituted C 6 -C 30 aryloxy group, a substituted or unsubstituted C 1 -C 30 alkylthio group, a substituted or unsubstituted C 5 -C 30 A substituted or unsubstituted alkylamine group having 1 to 30 carbon atoms, a substituted or unsubstituted arylamine group having 5 to 30 carbon atoms, a substituted or unsubstituted aliphatic hydrocarbon group having 5 to 50 carbon atoms A substituted or unsubstituted aryl group having 5 to 50 carbon atoms, a substituted or unsubstituted aryl group having 3 to 50 carbon atoms, a substituted or unsubstituted heteroaryl group having 3 to 50 carbon atoms, a substituted or unsubstituted aryl group having 5 to 50 carbon atoms, A substituted or unsubstituted C 2 -C 50 heteroaryl group, a substituted or unsubstituted silyl group, a substituted or unsubstituted germanium group, a substituted or unsubstituted boron group , A carbonyl group, a phosphoryl group, an amino group, a thiol group, a cyano group, a hydroxyl group, a nitro group, a halogen group and an amide group.

또한, 상기 R1 내지 R10 및 이들의 치환기는 서로 결합하거나 인접한 치환기와 연결되어 지환족, 방향족의 단일환 또는 다환 고리를 형성할 수 있으며, 상기 형성된 지환족, 방향족의 단일환 또는 다환 고리의 탄소원자는 N, S 및 O 중에서 선택되는 어느 하나 이상의 헤테로원자로 치환될 수 있다.
R 1 to R 10 and substituents thereof may be bonded to each other or may be connected to adjacent substituents to form a single ring or polycyclic ring of an alicyclic or aromatic group and may form a single ring or multicyclic ring of the formed alicyclic or aromatic ring The carbon atom may be substituted with any one or more heteroatoms selected from N, S and O.

또한, 상기 R1 내지 R10은 각각 독립적으로 하기 [구조식 1] 또는 [구조식 2]인 것을 특징으로 한다.Each of R 1 to R 10 independently represents a group represented by the following formula 1 or 2:

[구조식 1] [구조식 2][Structural formula 1] [Structural formula 2]

Figure pat00003
Figure pat00003

상기 [구조식 1] 또는 [구조식 2]에서,In the structural formula 1 or the structural formula 2,

L은 단일결합이거나, 치환 또는 비치환된 탄소수 1 내지 30의 알킬렌기, 치환 또는 비치환된 탄소수 2 내지 30의 알케닐렌기, 치환 또는 비치환된 탄소수 2 내지 30의 알키닐렌기, 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬렌기, 치환 또는 비치환된 탄소수 5 내지 50의 아릴렌기, 치환 또는 비치환된 탄소수 2 내지 50의 헤테로아릴렌기, 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬이 하나 이상 융합된 치환 또는 비치환된 탄소수 5 내지 50의 아릴렌기 및 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬이 하나 이상 융합된 치환 또는 비치환된 탄소수 2 내지 50의 헤테로아릴렌기 중에서 선택되고, n은 0 내지 4의 정수이며, 상기 n이 2 이상인 경우 복수의 L은 서로 동일하거나 상이할 수 있다.L is a single bond, a substituted or unsubstituted alkylene group having 1 to 30 carbon atoms, a substituted or unsubstituted aliphatic hydrocarbon group having 2 to 30 carbon atoms A substituted or unsubstituted C2-C30 alkynylene group, a substituted or unsubstituted C3-C30 A substituted or unsubstituted C2 to C30 heteroarylene group, a substituted or unsubstituted C3 to C30 cycloalkyl, a substituted or unsubstituted C1 to C50 arylene group, a substituted or unsubstituted C2 to C30 heteroarylene group, A substituted or unsubstituted C2 to C50 heteroarylene group in which at least one unsubstituted C1 to C50 arylene group and substituted or unsubstituted C3 to C30 cycloalkyl are fused together and n is 0 to 4 And when n is 2 or more, a plurality of Ls may be the same or different from each other.

A1 내지 A3는 서로 동일하거나 상이하고, 각각 독립적으로 치환 또는 비치환된 탄소수 1 내지 30의 알킬기, 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬기, 치환 또는 비치환된 탄소수 5 내지 50의 아릴기, 치환 또는 비치환된 탄소수 2 내지 50의 헤테로아릴기, 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬이 하나 이상 융합된 치환 또는 비치환된 탄소수 5 내지 50의 아릴기 및 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬이 하나 이상 융합된 치환 또는 비치환된 탄소수 2 내지 50의 헤테로아릴기 중에서 선택된다.A 1 to A 3 are the same or different and each independently represents a substituted or unsubstituted alkyl group having 1 to 30 carbon atoms, a substituted or unsubstituted cycloalkyl group having 3 to 30 carbon atoms, a substituted or unsubstituted group having 5 to 50 carbon atoms A substituted or unsubstituted aryl group, a substituted or unsubstituted C2 to C50 heteroaryl group, a substituted or unsubstituted C3 to C30 cycloalkyl substituted or unsubstituted aryl group having 5 to 50 carbon atoms, And a substituted or unsubstituted C2 to C50 heteroaryl group in which one or more ring-opened cycloalkyl having 3 to 30 carbon atoms is fused.

상기 L, A1 내지 A3 및 이들의 치환기는 서로 결합하거나 인접한 치환기와 연결되어 지환족, 방향족의 단일환 또는 다환 고리를 형성할 수 있으며, 상기 형성된 지환족, 방향족의 단일환 또는 다환 고리의 탄소원자는 N, S 및 O 중에서 선택되는 어느 하나 이상의 헤테로원자로 치환될 수 있다.Wherein L, A 1 to A 3, and these substituents may be coupled or the adjacent connection with substituents each cycloaliphatic, may form a monocyclic or polycyclic ring of the aromatic group, the monocyclic or polycyclic ring of an alicyclic, aromatic so formed The carbon atom may be substituted with any one or more heteroatoms selected from N, S and O.

한편, 상기 L 및 A1 내지 A3는 보다 구체적으로 각각 독립적으로 하기 [구조식 3] 중에서 선택될 수 있다.On the other hand, L and A 1 to A 3 may be more specifically selected independently from each other in the following Structural Formula 3.

[구조식 3][Structural Formula 3]

Figure pat00004
Figure pat00004

상기 [구조식 3]에서,In the above formula 3,

Z는 CR1, NR2, CR3R4, SiR5R6, GeR7R8, PR9, BR10, Te, O 및 S 중에서 선택되고, 상기 R1 내지 R10은 상기 [화학식 1] 또는 [화학식 2]에서의 정의와 동일하다.
Z is CR 1, NR 2, CR 3 R 4, SiR 5 R 6, GeR 7 R 8, PR 9, BR 10, Te, O , and is selected from S, wherein R 1 to R 10 are the Formula 1 Or the formula (2).

상기 L, A1 내지 A3 및 R1 내지 R10은 각각 독립적으로 1종 이상의 치환기로 더 치환될 수 있고, 상기 1종 이상의 치환기는 수소, 중수소, 치환 또는 비치환된 탄소수 1 내지 30의 알킬기, 치환 또는 비치환된 탄소수 2 내지 30의 알케닐기, 치환 또는 비치환된 탄소수 2 내지 30의 알키닐기, 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬기, 치환 또는 비치환된 탄소수 2 내지 30의 헤테로시클로알킬기, 치환 또는 비치환된 탄소수 5 내지 30의 시클로알케닐기, 치환 또는 비치환된 탄소수 1 내지 30의 알콕시기, 치환 또는 비치환된 탄소수 6 내지 30의 아릴옥시기, 치환 또는 비치환된 탄소수 1 내지 30의 알킬티옥시기, 치환 또는 비치환된 탄소수 5 내지 30의 아릴티옥시기, 치환 또는 비치환된 탄소수 1 내지 30의 알킬아민기, 치환 또는 비치환된 탄소수 5 내지 30의 아릴아민기, 치환 또는 비치환된 탄소수 5 내지 50의 아릴기, 치환 또는 비치환된 탄소수 3 내지 50의 헤테로아릴기, 치환 또는 비치환된 실릴기, 치환 또는 비치환된 게르마늄기, 치환 또는 비치환된 붕소기, 치환 또는 비치환된 알루미늄기, 카르보닐기, 포스포릴기, 아미노기, 싸이올기, 시아노기, 히드록시기, 니트로기, 할로겐기, 셀레늄기, 텔루륨기, 아미드기, 에테르기 및 에스테르기 중에서 선택될 수 있다.
The L, A 1 to A 3, and R 1 to R 10 may each be independently substituted with one or more substituents, and the one or more substituents may be selected from the group consisting of hydrogen, deuterium, substituted or unsubstituted C1- , A substituted or unsubstituted C2-C30 alkenyl group, a substituted or unsubstituted C2-C30 alkynyl group, a substituted or unsubstituted C3-C30 cycloalkyl group, a substituted or unsubstituted C2- A substituted or unsubstituted C1-C30 alkoxy group, a substituted or unsubstituted C6-C30 aryloxy group, a substituted or unsubstituted C1-C30 alkoxy group, a substituted or unsubstituted C1- A substituted or unsubstituted aryloxy group having 5 to 30 carbon atoms, a substituted or unsubstituted alkylamine group having 1 to 30 carbon atoms, a substituted or unsubstituted alkylcarbonyl group having 5 to 30 carbon atoms An arylamine group, a substituted or unsubstituted aryl group having 5 to 50 carbon atoms, a substituted or unsubstituted heteroaryl group having 3 to 50 carbon atoms, a substituted or unsubstituted silyl group, a substituted or unsubstituted germanium group, A nitro group, a halogen group, a selenium group, a tellurium group, an amide group, an ether group, and an ester group among a substituted boron group, a substituted boron group, a substituted or unsubstituted aluminum group, a carbonyl group, a phosphoryl group, an amino group, a thiol group, a cyano group, Can be selected.

본 발명에 있어서, 상기 치환기들의 예시들에 대해서 아래에서 구체적으로 설명하나, 이에 한정되는 것은 아니다.In the present invention, examples of the substituents will be specifically described below, but the present invention is not limited thereto.

본 발명에 있어서, 상기 알킬기는 직쇄 또는 분지쇄일 수 있고, 탄소수는 특별히 한정되지 않으나 1 내지 50인 것이 바람직하다. 구체적인 예로는 메틸기, 에틸기, 프로필기, n-프로필기, 이소프로필기, 부틸기, n-부틸기, 이소부틸기, tert-부틸기, sec-부틸기, 1-메틸-부틸기, 1-에틸-부틸기, 펜틸기, n-펜틸기, 이소펜틸기, 네오펜틸기, tert-펜틸기, 헥실기, n-헥실기, 1-메틸펜틸기, 2-메틸펜틸기, 4-메틸-2-펜틸기, 3,3-디메틸부틸기, 2-에틸부틸기, 헵틸기, n-헵틸기, 1-메틸헥실기, 시클로펜틸메틸기, 시클로헥틸메틸기, 옥틸기, n-옥틸기, tert-옥틸기, 1-메틸헵틸기, 2-에틸헥실기, 2-프로필펜틸기, n-노닐기, 2,2-디메틸헵틸기, 1-에틸-프로필기, 1,1-디메틸-프로필기, 이소헥실기, 2-메틸펜틸기, 4-메틸헥실기, 5-메틸헥실기 등이 있으나, 이들에 한정되지 않는다.In the present invention, the alkyl group may be linear or branched, and the number of carbon atoms is not particularly limited, but is preferably 1 to 50. Specific examples include methyl, ethyl, propyl, n-propyl, isopropyl, butyl, n-butyl, isobutyl, Ethyl, propyl, isopropyl, n-butyl, isobutyl, isobutyl, isobutyl, A tert-butyl group, a tert-butyl group, a 2-pentyl group, a 3,3-dimethylbutyl group, a 2-ethylbutyl group, a heptyl group, Ethylhexyl group, 2-propylpentyl group, n-nonyl group, 2,2-dimethylheptyl group, 1-ethyl-propyl group, 1,1-dimethyl-propyl group , Isohexyl group, 2-methylpentyl group, 4-methylhexyl group, 5-methylhexyl group and the like, but are not limited thereto.

본 발명에 있어서, 알콕시기는 직쇄 또는 분지쇄일 수 있다. 알콕시기의 탄소수는 특별히 한정되지 않으나, 입체적 방해를 주지 않는 범위인 1 내지 30개인 것이 바람직하다. 구체적으로, 메톡시기, 에톡시기, n-프로폭시기, 이소프로폭시기, i-프로필옥시기, n-부톡시기, 이소부톡시기, tert-부톡시기, sec-부톡시기, n-펜틸옥시기, 네오펜틸옥시기, 이소펜틸옥시기, n-헥실옥시기, 3,3-디메틸부틸옥시기, 2-에틸부틸옥시기, n-옥틸옥시기, n-노닐옥시기, n-데실옥시기, 벤질옥시기, p-메틸벤질옥시기 등이 될 수 있으나, 이에 한정되는 것은 아니다.In the present invention, the alkoxy group may be linear or branched. The number of carbon atoms of the alkoxy group is not particularly limited, but is preferably in the range of 1 to 30, which does not cause steric hindrance. Specific examples thereof include a methoxy group, an ethoxy group, an n-propoxy group, an isopropoxy group, an i-propyloxy group, a n-butoxy group, an isobutoxy group, a tert- , Neopentyloxy group, isopentyloxy group, n-hexyloxy group, 3,3-dimethylbutyloxy group, 2-ethylbutyloxy group, n-octyloxy group, n- , A benzyloxy group, a p-methylbenzyloxy group, and the like, but are not limited thereto.

본 발명에 있어서, 상기 알케닐기는 직쇄 또는 분지쇄일 수 있고, 탄소수는 특별히 한정되지 않으나, 2 내지 40인 것이 바람직하다. 구체적인 예로는 비닐기, 1-프로페닐기, 이소프로페닐기, 1-부테닐기, 2-부테닐기, 3-부테닐기, 1-펜테닐기, 2-펜테닐기, 3-펜테닐기, 3-메틸-1-부테닐기, 1,3-부타디에닐기, 알릴기, 1-페닐비닐-1-일기, 2-페닐비닐-1-일기, 2,2-디페닐비닐-1-일기, 2-페닐-2-(나프틸-1-일)비닐-1-일기, 2,2-비스(디페닐-1-일)비닐-1-일기, 스틸베닐기, 스티레닐기 등이 있으나 이들에 한정되지 않는다.In the present invention, the alkenyl group may be straight-chain or branched, and the number of carbon atoms is not particularly limited, but is preferably 2 to 40. Specific examples include a vinyl group, a 1-propenyl group, an isopropenyl group, a 1-butenyl group, a 2-butenyl group, a 3-butenyl group, a 1-pentenyl group, a 2-pentenyl group, a 3-pentenyl group, 2-phenylvinyl-1-yl group, 2,2-diphenylvinyl-1-yl group, 2-phenyl-2-yl group, But are not limited to, - (naphthyl-1-yl) vinyl-1-yl group, 2,2-bis (diphenyl-1-yl) vinyl-1-yl group, stilbenyl group, styrenyl group and the like.

본 발명에 있어서, 아릴기는 단환식 또는 다환식일 수 있고, 탄소수는 특별히 한정되지 않으나 6 내지 60인 것이 바람직하다. 단환식 아릴기의 예로는 페닐기, 비페닐기, 터페닐기, 스틸벤기 등이 있고, 다환식 아릴기의 예로는 나프틸기, 안트라세닐기, 페난트레닐기, 파이레닐기, 페릴레닐기, 테트라세닐기, 크라이세닐기, 플루오레닐기, 아세나프타센닐기, 트리페닐렌기, 플루오안트렌(fluoranthrene)기 등이 있으나, 본 발명의 범위가 이들 예로만 한정되는 것은 아니다.In the present invention, the aryl group may be monocyclic or polycyclic, and the number of carbon atoms is not particularly limited, but is preferably 6 to 60. [ Examples of the monocyclic aryl group include a phenyl group, a biphenyl group, a terphenyl group and a stilbene group. Examples of the polycyclic aryl group include a naphthyl group, an anthracenyl group, a phenanthrenyl group, a pyrenyl group, a perylenyl group, , A chlorenyl group, a fluorenyl group, an acenaphthacenyl group, a triphenylene group, and a fluororanthrene group, but the scope of the present invention is not limited to these examples.

본 발명에 있어서, 헤테로고리기는 이종원자로 O, N 또는 S를 포함하는 헤테로고리기로서, 탄소수는 특별히 한정되지 않으나 탄소수 2 내지 60인 것이 바람직하다. 헤테로고리기의 예로는 티오펜기, 퓨란기, 피롤기, 이미다졸기, 티아졸기, 옥사졸기, 옥사디아졸기, 트리아졸기, 피리딜기, 비피리딜기, 피리미딜기, 트리아진기, 트리아졸기, 아크리딜기, 피리다진기, 피라지닐기, 퀴놀리닐기, 퀴나졸린기, 퀴녹살리닐기, 프탈라지닐기, 피리도 피리미디닐기, 피리도 피라지닐기, 피라지노 피라지닐기, 이소퀴놀린기, 인돌기, 카바졸기, 벤조옥사졸기, 벤조이미다졸기, 벤조티아졸기, 벤조카바졸기, 벤조티오펜기, 디벤조티오펜기, 벤조퓨라닐기, 디벤조퓨라닐기, 페난트롤린기, 티아졸릴기, 이소옥사졸릴기, 옥사디아졸릴기, 티아디아졸릴기, 벤조티아졸릴기, 페노티아지닐기 등이 있으나, 이들에만 한정되는 것은 아니다.In the present invention, the heterocyclic group is a heterocyclic group containing O, N or S as a heteroatom, and the number of carbon atoms is not particularly limited, but is preferably 2 to 60 carbon atoms. Examples of the heterocyclic group include a thiophene group, a furane group, a furyl group, an imidazole group, a thiazole group, an oxazole group, an oxadiazole group, a triazole group, a pyridyl group, a bipyridyl group, a pyrimidyl group, A pyridazinyl group, a pyrazinopyrazinyl group, an isoquinoline group, an isoquinolinyl group, an isoquinolinyl group, an isoquinolinyl group, an isoquinolinyl group, an isoquinolyl group, , An indole group, a carbazole group, a benzoxazole group, a benzoimidazole group, a benzothiazole group, a benzocarbazole group, a benzothiophene group, a dibenzothiophene group, a benzofuranyl group, a dibenzofurancyl group, a phenanthroline group, An isothiazolyl group, an isoxazolyl group, an oxadiazolyl group, a thiadiazolyl group, a benzothiazolyl group, a phenothiazinyl group and the like, but is not limited thereto.

본 발명에 있어서, 아릴옥시기, 아릴티옥시기, 아릴술폭시기 및 아랄킬아민기 중의 아릴기는 전술한 아릴기의 예시와 같다. 구체적으로 아릴옥시기로는 페녹시기, p-토릴옥시기, m-토릴옥시기, 3,5-디메틸-페녹시기, 2,4,6-트리메틸페녹시기, ptert-부틸페녹시기, 3-비페닐옥시기, 4-비페닐옥시기, 1-나프틸옥시기, 2-나프틸옥시기, 4-메틸-1-나프틸옥시기, 5-메틸-2-나프틸옥시기, 1-안트릴옥시기, 2-안트릴옥시기, 9-안트릴옥시기, 1-페난트릴옥시기, 3-페난트릴옥시기, 9-페난트릴옥시기 등이 있고, 아릴티옥시기로는 페닐티옥시기기, 2-메틸페닐티옥시기, 4-tert-부틸페닐티옥시기 등이 있으며, 아릴술폭시기로는 벤젠술폭시기, p-톨루엔술폭시기 등이 있으나, 이에 한정되지 않는다.In the present invention, the aryl group in the aryloxy group, arylthioxy group, arylsulfoxy group and aralkylamine group is the same as the aforementioned aryl group. Specific examples of the aryloxy group include a phenoxy group, a p-tolyloxy group, an m-tolyloxy group, a 3,5-dimethyl-phenoxy group, a 2,4,6-trimethylphenoxy group, a ptert- Anthryloxy group, 2-naphthyloxy group, 2-naphthyloxy group, 4-methyl-1-naphthyloxy group, Anthryloxy group, 9-anthryloxy group, 1-phenanthryloxy group, 3-phenanthryloxy group, 9-phenanthryloxy group and the like. Examples of the arylthioxy group include phenylthioxy group, 2- A 4-tert-butylphenyloxy group, and the like. Examples of the arylsulfoxy group include benzene sulfoxy group and p-toluenesulfoxy group. However, the present invention is not limited thereto.

본 발명에 있어서, 시클로알킬기는 특별히 한정되지 않으나, 탄소수 3 내지 60인 것이 바람직하며, 구체적으로 시클로프로필기 시클로부틸기 시클로펜틸기 3-메틸시클로펜틸기 2,3-디메틸시클로펜틸기, 시클로헥실기, 3-메틸시클로헥실기, 4-메틸시클로헥실기, 2,3-디메틸시클로헥실기, 3,4,5-트리메틸시클로헥실기, 4-tert-부틸시클로헥실기, 시클로헵틸기, 시클로옥틸기 등이 있으나, 이에 한정되지 않는다.In the present invention, the cycloalkyl group is not particularly limited, but preferably has 3 to 60 carbon atoms, and specifically includes cyclopropyl group, cyclobutyl group, cyclopentyl group, 3-methylcyclopentyl group, 2,3-dimethylcyclopentyl group, Methylcyclohexyl group, 2,3-dimethylcyclohexyl group, 3,4,5-trimethylcyclohexyl group, 4-tert-butylcyclohexyl group, cycloheptyl group, cyclo An octyl group, and the like, but are not limited thereto.

본 발명에 있어서, 할로겐기의 예로는 불소, 염소, 브롬 또는 요오드가 있다.In the present invention, examples of the halogen group include fluorine, chlorine, bromine or iodine.

본 발명에 있어서, 아릴아민기의 예로는 치환 또는 비치환된 모노아릴아민기, 치환 또는 비치환된 디아릴아민기, 또는 치환 또는 비치환된 트리아릴아민기가 있다. 상기 아릴아민기 중의 아릴기는 단환식 아릴기일 수 있고, 다환식 아릴기일 수 있다. 상기 아릴기가 2 이상을 포함하는 아릴아민기는 단환식 아릴기, 다환식 아릴기, 또는 단환식아릴기와 다환식 아릴기를 동시에 포함할 수 있다.In the present invention, examples of the arylamine group include a substituted or unsubstituted monoarylamine group, a substituted or unsubstituted diarylamine group, or a substituted or unsubstituted triarylamine group. The aryl group in the arylamine group may be a monocyclic aryl group or a polycyclic aryl group. The arylamine group having at least two aryl groups may contain a monocyclic aryl group, a polycyclic aryl group, or a monocyclic aryl group and a polycyclic aryl group at the same time.

상기 아릴아민기의 구체적인 예로는 페닐아민기, 나프틸아민기, 비페닐아민기, 안트라세닐아민기, 3-메틸-페닐아민기, 4-메틸-나프틸아민기, 2-메틸-비페닐아민기, 9-메틸-안트라세닐아민기, 디페닐 아민기, 페닐 나프틸 아민기, 디톨릴 아민기, 페닐 톨릴 아민기, 카바졸기 및 트리페닐 아민기 등이 있으나, 이에 한정되는 것은 아니다.Specific examples of the arylamine group include a phenylamine group, a naphthylamine group, a biphenylamine group, an anthracenylamine group, a 3-methylphenylamine group, a 4-methylnaphthylamine group, But are not limited to, an amine group, a 9-methyl-anthracenylamine group, a diphenylamine group, a phenylnaphthylamine group, a ditolylamine group, a phenyltolylamine group, a carbazole group and a triphenylamine group.

본 발명에 있어서, 실릴기는 구체적으로 트리메틸실릴기, 트리에틸실릴기, t-부틸디메틸실릴기, 비닐디메틸실릴기, 프로필디메틸실릴기, 트리페닐실릴기, 디페닐실릴기, 페닐실릴기 등이 있으나 이에 한정되지 않는다.In the present invention, the silyl group is specifically exemplified by trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, vinyldimethylsilyl, propyldimethylsilyl, triphenylsilyl, diphenylsilyl, But are not limited thereto.

본 발명에 있어서, 헤테로아릴아민기 중의 헤테로 아릴기는 전술한 헤테로고리기의 예시 중에서 선택될 수 있다.In the present invention, the heteroaryl group in the heteroarylamine group can be selected from the examples of the above-mentioned heterocyclic group.

본 발명에 있어서, 알킬티옥시기, 알킬술폭시기 중의 알킬기는 전술한 알킬기의 예시와 같다. 구체적으로 알킬티옥시기로는 메틸티옥시기, 에틸티옥시기, tert-부틸티옥시기, 헥실티옥시기, 옥틸티옥시기 등이 있고, 알킬술폭시기로는 메실, 에틸술폭시기, 프로필술폭시기, 부틸술폭시기 등이 있으나, 이에 한정되지 않는다.In the present invention, the alkyloxy group in the alkylthio group and the alkyl group in the alkylsulfoxy group are the same as the aforementioned alkyl groups. Specific examples of the alkyloxy group include a methylthio group, an ethylthio group, a tert-butylthio group, a hexylthio group and an octylthio group. Examples of the alkylsulfoxy group include a mesyl group, an ethylsulfoxy group, a propylsulfoxy group, But are not limited thereto.

본 발명에 있어서, "치환 또는 비치환된"이란, 중수소, 할로겐기, 니트릴기, 니트로기, 히드록시기, 알킬기, 시클로알킬기, 알콕시기, 아릴옥시기, 알킬티옥시기, 아릴티옥시기, 알킬술폭시기, 아릴술폭시기, 알케닐기, 실릴기, 붕소기, 알킬아민기, 아랄킬아민기, 아릴아민기, 아릴기, 플루오레닐기, 카바졸기 및 N, O 및 S 원자 중 1개 이상을 포함하는 헤테로고리기 중 적어도 하나의 치환기로 치환 또는 비치환된 것을 의미한다.In the present invention, the "substituted or unsubstituted" means a group selected from the group consisting of deuterium, halogen, nitrile, nitro, hydroxy, alkyl, cycloalkyl, , An arylsulfoxy group, an alkenyl group, a silyl group, a boron group, an alkylamine group, an aralkylamine group, an arylamine group, an aryl group, a fluorenyl group, a carbazole group and at least one of N, O and S atoms Substituted or unsubstituted with at least one substituent in the heterocyclic group.

본 발명에 있어서, 치환된 아릴렌기라 함은, 페닐기, 비페닐기, 나프탈렌기, 플루오레닐기, 파이레닐기, 페난트레닐기, 페릴렌기, 테트라세닐기. 안트라센닐기 등이 다른 치환기로 치환된 것을 의미한다.In the present invention, the substituted arylene group means a phenyl group, a biphenyl group, a naphthalene group, a fluorenyl group, a pyrenyl group, a phenanthrenyl group, a perylene group, a tetracenyl group. Anthracenyl group and the like are substituted with other substituents.

본 발명에 있어서, 치환된 헤테로아릴렌기라 함은, 피리딜기, 티오페닐기, 트리아진기, 퀴놀린기, 페난트롤린기, 이미다졸기, 티아졸기, 옥사졸기, 카바졸기 및 이들의 축합헤테로고리기, 예컨대 벤즈퀴놀린기, 벤즈이미다졸기, 벤즈옥사졸기, 벤즈티아졸기, 벤즈카바졸기, 디벤조티오페닐기, 디벤조퓨란기 등이 다른 치환기로 치환된 것을 의미한다.
In the present invention, the substituted heteroarylene group includes a pyridyl group, a thiophenyl group, a triazine group, a quinoline group, a phenanthroline group, an imidazole group, a thiazole group, an oxazole group, a carbazole group and condensed heterocyclic groups, Such as a benzoquinoline group, a benzimidazole group, a benzoxazole group, a benzothiazole group, a benzzcarbazole group, a dibenzothiophenyl group, a dibenzofurane group and the like are substituted with other substituents.

상기 [화학식 1] 또는 [화학식 2]로 표시되는 본 발명에 따른 유기발광 화합물은 그 구조적 특이성으로 인하여 유기전계발광소자의 유기물층으로 사용될 수 있고, 보다 구체적으로 유기물층 내의 정공수송 기능층에 정공수송물질로 사용될 수 있다.The organic luminescent compound according to the present invention represented by Formula 1 or Formula 2 may be used as an organic material layer of an organic electroluminescent device due to its structural specificity, and more specifically, a hole transport material .

특히, 본 발명에 따른 [화학식 1] 또는 [화학식 2]로 표시되는 정공수송 기능층에 채용될 수 있는 유기발광 화합물의 구체적인 예로는 하기 화합물들이 있으나, 이들에만 한정되는 것은 아니다.Particularly, specific examples of the organic luminescent compound which can be employed in the hole transporting functional layer represented by the formula (1) or (2) according to the present invention include, but are not limited to, the following compounds.

Figure pat00005
Figure pat00005

Figure pat00006
Figure pat00006

Figure pat00007
Figure pat00007

Figure pat00008
Figure pat00008

Figure pat00009
Figure pat00009

Figure pat00010
Figure pat00010

Figure pat00011
Figure pat00011

Figure pat00012
Figure pat00012

Figure pat00013
Figure pat00013

Figure pat00014
Figure pat00014

Figure pat00015
Figure pat00015

Figure pat00016
Figure pat00016

Figure pat00017
Figure pat00017

Figure pat00018
Figure pat00018

Figure pat00019
Figure pat00019

Figure pat00020
Figure pat00020

Figure pat00021
Figure pat00021

Figure pat00022
Figure pat00022

Figure pat00023

Figure pat00023

또한, 상기 [화학식 1] 또는 [화학식 2]로 표시되는 본 발명에 따른 유기발광 화합물은 그 구조적 특이성으로 인하여 유기전계발광소자의 유기물층으로 사용될 수 있고, 보다 구체적으로 발광층의 인광 호스트 화합물로 사용될 수 있다.The organic luminescent compound according to the present invention represented by the above formula (1) or (2) can be used as an organic material layer of an organic electroluminescent device due to its structural specificity, and more specifically, have.

본 발명에 따른 [화학식 1] 또는 [화학식 2]로 표시되는 발광층의 인광 호스트 화합물로 채용될 수 있는 유기발광 화합물의 구체적인 예로는 하기 화합물들이 있으나, 이들에만 한정되는 것은 아니다.Specific examples of the organic luminescent compound that can be employed as the phosphorescent host compound of the luminescent layer represented by the formula (1) or (2) according to the present invention include, but are not limited to, the following compounds.

Figure pat00024
Figure pat00024

Figure pat00025
Figure pat00025

Figure pat00026
Figure pat00026

Figure pat00027
Figure pat00027

Figure pat00028
Figure pat00028

Figure pat00029
Figure pat00029

Figure pat00030
Figure pat00030

Figure pat00031
Figure pat00031

Figure pat00032
Figure pat00032

Figure pat00033
Figure pat00033

Figure pat00034
Figure pat00034

Figure pat00035
Figure pat00035

Figure pat00036
Figure pat00036

Figure pat00037
Figure pat00037

Figure pat00038
Figure pat00038

Figure pat00039
Figure pat00039

Figure pat00040
Figure pat00040

Figure pat00041
Figure pat00041

Figure pat00042
Figure pat00042

Figure pat00043
Figure pat00043

Figure pat00044
Figure pat00044

Figure pat00045
Figure pat00045

Figure pat00046
Figure pat00046

Figure pat00047
Figure pat00047

Figure pat00048
Figure pat00048

Figure pat00049
Figure pat00049

Figure pat00051
Figure pat00051

Figure pat00052
Figure pat00052

Figure pat00053
Figure pat00053

Figure pat00054
Figure pat00054

Figure pat00055
Figure pat00055

Figure pat00056

Figure pat00056

상기와 같은 구조의 코어 구조에 다양한 치환기를 도입함으로써 도입된 치환기의 고유 특성을 갖는 유기발광 화합물을 합성할 수 있다. 예컨대, 유기전계발광소자의 제조시 사용되는 정공 주입층 물질, 정공 수송층 물질, 발광층 물질, 및 전자 수송층 물질에 사용되는 치환기를 상기 구조에 도입함으로써 각 유기물층에서 요구하는 조건들을 충족시키는 물질을 제조할 수 있다.An organic luminescent compound having the intrinsic characteristics of the substituent introduced by introducing various substituents into the core structure having the above structure can be synthesized. For example, by introducing a substituent used in a hole injecting layer material, a hole transporting layer material, a light emitting layer material, and an electron transporting layer material used in manufacturing an organic electroluminescent device into the structure, a material meeting the requirements of each organic material layer is manufactured .

특히, 본 발명에 따른 [화학식 1] 또는 [화학식 2]로 표시되는 유기발광 화합물은 상기에서 살펴본 바와 같이, 특징적 코어 구조체에 치환기를 도입한 결과 평판 구조도가 우수하고, 높은 삼중항(triplet) 상태를 가짐을 확인하였는 바, 이를 유기전계발광소자의 유기물층에 채용시 효율, 구동전압, 수명 등에서 우수한 특성을 나타내는 유기전계발광소자의 구현이 가능하다.
In particular, as described above, the organic luminescent compound represented by the formula (1) or (2) according to the present invention has an excellent flat structure and a high triplet state It is possible to realize an organic electroluminescent device exhibiting excellent characteristics in terms of efficiency, drive voltage, lifetime, etc. in the organic material layer of the organic electroluminescent device.

본 발명의 화합물은 유기전계발광소자의 통상의 제조방법에 따라 소자에 적용할 수 있다.The compound of the present invention can be applied to a device according to a conventional method of manufacturing an organic electroluminescent device.

본 발명의 하나의 실시예에 따른 유기전계발광소자는 제1 전극과 제2 전극 및 이 사이에 배치된 유기물층을 포함하는 구조로 이루어질 수 있으며, 본 발명에 따른 유기발광 화합물을 소자의 유기물층에 사용한다는 것을 제외하고는 통상의 소자의 제조 방법 및 재료를 사용하여 제조될 수 있다.The organic electroluminescent device according to one embodiment of the present invention may have a structure including a first electrode, a second electrode and an organic material layer disposed therebetween, and the organic electroluminescent compound according to the present invention may be used for an organic material layer And can be manufactured using conventional device manufacturing methods and materials.

본 발명에 따른 유기전계발광소자의 유기물층은 단층 구조로 이루어질 수도 있으나, 2층 이상의 유기물층이 적층된 다층 구조로 이루어질 수 있다. 예컨대, 정공 주입층, 정공 수송층, 발광층, 전자 수송층, 전자 주입층 등을 포함하는 구조를 가질 수 있다. 그러나, 이에 한정되지 않고 더 적은 수의 유기물층을 포함할 수도 있다.The organic material layer of the organic electroluminescent device according to the present invention may have a single layer structure, but may have a multilayer structure in which two or more organic material layers are stacked. For example, a structure including a hole injecting layer, a hole transporting layer, a light emitting layer, an electron transporting layer, and an electron injecting layer. However, it is not limited to this and may include a smaller number of organic layers.

따라서, 본 발명의 유기전계발광소자에서, 상기 유기물층은 정공 주입층, 정공 수송층, 전자 수송층, 전자 주입층, 정공 주입 및 정공 수송을 동시에 하는 층, 전자 주입 및 전자수송을 동시에 하는 층 및 발광층 중 1층 이상을 포함할 수 있고, 상기 층들 중 1층 이상이 상기 [화학식 1] 또는 [화학식 2]로 표시되는 화합물을 포함할 수 있다.Therefore, in the organic electroluminescent device of the present invention, the organic material layer may be a hole injecting layer, a hole transporting layer, an electron transporting layer, an electron injecting layer, a layer simultaneously injecting and transporting holes, a layer simultaneously performing electron injection and electron transporting, One or more layers may be included, and at least one of the layers may include a compound represented by the formula (1) or (2).

특히, 본 발명에 따른 유기발광 화합물은 정공수송 기능층 또는 발광층에 포함될 수 있으며, 발광층 내 호스트 물질로서 포함될 수 있다.In particular, the organic luminescent compound according to the present invention may be contained in the hole transporting functional layer or the luminescent layer, and may be included as a host material in the luminescent layer.

상기 [화학식 1] 또는 [화학식 2]로 표시되는 화합물이 발광층 내 호스트 물질로서 포함되는 경우에, 상기 발광층은 1종 이상의 인광 도펀트를 포함할 수 있으며, 상기 발광층이 호스트 및 도펀트를 포함할 경우, 도펀트의 함량은 통상적으로 호스트 약 100 중량부를 기준으로 하여 약 0.01 내지 약 20 중량부의 범위에서 선택될 수 있다.When the compound represented by Formula 1 or Formula 2 is included as a host material in the light emitting layer, the light emitting layer may include at least one phosphorescent dopant, and when the light emitting layer includes a host and a dopant, The content of the dopant may be selected in the range of about 0.01 to about 20 parts by weight, based on 100 parts by weight of the host.

본 발명의 일 실시예에 의하면, 상기 발광층에 본 발명에 따른 [화학식 1]로 표시되는 호스트 화합물과 하기의 [구조식 4] 내지 [구조식 10] 중에서 선택되는 도펀트 화합물을 1종 이상 더 포함할 수 있다.According to an embodiment of the present invention, the light emitting layer may further contain at least one dopant compound selected from the following [structural formulas 4] to [structural formula 10] in the host compound represented by the general formula [1] have.

[구조식 4][Structural Formula 4]

Figure pat00057
Figure pat00057

Figure pat00058
Figure pat00058

Figure pat00059
Figure pat00059

Figure pat00060
Figure pat00060

Figure pat00061

Figure pat00061

[구조식 5][Structural Formula 5]

Figure pat00062

Figure pat00062

[구조식 6][Structural Formula 6]

Figure pat00063

Figure pat00063

[구조식 7][Structural Formula 7]

Figure pat00064

Figure pat00064

[구조식 8][Structural formula 8]

Figure pat00065

Figure pat00065

[구조식 8][Structural formula 8]

Figure pat00066

Figure pat00066

[구조식 10][Structural Formula 10]

Figure pat00067

Figure pat00067

이와 같은 다층 구조의 유기물층에서 상기 [화학식 1] 또는 [화학식 2]로 표시되는 화합물은 발광층, 정공 주입/정공 수송과 발광을 동시에 하는 층, 정공 수송과 발광을 동시에 하는 층, 또는 전자 수송과 발광을 동시에 하는 층 등에 포함될 수 있다.In the organic compound layer having such a multi-layer structure, the compound represented by the formula (1) or (2) may be used as a light emitting layer, a layer that simultaneously transports holes and holes, a layer that simultaneously transports holes and emits light, And the like.

예컨대, 본 발명에 따른 유기 전자 소자의 구조는 도 1 내지 5에 예시되어 있다.For example, the structure of an organic electronic device according to the present invention is illustrated in Figs.

도 1에는 기판(1) 위에 양극(2), 정공 주입층(3), 정공 수송층(4), 발광층(5), 전자 수송층(6) 및 음극(7)이 순차적으로 적층된 유기 전자 소자의 구조가 예시되어 있다. 이와 같은 구조에 있어서, 상기 [화학식 1] 또는 [화학식 2]로 표시되는 화합물은 상기 정공 주입층(3), 정공 수송층(4), 발광층(5) 또는 전자 수송층(6)에 포함될 수 있다.1 shows an organic electronic device in which an anode 2, a hole injecting layer 3, a hole transporting layer 4, a light emitting layer 5, an electron transporting layer 6 and a cathode 7 are sequentially laminated on a substrate 1 Structure is illustrated. In such a structure, the compound represented by Formula 1 or Formula 2 may be included in the hole injection layer 3, the hole transport layer 4, the light emitting layer 5, or the electron transport layer 6.

도 2에는 기판(1) 위에 양극(2), 정공 주입층(3), 정공 수송층(4), 발광층(5) 및 음극(7)이 순차적으로 적층된 유기 전자 소자의 구조가 예시되어 있다. 이와 같은 구조에 있어서, 상기 [화학식 1] 또는 [화학식 2]로 표시되는 화합물은 상기 정공 주입층(3), 정공 수송층(4) 또는 전자 수송층(6)에 포함될 수 있다.2 shows the structure of an organic electronic device in which an anode 2, a hole injecting layer 3, a hole transporting layer 4, a light emitting layer 5 and a cathode 7 are sequentially laminated on a substrate 1. In such a structure, the compound represented by Formula 1 or Formula 2 may be included in the hole injecting layer 3, the hole transporting layer 4, or the electron transporting layer 6.

도 3에는 기판(1) 위에 양극(2), 정공 수송층(4), 발광층(5), 전자 수송층(6) 및 음극(7)이 순차적으로 적층된 유기 전자 소자의 구조가 예시되어 있다. 이와 같은 구조에 있어서, 상기 [화학식 1] 또는 [화학식 2]로 표시되는 화합물은 상기 정공 수송층(4), 발광층(5) 또는 전자 수송층(6)에 포함될 수 있다.3 illustrates the structure of an organic electronic device in which an anode 2, a hole transporting layer 4, a light emitting layer 5, an electron transporting layer 6, and a cathode 7 are sequentially stacked on a substrate 1. In such a structure, the compound represented by the formula (1) or (2) may be included in the hole transport layer (4), the light emitting layer (5), or the electron transport layer (6).

도 4에는 기판(1) 위에 양극(2), 발광층(5), 전자 수송층(6) 및 음극(7)이 순차적으로 적층된 유기 전자 소자의 구조가 예시되어 있다. 이와 같은 구조에 있어서, 상기 [화학식 1] 또는 [화학식 2]로 표시되는 화합물은 상기 발광층(5) 또는 전자 수송층(6)에 포함될 수 있다.4 illustrates the structure of an organic electronic device in which an anode 2, a light emitting layer 5, an electron transport layer 6, and a cathode 7 are sequentially laminated on a substrate 1. In FIG. In such a structure, the compound represented by the formula (1) or (2) may be included in the light emitting layer (5) or the electron transport layer (6).

도 5에는 기판(1) 위에 양극(2), 발광층(5) 및 음극(7)이 순차적으로 적층된 유기 전자 소자의 구조가 예시되어 있다. 이와 같은 구조에 있어서, 상기 [화학식 1] 또는 [화학식 2]로 표시되는 화합물은 상기 발광층(5)에 포함될 수 있다.5 illustrates the structure of an organic electronic device in which an anode 2, a light-emitting layer 5, and a cathode 7 are sequentially stacked on a substrate 1. As shown in Fig. In such a structure, the compound represented by the formula (1) or (2) can be included in the luminescent layer (5).

예컨대, 본 발명에 따른 유기 전자 소자의 구조는 도 1 내지 5에 예시되어 있다.For example, the structure of an organic electronic device according to the present invention is illustrated in Figs.

도 1에는 기판(1) 위에 양극(2), 정공 주입층(3), 정공 수송층(4), 발광층(5), 전자 수송층(6) 및 음극(7)이 순차적으로 적층된 유기전계발광소자의 구조가 예시되어 있다. 이와 같은 구조에 있어서, 상기 [화학식 1] 또는 [화학식 2]로 표시되는 화합물은 상기 정공 주입층(3), 정공 수송층(4), 발광층(5) 또는 전자 수송층(6)에 포함될 수 있다.1 shows an organic electroluminescent device 1 in which an anode 2, a hole injecting layer 3, a hole transporting layer 4, a light emitting layer 5, an electron transporting layer 6 and a cathode 7 are sequentially laminated on a substrate 1 Are illustrated. In such a structure, the compound represented by Formula 1 or Formula 2 may be included in the hole injection layer 3, the hole transport layer 4, the light emitting layer 5, or the electron transport layer 6.

도 2에는 기판(1) 위에 양극(2), 정공 주입층(3), 정공 수송층(4), 발광층(5) 및 음극(7)이 순차적으로 적층된 유기전계발광소자의 구조가 예시되어 있다. 이와 같은 구조에 있어서, 상기 [화학식 1] 또는 [화학식 2]로 표시되는 화합물은 상기 정공 주입층(3), 정공 수송층(4) 또는 전자 수송층(6)에 포함될 수 있다.2 shows a structure of an organic electroluminescent device in which an anode 2, a hole injecting layer 3, a hole transporting layer 4, a light emitting layer 5 and a cathode 7 are sequentially laminated on a substrate 1 . In such a structure, the compound represented by Formula 1 or Formula 2 may be included in the hole injecting layer 3, the hole transporting layer 4, or the electron transporting layer 6.

도 3에는 기판(1) 위에 양극(2), 정공 수송층(4), 발광층(5), 전자 수송층(6) 및 음극(7)이 순차적으로 적층된 유기전계발광소자의 구조가 예시되어 있다. 이와 같은 구조에 있어서, 상기 [화학식 1] 또는 [화학식 2]로 표시되는 화합물은 상기 정공 수송층(4), 발광층(5) 또는 전자 수송층(6)에 포함될 수 있다.3 illustrates the structure of an organic electroluminescent device in which an anode 2, a hole transport layer 4, a light emitting layer 5, an electron transport layer 6, and a cathode 7 are sequentially laminated on a substrate 1. In such a structure, the compound represented by the formula (1) or (2) may be included in the hole transport layer (4), the light emitting layer (5), or the electron transport layer (6).

도 4에는 기판(1) 위에 양극(2), 발광층(5), 전자 수송층(6) 및 음극(7)이 순차적으로 적층된 유기전계발광소자의 구조가 예시되어 있다. 이와 같은 구조에 있어서, 상기 [화학식 1] 또는 [화학식 2]로 표시되는 화합물은 상기 발광층(5) 또는 전자 수송층(6)에 포함될 수 있다.4 shows the structure of an organic electroluminescent device in which an anode 2, a light emitting layer 5, an electron transport layer 6 and a cathode 7 are sequentially laminated on a substrate 1. [ In such a structure, the compound represented by the formula (1) or (2) may be included in the light emitting layer (5) or the electron transport layer (6).

도 5에는 기판(1) 위에 양극(2), 발광층(5) 및 음극(7)이 순차적으로 적층된 유기전계발광소자의 구조가 예시되어 있다. 이와 같은 구조에 있어서, 상기 [화학식 1] 또는 [화학식 2]로 표시되는 화합물은 상기 발광층(5)에 포함될 수 있다.5 illustrates the structure of an organic electroluminescent device in which an anode 2, a light-emitting layer 5, and a cathode 7 are sequentially laminated on a substrate 1. As shown in FIG. In such a structure, the compound represented by the formula (1) or (2) can be included in the luminescent layer (5).

예컨대, 본 발명에 따른 유기전계발광소자는 스퍼터링(sputtering)이나 전자빔 증발(e-beam evaporation)과 같은 PVD(physical vapor deposition) 방법을 이용하여, 기판 상에 금속 또는 전도성을 가지는 금속 산화물 또는 이들의 합금을 증착시켜 양극을 형성하고, 그 위에 정공 주입층, 정공 수송층, 발광층, 전자 수송층을 포함하는 유기물층을 형성한 후, 그 위에 음극으로 사용할 수 있는 물질을 증착시킴으로써 제조될 수 있다.For example, the organic electroluminescent device according to the present invention can be manufactured by using a physical vapor deposition (PVD) method such as sputtering or e-beam evaporation to form a metal oxide or a conductive metal oxide on the substrate, An anode is formed by depositing an alloy on the anode, and an organic material layer including a hole injecting layer, a hole transporting layer, a light emitting layer, and an electron transporting layer is formed on the anode, and then a substance usable as a cathode is deposited thereon.

이와 같은 방법 외에도, 기판 상에 음극 물질부터 유기물층, 양극 물질을 차례로 증착시켜 유기전계발광소자를 만들 수도 있다. 상기 유기물층은 정공 주입층, 정공 수송층, 발광층 및 전자 수송층 등을 포함하는 다층 구조일 수도 있으나, 이에 한정되지 않고 단층 구조일 수 있다. 또한, 상기 유기물층은 다양한 고분자 소재를 사용하여 증착법이 아닌 솔벤트 프로세스(solvent process), 예컨대 스핀 코팅, 딥 코팅, 닥터 블레이딩, 스크린 프린팅, 잉크젯 프린팅 또는 열 전사법 등의 방법에 의하여 더 적은 수의 층으로 제조할 수 있다.In addition to such a method, an organic electroluminescent device may be formed by sequentially depositing a cathode material, an organic material layer, and a cathode material on a substrate. The organic material layer may have a multi-layer structure including a hole injection layer, a hole transport layer, a light emitting layer, and an electron transport layer, but is not limited thereto and may have a single layer structure. In addition, the organic material layer may be formed using a variety of polymer materials by a solvent process such as a spin coating process, a dip coating process, a doctor blading process, a screen printing process, an inkjet printing process or a thermal transfer process, Layer.

상기 양극 물질로는 통상 유기물층으로 정공주입이 원활할 수 있도록 일함수가 큰 물질이 바람직하다. 본 발명에서 사용될 수 있는 양극 물질의 구체적인 예로는 바나듐, 크롬, 구리, 아연, 금과 같은 금속 또는 이들의 합금, 아연 산화물, 인듐 산화물, 인듐 주석 산화물(ITO), 인듐 아연 산화물(IZO)과 같은 금속 산화물, ZnO:Al 또는 SnO2:Sb와 같은 금속과 산화물의 조합, 폴리(3-메틸티오펜), 폴리[3,4-(에틸렌-1,2-디옥시)티오펜](PEDT), 폴리피롤 및 폴리아닐린과 같은 전도성 고분자 등이 있으나, 이들에만 한정되는 것은 아니다.As the anode material, a material having a large work function is preferably used so that hole injection can be smoothly conducted into the organic material layer. Specific examples of the cathode material that can be used in the present invention include metals such as vanadium, chromium, copper, zinc and gold or alloys thereof, zinc oxide, indium oxide, indium tin oxide (ITO), indium zinc oxide (IZO) metal oxides, ZnO: Al or SnO 2: a combination of a metal and an oxide such as Sb, poly (3-methylthiophene), poly [3,4- (ethylene-1,2-dioxy) thiophene] (PEDT) , Conductive polymers such as polypyrrole and polyaniline, but are not limited thereto.

상기 음극 물질로는 통상 유기물층으로 전자 주입이 용이하도록 일함수가 작은 물질인 것이 바람직하다. 음극 물질의 구체적인 예로는 마그네슘, 칼슘, 나트륨, 칼륨, 타이타늄, 인듐, 이트륨, 리튬, 가돌리늄, 알루미늄, 은, 주석 및 납과 같은 금속 또는 이들의 합금, LiF/Al 또는 LiO2/Al과 같은 다층 구조 물질 등이 있으나, 이들에만 한정되는 것은 아니다.The negative electrode material is preferably a material having a small work function to facilitate electron injection into the organic material layer. Specific examples of the negative electrode material include a metal such as magnesium, calcium, sodium, potassium, titanium, indium, yttrium, lithium, gadolinium, aluminum, silver, tin and lead or an alloy thereof, a multilayer such as LiF / Al or LiO 2 / Structural materials, and the like, but are not limited thereto.

정공 주입 물질로는 낮은 전압에서 양극으로부터 정공을 잘 주입받을 수 있는 물질로서, 정공 주입 물질의 HOMO(highest occupied molecular orbital)가 양극 물질의 일함수와 주변 유기물층의 HOMO 사이인 것이 바람직하다. 정공 주입 물질의 구체적인 예로는 금속 포피린(porphyrine), 올리고티오펜, 아릴아민 계열의 유기물, 헥사니트릴 헥사아자트리페닐렌, 퀴나크리돈(quinacridone) 계열의 유기물, 페릴렌(perylene) 계열의 유기물, 안트라퀴논 및 폴리아닐린과 폴리티오펜 계열의 전도성 고분자 등이 있으나, 이들에만 한정되는 것은 아니다.As the hole injecting material, it is preferable that the highest occupied molecular orbital (HOMO) of the hole injecting material be between the work function of the anode material and the HOMO of the surrounding organic layer. Specific examples of the hole injecting material include metal porphyrine, oligothiophene, arylamine-based organic materials, hexanitrile hexaazatriphenylene, quinacridone-based organic materials, perylene-based organic materials, Anthraquinone, polyaniline and a polythiophene-based conductive polymer, but are not limited thereto.

정공 수송 물질로는 양극이나 정공 주입층으로부터 정공을 수송 받아 발광층으로 옮겨줄 수 있는 물질로 정공에 대한 이동성이 큰 물질이 적합하다. 구체적인 예로는 아릴아민 계열의 유기물, 전도성 고분자, 및 공액 부분과 비공액 부분이 함께 있는 블록 공중합체 등이 있으나, 이들에만 한정되는 것은 아니다.As the hole transporting material, a material capable of transporting holes from the anode or the hole injection layer to the light emitting layer and having high mobility to holes is suitable. Specific examples include arylamine-based organic materials, conductive polymers, and block copolymers having a conjugated portion and a non-conjugated portion together, but are not limited thereto.

발광 물질로는 정공 수송층과 전자 수송층으로부터 정공과 전자를 각각 수송받아 결합시킴으로써 가시광선 영역의 빛을 낼 수 있는 물질로서, 형광이나 인광에 대한 양자효율이 좋은 물질이 바람직하다. 구체적인 예로는 8-히드록시-퀴놀린 알루미늄 착물(Alq3), 카르바졸 계열 화합물, 이량체화 스티릴(dimerized styryl) 화합물, BAlq, 10-히드록시벤조 퀴놀린-금속 화합물, 벤족사졸, 벤즈티아졸 및 벤즈이미다졸 계열의 화합물, 폴리(p-페닐렌비닐렌)(PPV) 계열의 고분자, 스피로(spiro) 화합물, 폴리플루오렌, 루브렌 등이 있으나, 이들에만 한정되는 것은 아니다.The light emitting material is preferably a material capable of emitting light in the visible light region by transporting and combining holes and electrons from the hole transporting layer and the electron transporting layer, respectively, and having a high quantum efficiency for fluorescence or phosphorescence. Specific examples include 8-hydroxy-quinoline aluminum complex (Alq 3 ), carbazol-based compounds, dimerized styryl compounds, BAlq, 10-hydroxybenzoquinoline-metal compounds, benzoxazole, benzthiazole and A benzimidazole-based compound, a poly (p-phenylene vinylene) (PPV) -based polymer, a spiro compound, polyfluorene, rubrene, and the like.

전자 수송 물질로는 음극으로부터 전자를 잘 주입 받아 발광층으로 옮겨줄 수 있는 물질로서, 전자에 대한 이동성이 큰 물질이 적합하다. 구체적인 예로는 8-히드록시퀴놀린의 Al 착물, Alq3를 포함한 착물, 유기 라디칼 화합물, 히드록시플라본-금속 착물 등이 있으나, 이들에만 한정되는 것은 아니다.
As the electron transporting material, a material capable of transferring electrons from the cathode well into the light emitting layer, which is highly mobile, is suitable. Specific examples thereof include, but are not limited to, an Al complex of 8-hydroxyquinoline, a complex containing Alq 3 , an organic radical compound, and a hydroxyflavone-metal complex.

본 발명에 따른 유기전계발광소자는 사용되는 재료에 따라 전면 발광형, 후면 발광형 또는 양면 발광형일 수 있다.The organic electroluminescent device according to the present invention may be a front emission type, a back emission type, or a both-sided emission type, depending on the material used.

또한, 본 발명에 따른 유기발광 화합물은 유기 태양 전지, 유기 감광체, 유기 트랜지스터 등을 비롯한 유기 전자 소자에서도 유기전계발광소자에 적용되는 것과 유사한 원리로 작용할 수 있다.
In addition, the organic electroluminescent compound according to the present invention can act on a principle similar to that applied to an organic electroluminescent device in an organic electronic device including an organic solar cell, an organophotoreceptor, an organic transistor and the like.

이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예를 제시한다. 그러나, 하기의 실시예는 본 발명을 예시하기 위한 것이며, 이에 의하여 본 발명의 범위가 한정되는 것은 아니다.
Hereinafter, preferred embodiments of the present invention will be described in order to facilitate understanding of the present invention. However, the following examples are intended to illustrate the invention and are not intended to limit the scope of the invention.

실시예Example 1 : 화합물 1 합성 1: Synthesis of compound 1

(1) (One) 제조예Manufacturing example 1 : 중간체 A의 합성 1: Synthesis of intermediate A

Figure pat00068
Figure pat00068

3-bromo-5-chloro-1,1-dimethyl-1H-isoindole(2.6 g, 0.010 mol)에 methyl 2-bromobenzoate(2.6 g, 0.012 mol)을 넣고 60 mL ehter에 녹이고, -78 ℃로 냉각시킨 후 2.5 M BuLi(0.01 mL, 0.0005 mol)을 dropping시킨 후, 1시간 동안 교반하였다. 이를 서서히 실온으로 올려 4시간 동안 더 교반하였다. 반응완료 후 물 100 mL로 추출하여 유기층을 감압 건조하였다. 이를 EtOH : Acetone으로 재결정하여 중간체 A(1.3 g, 41%)를 수득하였다(m/z= 313).
Methyl 2-bromobenzoate (2.6 g, 0.012 mol) was added to 3-bromo-5-chloro-1,1-dimethyl-1H-isoindole (2.6 g, 0.010 mol) and dissolved in a 60 mL ehter. After dropping 2.5 M BuLi (0.01 mL, 0.0005 mol), the mixture was stirred for 1 hour. The mixture was slowly warmed to room temperature and stirred for 4 hours. After completion of the reaction, the reaction mixture was extracted with 100 mL of water, and the organic layer was dried under reduced pressure. This was recrystallized from EtOH: Acetone to give intermediate A (1.3 g, 41%) (m / z = 313).

(2) (2) 제조예Manufacturing example 2 : 중간체 A-1의 합성 2: Synthesis of intermediate A-1

Figure pat00069
Figure pat00069

중간체 A(3.1 g, 0.010 mol)를 30 mL ehter에 녹이고, -78 ℃로 냉각시킨 후 2.5 M BuLi(0.01 mL, 0.0005 mol)을 dropping시킨 후, 1시간 동안 교반하였다. 이를 서서히 실온으로 올려 4시간 동안 더 교반하였다. 반응 완료 후 물 100 mL로 추출하여 유기층을 감압 건조하였다. 이를 EtOH : Acetone 으로 재결정하여 중간체 A-1(2.0 g, 63%)을 수득하였다(m/z= 313).
Intermediate A (3.1 g, 0.010 mol) was dissolved in a 30 mL ehter, cooled to -78 ° C, and 2.5 M BuLi (0.01 mL, 0.0005 mol) was dropwise added thereto, followed by stirring for 1 hour. The mixture was slowly warmed to room temperature and stirred for 4 hours. After completion of the reaction, the reaction mixture was extracted with 100 mL of water, and the organic layer was dried under reduced pressure. This was recrystallized from EtOH: Acetone to give intermediate A-1 (2.0 g, 63%) (m / z = 313).

(3) (3) 제조예Manufacturing example 3 : 중간체 A-2의 합성 3: Synthesis of intermediate A-2

Figure pat00070
Figure pat00070

중간체 A-1(3.1 g, 0.010 mol)를 50 mL의 농축된 H3PO4에 녹인 후 5시간 동안 교반시켰다. 이를 물 100 mL와 Ethyl Acetate 100 mL로 추출하고, 유기층을 감압 건조하였다. 이를 EtOH 100 mL로 재결정하여 중간체 A-2(2.1 g, 72%)를 수득하였다(m/z=295).
Intermediate A-1 (3.1 g, 0.010 mol) was dissolved in 50 mL of concentrated H 3 PO 4 and stirred for 5 hours. It was extracted with 100 mL of water and 100 mL of Ethyl Acetate, and the organic layer was dried under reduced pressure. This was recrystallized from 100 mL of EtOH to give intermediate A-2 (2.1 g, 72%) (m / z = 295).

(4) (4) 제조예Manufacturing example 4 : 중간체 1-1의 합성 4: Synthesis of intermediate 1-1

Figure pat00071
Figure pat00071

N-(biphenyl-4-yl)-N-(4-bromophenyl)-9,9-dimethyl-9H-fluoren-2-amine(5.2 g, 0.010 mol)에 bis(pinacolato)dibron(2.5 g, 0.012 mol), PdCl2(dppf)(0.4 g, 0.0005 mol), potassium-acetate(2.7 g, 0.020 mol)에 1,4-dioxane 100 mL를 넣고 95 ℃에서 24시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20 : MC에 층분리 후 컬럼정제(n-Hexane : MC)하여 중간체 1-1을 4.0 g(수율 71%) 수득하였다(m/z=563).
Bis (pinacolato) dibron (2.5 g, 0.012 mol) was added to N- (biphenyl-4-yl) -N- (4- bromophenyl) -9,9-dimethyl-9H- 100 mL of 1,4-dioxane was added to PdCl 2 (dppf) (0.4 g, 0.0005 mol) and potassium acetate (2.7 g, 0.020 mol), and the mixture was reacted at 95 ° C for 24 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC and subjected to column purification (n-hexane: MC) to obtain 4.0 g (m / z = 563) of intermediate 1-1.

(5) (5) 제조예Manufacturing example 5 : 화합물 1의 합성 5: Synthesis of Compound 1

Figure pat00072
Figure pat00072

중간체 A-2(3.0 g, 0.010 mol)에 중간체 1-1(6.8 g, 0.012 mol), Pd(pph3)4(0.6 g, 0.0005 mol), potassium carbonate(2.8 g, 0.020 mol)에 THF 100 mL를 넣고 65 ℃에서 18시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20 : MC에 층분리 후 컬럼정제(n-Hexane : MC)하여 <화합물 1>을 4.9 g(수율 70%) 수득하였다.To a solution of Intermediate 1-1 (6.8 g, 0.012 mol), Pd (pph 3 ) 4 (0.6 g, 0.0005 mol) and potassium carbonate (2.8 g, 0.020 mol) in THF 100 mL, and the mixture was reacted at 65 ° C for 18 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC and subjected to column purification (n-hexane: MC) to obtain 4.9 g (yield 70%) of <Compound 1>.

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.990/d, 7.87/d, 7.69/d, 7.62/d, 7.61/m, 7.55/d, 7.41/m, 7.38/m, 7.28/m, 7.23/d, 6.75/s, 6.58/d) 2H(7.52/d, 1.61/s) 3H(7.51/m) 4H(6.69/d, 1.72/s) 5H(7.54/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.990 / d, 7.87 / d, 7.69 / d, 7.62 / d, 7.61 / m, 7.55 / d, 7.41 / m, 7.38 / m, 7.28 / m D, 6.75 / s, 6.58 / d) 2H (7.52 / d, 1.61 / s) 3H (7.51 /

LC/MS: m/z=697 [(M+1)+]
LC / MS: m / z = 697 [(M + 1) &lt; + &

실시예Example 2 : 화합물 2 합성 2: Synthesis of compound 2

(1) (One) 제조예Manufacturing example 1 : 중간체 2-1의 합성 1: Synthesis of intermediate 2-1

Figure pat00073
Figure pat00073

bis(9,9-dimethyl-9H-fluoren-2-yl)amine(4.0 g, 0.010 mol)에 1,4-dibromo-2,5-dimethylbenzene(2.6 g, 0.010 mol), Pd(dba)2(0.5 g, 0.0005 mol), sodium-tert-butoxide(1.9 g, 0.020 mol)에 Tol 100 mL를 넣고 95 ℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20 : MC에 층분리 후 컬럼정제(n-Hexane : MC)하여 중간체 2-1을 4.5 g(수율 77%) 수득하였다.(m/z=585)
dibromo-2,5-dimethylbenzene (2.6 g, 0.010 mol), Pd (dba) 2 (0.09 mol) and bis (9,9- 0.5 g, 0.0005 mol) and sodium-tert-butoxide (1.9 g, 0.020 mol) were added 100 mL of Tol and reacted at 95 ° C for 4 hours with stirring. After completion of the reaction, the reaction product was cooled, and the product was separated into H 2 O: MC and subjected to column purification (n-hexane: MC) to obtain 4.5 g (m / z = 585)

(2) (2) 제조예Manufacturing example 2 : 중간체 2-2의 합성 2: Synthesis of intermediate 2-2

Figure pat00074
Figure pat00074

중간체 2-1(5.9 g, 0.010 mol)에 bis(pinacolato)dibron(3.0 g, 0.012 mol)를 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <중간체 2-2> 4.3 g(수율 72%)을 얻었다.(m/z=591)
<Intermediate 2-2> 4.3 g (0.012 mol) of bis (pinacolato) dibron was added to Intermediate 2-1 (5.9 g, 0.010 mol) g (yield: 72%). (m / z = 591)

(3) (3) 제조예Manufacturing example 3 : 화합물 2의 합성 3: Synthesis of Compound 2

Figure pat00075
Figure pat00075

중간체 A-2(3.0 g, 0.010 mol)에 중간체 2-2(7.1 g, 0.012 mol)를 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <화합물 2> 5.5 g(수율 72%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (4), except that Intermediate 2-2 (7.1 g, 0.012 mol) was added to Intermediate A-2 (3.0 g, 0.010 mol) 72%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.90/d, 7.69/d, 7.61/m, 7.54/d, 7.51/m, 7.42/d, 7.23/d, 6.49/s, 2.59/s, 2.12/s) 2H(7.87/d, 7.62/d, 7.55/d, 7.38/m, 7.28/m, 6.75/d, 6.58/d, 1.61/s) 6H(1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.90 / d, 7.69 / d, 7.61 / m, 7.54 / d, 7.51 / m, 7.42 / d, 7.23 / d, 6.49 / s, 2.59 / s , 2.12 / s) 2H (7.87 d, 7.62 d, 7.55 d, 7.38 m, 7.28 m, 6.75 d, 6.58 d,

LC/MS: m/z=766[(M+1)+]
LC / MS: m / z = 766 [(M + 1) &lt; + &

실시예Example 3 : 화합물 3 합성 3: Synthesis of compound 3

(1) (One) 제조예Manufacturing example 1 : 중간체 3-1 합성 1: Intermediate 3-1 Synthesis

Figure pat00076
Figure pat00076

N-(biphenyl-4-yl)-9,9-dimethyl-9H-fluoren-2-amine(3.6 g, 0.010 mol)에 2,6-dibromonaphthalene(2.9 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 3-1> 4.4 g(수율 77%)을 얻었다.(m/z=566)
2,6-dibromonaphthalene (2.9 g, 0.010 mol) was added to N- (biphenyl-4-yl) -9,9-dimethyl-9H-fluoren- Synthesis was conducted in the same manner as in Example (1) to obtain 4.4 g (yield 77%) of Intermediate 3-1 (m / z = 566)

(2) (2) 제조예Manufacturing example 2 : 중간체 3-2 합성 2: Intermediate 3-2 Synthesis

Figure pat00077
Figure pat00077

중간체 3-1(5.7 g, 0.010 mol)에 bis(pinacolato)dibron(3.0 g, 0.012 mol)를 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <중간체 3-2> 4.4 g (수율 72%)을 얻었다.(m/z=613)
Intermediate 3-2 was prepared according to the same procedure as in Example 1 (4), except that bis (pinacolato) dibron (3.0 g, 0.012 mol) was added to Intermediate 3-1 (5.7 g, 0.010 mol) g (yield: 72%). (m / z = 613)

(3) (3) 제조예Manufacturing example 3 : 화합물 3 합성 3: Synthesis of compound 3

Figure pat00078
Figure pat00078

중간체 A-2(3.0 g, 0.010 mol)에 중간체 4-2(7.4 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 3> 5.4 g(수율 72%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (5), except that Intermediate 4-2 (7.4 g, 0.012 mol) was added to Intermediate A-2 (3.0 g, 0.010 mol) 72%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.90/d, 7.87/d, 7.84/d, 7.74/s, 7.64/d, 7.63/d, 7.61/m, 7.55/d, 7.54/d, 7.51/m, 7.49/d, 7.46/s, 7.38/m, 7.28/m, 7.23/d, 6.75/s, 6.58/d) 2H(7.54/d, 7.52/d, 7.51/m, 6.69/d, 1.61/s) 4H(7.69/d, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.90 / d, 7.87 / d, 7.84 / d, 7.74 / s, 7.64 / d, 7.63 / d, 7.61 / m, 7.55 / d, 7.54 / d 7.51 / m, 7.49 / d, 7.46 / s, 7.38 / m, 7.28 / m, 7.23 / d, 6.75 / , 1.61 / s) 4H (7.69 / d, 1.72 / s)

LC/MS: m/z= 747[(M+1)+]
LC / MS: m / z = 747 [(M + 1) &lt; + &

실시예Example 4 : 화합물 4 합성 4: Synthesis of compound 4

(1) (One) 제조예Manufacturing example 1 : 중간체 4-1의 합성 1: Synthesis of Intermediate 4-1

Figure pat00079
Figure pat00079

dip-tolylamine(2.0 g, 0.010 mol)에 1,3,5-tribromobenzene(3.1 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 4-1> 4.2 g (수율 77%)을 얻었다.(m/z=547)
Intermediate 4-1 was synthesized by the same method as in Example 2 (1) except that 1,3,5-tribromobenzene (3.1 g, 0.010 mol) was added to dip-tolylamine (2.0 g, 0.010 mol) 4.2 g (yield 77%) was obtained. (M / z = 547)

(2) (2) 제조예Manufacturing example 2 : 중간체 4-2의 합성 2: Synthesis of intermediate 4-2

Figure pat00080
Figure pat00080

중간체 4-1(5.5 g, 0.010 mol)에 bis(pinacolato)dibron(3.0 g, 0.012 mol)를 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <중간체 4-2> 4.3 g(수율 72%)을 얻었다.(m/z=595)
Intermediate 4-2 was synthesized as in Intermediate 4-1 (5.5 g, 0.010 mol) by the same procedure as in Example 1 (4) except that bis (pinacolato) dibron (3.0 g, 0.012 mol) g (yield: 72%). (m / z = 595)

(3) (3) 제조예Manufacturing example 3 : 화합물 4의 합성 3: Synthesis of Compound 4

Figure pat00081
Figure pat00081

중간체 A-2(3.0 g, 0.010 mol)에 중간체 4-2(7.1 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 4> 5.2 g(수율 71%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (5), except that Intermediate 4-2 (7.1 g, 0.012 mol) was added to Intermediate A-2 (3.0 g, 0.010 mol) 71%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.90/d, 7.69/d, 7.61/m, 7.54/d, 7.51/m, 7.23/d, 5.73/s) 2H(6.25/s, 1.72/s, 1.61/s) 4H(2.34/s) 8H(6.98/d, 6.51/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.90 / d, 7.69 / d, 7.61 / m, 7.54 / d, 7.51 / m, 7.23 / d, 5.73 / s) 2H (6.25 / s, 1.72 / s, 1.61 / s) 4H (2.34 / s) 8H (6.98 / d, 6.51 / d)

LC/MS: m/z=728 [(M+1)+]
LC / MS: m / z = 728 [(M + 1) &lt; + &

실시예Example 5 : 화합물 5 합성 5: Synthesis of compound 5

(1) (One) 제조예Manufacturing example 1 : 중간체 5-1의 합성 1: Synthesis of intermediate 5-1

Figure pat00082
Figure pat00082

4-tert-butylphenylboronic acid(1.8 g, 0.010 mol)에 1-bromo-4-chloro-2,5-dimethylbenzene(1.8 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 5-1> 1.6 g (수율 72%)을 얻었다.(m/z=272)
4-chloro-2,5-dimethylbenzene (1.8 g, 0.012 mol) was added to 4-tert-butylphenylboronic acid (1.8 g, 0.010 mol) in the same manner as in Example 1- To obtain 1.6 g (yield 72%) of Intermediate 5-1 (m / z = 272)

(2) (2) 제조예Manufacturing example 2 : 중간체 5-2의 합성 2: Synthesis of Intermediate 5-2

Figure pat00083
Figure pat00083

중간체 5-1(2.7 g, 0.010 mol)에 9,9-dimethyl-9H-fluoren-2-amine(2.1 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 5-2> 3.4 g (수율 77%)을 얻었다.(m/z=445)
Synthesis was carried out in the same manner as in Example 2 (1) except that 9,9-dimethyl-9H-fluoren-2-amine (2.1 g, 0.010 mol) was added to Intermediate 5-1 (2.7 g, 0.010 mol) 3.4 g (yield 77%) of Intermediate 5-2 (m / z = 445) was obtained.

(3) (3) 제조예Manufacturing example 3 : 중간체 5-3의 합성 3: Synthesis of intermediate 5-3

Figure pat00084
Figure pat00084

중간체 5-2(4.4 g, 0.010 mol)에 1,4-dibromobenzene(2.4 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 5-3> 4.6 g (수율 77%)을 얻었다.(m/z=600)
<Intermediate 5-3> 4.6 g (0.010 mol) of 1,4-dibromobenzene was added to Intermediate 5-2 (4.4 g, 0.010 mol) g (yield: 77%). (m / z = 600)

(4) (4) 제조예Manufacturing example 4 : 중간체 5-4의 합성 4: Synthesis of intermediate 5-4

Figure pat00085
Figure pat00085

중간체 5-3(6.0 g, 0.010 mol)에 bis(pinacolato)dibron(3.0 g, 0.012 mol)를 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <중간체 2-2> 4.7 g (수율 72%)을 얻었다.(m/z=647)
<Intermediate 2-2> 4.7 g (0.012 mol) of bis (pinacolato) dibron (3.0 g, 0.012 mol) was added to Intermediate 5-3 (6.0 g, 0.010 mol) g (yield: 72%). (m / z = 647)

(5) (5) 제조예Manufacturing example 5 : 화합물 5의 합성 5: Synthesis of Compound 5

Figure pat00086
Figure pat00086

중간체 A-2(3.0 g, 0.010 mol)에 중간체 4-2(7.8 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 5> 5.5 g (수율 70%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (5), except that Intermediate 4-2 (7.8 g, 0.012 mol) was added to Intermediate A-2 (3.0 g, 0.010 mol) 70%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.90/d, 7.87/d, 7.69/d, 7.62/d, 7.61/m, 7.55/d, 7.51/m, 7.42/s, 7.38/m, 7.28/m, 7.23/d, 6.75/s, 6.58/d, 6.49/s, 2.59/s, 2.12/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.90 / d, 7.87 / d, 7.69 / d, 7.62 / d, 7.61 / m, 7.55 / d, 7.51 / m, 7.42 / s, 7.38 / m , 7.28 / m, 7.23 / d, 6.75 / s, 6.58 / d, 6.49 / s, 2.59 / s, 2.12 /

LC/MS: m/z=782 [(M+1)+]
LC / MS: m / z = 782 [(M + 1) &lt; + &

실시예Example 6 : 화합물 6 합성 6: Synthesis of Compound 6

(1) (One) 제조예Manufacturing example 1 : 중간체 6-1의 합성 1: Synthesis of intermediate 6-1

Figure pat00087
Figure pat00087

1-bromo-3-chloronaphthalene(2.4 g, 0.010 mol)에 phenyl-boronic acid (1.4 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 6-1> 1.7 g (수율 72%)을 얻었다.(m/z=238)
Boronic acid (1.4 g, 0.012 mol) was added to 1-bromo-3-chloronaphthalene (2.4 g, 0.010 mol) and the intermediate <6-1 > 1.7 g (yield 72%). (M / z = 238)

(2) (2) 제조예Manufacturing example 2 : 중간체 6-2의 합성 2: Synthesis of intermediate 6-2

Figure pat00088
Figure pat00088

중간체 6-1(2.4 g, 0.010 mol)에 4-bromoaniline(1.7 g, 0.010 mol)를 넣고 실시예 2=제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 6-2> 2.5 g (수율 77%)을 얻었다.(m/z=329)
Intermediate 6-2 was synthesized in the same manner as in Example 2 (1) except that 4-bromoaniline (1.7 g, 0.010 mol) was added to Intermediate 6-1 (2.4 g, 0.010 mol) Yield: 77%). (M / z = 329)

(3) (3) 제조예Manufacturing example 3 : 중간체 6-3의 합성 3: Synthesis of intermediate 6-3

Figure pat00089
Figure pat00089

중간체 6-2(3.3 g, 0.010 mol)에 bis(pinacolato)dibron(3.0 g, 0.012 mol)를 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <중간체 2-2> 2.9 g (수율 70%)을 얻었다.(m/z=421)
<Intermediate 2-2> 2.9 (3 g, 0.012 mol) was synthesized in the same manner as in Example 1 (4) except that bis (pinacolato) dibron (3.0 g, 0.012 mol) was added to Intermediate 6-2 g (yield 70%). (m / z = 421)

(4) (4) 제조예Manufacturing example 4 : 중간체 6-4의 합성 4: Synthesis of intermediate 6-4

Figure pat00090
Figure pat00090

중간체 6-3(4.2 g, 0.010 mol)에 4-bromo-N,N-diphenylaniline(32.6 g, 0.008 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 6-4> 3.9 g (수율 74%)을 얻었다.(m/z=664)
Intermediate 6 (4.2 g, 0.010 mol) was reacted with 4-bromo-N, N-diphenylaniline (32.6 g, 0.008 mol) in the same manner as in Example 1- -4> 3.9 g (yield: 74%). (M / z = 664)

(5) (5) 제조예Manufacturing example 5 : 화합물 6의 합성 5: Synthesis of Compound 6

Figure pat00091
Figure pat00091

중간체 A-2(3.0 g, 0.010 mol)에 중간체 4-2(8.0 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 6> 5.8 g (수율 72%)을 얻었다.Synthesis was conducted in the same manner as in Example 1-Preparation Example (5), except that Intermediate 4-2 (8.0 g, 0.012 mol) was added to Intermediate A-2 (3.0 g, 0.010 mol) 72%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.43/d, 7.90/d, 7.85/d, 7.69/d, 7.61/m, 7.51/m, 7.46/m, 7.41/m, 7.32/m, 7.23/d, 6.99/s, 6.76/s) 2H(7.79/d, 7.51/m, 6.81/m, 6.69/d, 1.72/s, 1.61/s) 3H(7.54/d) 4H(7.20/m, 6.63/d, 6.38/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.43 / d, 7.90 / d, 7.85 / d, 7.69 / d, 7.61 / m, 7.51 / m, 7.46 / m, 7.41 / m, 7.32 / m D, 6.99 / s, 6.76 / s) 2H (7.79 / d, 7.51 / m, 6.81 / , 6.63 / d, 6.38 / d)

LC/MS: m/z=799 [(M+1)+]
LC / MS: m / z = 799 [(M + 1) &lt; + &

실시예Example 7 : 화합물 7 합성 7: Synthesis of Compound 7

(1) (One) 제조예Manufacturing example 1 : 중간체 7-1의 합성 1: Synthesis of Intermediate 7-1

Figure pat00092
Figure pat00092

중간체 6-3(6.6 g, 0.010 mol)에 bromobenzene(1.3 g, 0.008 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 7-1> 3.8 g (수율 77%)을 얻었다.(m/z=497)
(1.3 g, 0.008 mol) was added to Intermediate 6-3 (6.6 g, 0.010 mol) in the same manner as in Example 2-Preparation Example (1) %). (M / z = 497)

(2) (2) 제조예Manufacturing example 2 : 화합물 7의 합성 2: Synthesis of Compound 7

Figure pat00093
Figure pat00093

중간체 A-2(3.0 g, 0.010 mol)에 중간체 7-1(6.0 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 7> 4.5 g (수율 71%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (5), except that Intermediate 7-1 (6.0 g, 0.012 mol) was added to Intermediate A-2 (3.0 g, 0.010 mol) 71%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.43/d, 7.90/d, 7.85/d, 7.69/d, 7.61/m, 7.51/m, 7.46/m, 7.41/m, 7.32/m, 7.23/d, 6.99/s, 6.81/m, 6.76/s) 2H(7.79/d, 7.51/m, 7.20/m, 6.69/d, 6.63/d, 1.72/s, 1.61/s) 3H(7.54/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.43 / d, 7.90 / d, 7.85 / d, 7.69 / d, 7.61 / m, 7.51 / m, 7.46 / m, 7.41 / m, 7.32 / m 7.51 / m, 7.20 / m, 6.69 / d, 6.63 / d, 1.72 / s, 1.61 / s) 3H (7.54 / d)

LC/MS: m/z=631[(M+1)+]
LC / MS: m / z = 631 [(M + 1) &lt; + &

실시예Example 8 : 화합물 8 합성 8: Compound 8 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 8-1의 합성 1: Synthesis of Intermediate 8-1

Figure pat00094
Figure pat00094

중간체 6-3(6.6 g, 0.010 mol)에 2-bromo-9,9-dimethyl-9H-fluorene(2.2 g, 0.008 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 8-1> 3.8 g (수율 77%)을 얻었다.(m/z=613)
Synthesis was conducted in the same manner as in Example 2 (1) except that 2-bromo-9,9-dimethyl-9H-fluorene (2.2 g, 0.008 mol) was added to Intermediate 6-3 (6.6 g, 0.010 mol) 3.8 g (yield: 77%) of Intermediate 8-1 (m / z = 613) was obtained.

(2) (2) 제조예Manufacturing example 2 : 화합물 8의 합성 2: Synthesis of Compound 8

Figure pat00095
Figure pat00095

중간체 A-2(3.0 g, 0.010 mol)에 중간체 8-1(7.4 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 8> 5.4g (수율 72%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (5), except that Intermediate 8-1 (7.4 g, 0.012 mol) was added to Intermediate A-2 (3.0 g, 0.010 mol) 72%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.43/d, 7.90/d, 7.87/d, 7.85/d, 7.69/d, 7.62/d, 7.61/m, 7.55/d, 7.51/m, 7.46/m, 7.41/m, 7.38/m, 7.32/m, 7.28/m, 7.23/d, 6.99/s, 6.76/s, 6.75/s, 6.58/d) 2H(7.79/d, 7.51/m, 6.69/d, 1.61/s) 3H(7.54/d) 4H(1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.43 / d, 7.90 / d, 7.87 / d, 7.85 / d, 7.69 / d, 7.62 / d, 7.61 / m, 7.55 / d, 7.51 / m , 7.46 / m, 7.41 / m, 7.38 / m, 7.32 / m, 7.28 / m, 7.23 / d, 6.99 / s, 6.76 / s, 6.75 / s, 6.58 / , 6.69 / d, 1.61 / s) 3H (7.54 / d) 4H (1.72 / s)

LC/MS: m/z=747 [(M+1)+]
LC / MS: m / z = 747 [(M + 1) &lt; + &

실시예Example 9 : 화합물 9 합성 9: Synthesis of Compound 9

(1) (One) 제조예Manufacturing example 1 : 중간체 B의 합성 1: Synthesis of intermediate B

Figure pat00096
Figure pat00096

3,7-dibromo-5-chloro-1,1-dimethyl-1H-isoindole(3.4 g, 0.010 mol)에 methyl-2-bromobenzoate(2.6 g, 0.012 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 B> 1.8 g (수율 46%)을 얻었다.(m/z=392)
2-bromobenzoate (2.6 g, 0.012 mol) was added to 3,7-dibromo-5-chloro-1,1-dimethyl-1H-isoindole (3.4 g, 0.010 mol) (M / z = 392) (1.8 g, yield 46%). &Lt;

(2) (2) 제조예Manufacturing example 2 : 중간체 B-1의 합성 2: Synthesis of intermediate B-1

Figure pat00097
Figure pat00097

중간체 B(3.9 g, 0.010 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 B-1> 2.6 g (수율 66%)을 얻었다.(m/z=392)
Synthesis was conducted in the same manner as in Example 1 (2), except that Intermediate B (3.9 g, 0.010 mol) was added to obtain 2.6 g (yield 66%) of Intermediate B-1. M / z = 392 )

(3) (3) 제조예Manufacturing example 3 : 중간체 B-2의 합성 3: Synthesis of intermediate B-2

Figure pat00098
Figure pat00098

중간체 B-1(3.9 g, 0.010 mol)를 넣고 실시예 1-제조예 (3)에서 사용된 동일한 방법으로 합성하여 <중간체 B-2> 2.5 g(수율 66%)을 얻었다.(m/z=374)
2.5 g (yield 66%) of <Intermediate B-2> was obtained by the same method as employed in the preparation example (3) of Example 1, except that Intermediate B-1 (3.9 g, 0.010 mol) = 374)

(4) (4) 제조예Manufacturing example 4 : 중간체 9-1의 합성 4: Synthesis of intermediate 9-1

Figure pat00099
Figure pat00099

중간체 B-2(3.7 g, 0.010 mol)에 4-(diphenylamino)phenylboronic acid(3.5 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 9-1> 3.9 g (수율 72%)을 얻었다.(m/z=539)
Synthesis was conducted in the same manner as in Example 1 (5), except that 4- (diphenylamino) phenylboronic acid (3.5 g, 0.012 mol) was added to Intermediate B-2 (3.7 g, 0.010 mol) > 3.9 g (yield 72%). (M / z = 539)

(5) (5) 제조예Manufacturing example 5 : 화합물 9의 합성 5: Synthesis of Compound 9

Figure pat00100
Figure pat00100

중간체 9-1(5.4 g, 0.010 mol)에 중간체 6-3(6.0 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 9> 5.8 g (수율 73%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (5), except that Intermediate 6-3 (6.0 g, 0.012 mol) was added to Intermediate 9-1 (5.4 g, 0.010 mol) 73%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.43/d, 7.90/d, 7.85/d, 7.61/m, 7.54/d, 7.51/m, 7.46/m, 7.41/m, 7.32/m, 6.99/s, 6.76/s, 6.55/s) 2H(7.79/d, 7.54/d, 7.51/m, 6.69/d, 1.72/s, 1.61/s) 3H(6.81/m) 6H(7.20/m, 6.63/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.43 / d, 7.90 / d, 7.85 / d, 7.61 / m, 7.54 / d, 7.51 / m, 7.46 / m, 7.41 / m, 7.32 / m M, 6.99 / s, 6.76 / s, 6.55 / s) 2H (7.79 / d, 7.54 / d, 7.51 / , 6.63 (d)

LC/MS: m/z= 799[(M+1)+]
LC / MS: m / z = 799 [(M + 1) &lt; + &

실시예Example 10 : 화합물 10 합성 10: Compound 10 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 10-1의 합성 1: Synthesis of intermediate 10-1

Figure pat00101
Figure pat00101

dip-tolylamine(2.0 g, 0.010 mol)에 1,3,5-tribromobenzene(3.1 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 10-1> 3.3g (수율 77%)을 얻었다.(m/z=431)
(3.1 g, 0.010 mol) was added to dip-tolylamine (2.0 g, 0.010 mol) in the same manner as in Example 2 (1) (Yield: 77%) of the title compound (m / z = 431)

(2) (2) 제조예Manufacturing example 2 : 중간체 10-2의 합성 2: Synthesis of intermediate 10-2

Figure pat00102
Figure pat00102

4-bromo-4'-methylbiphenyl(2.5 g, 0.010 mol)에 9,9-dimethyl-9H-fluoren-2-amine(2.1 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 10-2> 3.0 g (수율 80%)을 얻었다.(m/z=375)
2-amine (2.1 g, 0.010 mol) was added to 4-bromo-4'-methylbiphenyl (2.5 g, 0.010 mol) Synthesis was conducted in the same manner to obtain 3.0 g (yield 80%) of Intermediate 10-2 (m / z = 375)

(3) (3) 제조예Manufacturing example 3 : 중간체 10-3의 합성 3: Synthesis of intermediate 10-3

Figure pat00103
Figure pat00103

중간체 10-1(4.3 g, 0.010 mol)에 중간체 10-2(3.8 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 10-3> 5.6 g (수율 77%)을 얻었다.(m/z=725)
Intermediate 10-3 was synthesized in the same manner as in Example 2 (1) except that Intermediate 10-2 (3.8 g, 0.010 mol) was added to Intermediate 10-1 (4.3 g, 0.010 mol) (Yield: 77%). (M / z = 725)

(4) (4) 제조예Manufacturing example 4 : 중간체 10-4의 합성 4: Synthesis of intermediate 10-4

Figure pat00104
Figure pat00104

중간체 10-3(7.3 g, 0.010 mol)에 bis(pinacolato)dibron(3.0 g, 0.012 mol)를 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <중간체 2-2> 5.4 g (수율 70%)을 얻었다.(m/z=772)
<Intermediate 2-2> 5.4 (4 g, 0.012 mol) was obtained by the same method as in Example 1 (4), except that bis (pinacolato) dibron (3.0 g, 0.012 mol) was added to Intermediate 10-3 g (yield: 70%). (m / z = 772)

(5) (5) 제조예Manufacturing example 5 : 화합물 10의 합성 5: Synthesis of Compound 10

Figure pat00105
Figure pat00105

중간체 A-2(3.0 g, 0.010 mol)에 중간체 4-2(9.3 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 10> 6.8 g (수율 75%)을 얻었다.(m/z=000)Synthesis was conducted in the same manner as in Example 1-Preparation Example (5), except that Intermediate 4-2 (9.3 g, 0.012 mol) was added to Intermediate A-2 (3.0 g, 0.010 mol) 75%). (M / z = 000)

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.90/d, 7.87/d, 7.69/d, 7.62/s, 7.61/m, 7.55/d, 7.51/m, 7.38/m, 7.28/m, 7.23/d, 6.75/s, 6.58/d, 5.73/s) 2H(7.33/d, 7.29/d, 6.69/d, 6.25/s, 1.61/s) 3H(7.54/d, 2.34/s) 4H(6.98/d, 6.51/d, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.90 / d, 7.87 / d, 7.69 / d, 7.62 / s, 7.61 / m, 7.55 / d, 7.51 / m, 7.38 / m, 7.28 / m , 7.23 / d, 6.75 / s, 6.58 / d, 5.73 / s) 2H (7.33 / d, 7.29 / d, 6.69 / d, 6.25 / s, 1.61 / s) (6.98 / d, 6.51 / d, 1.72 / s)

LC/MS: m/z= 907[(M+1)+]
LC / MS: m / z = 907 [(M + 1) &lt; + &

실시예Example 11 : 화합물 11 합성 11: Compound 11 Synthesis

(1) 제조예 1 : 중간체 11-1의 합성 (1) Production example 1: Synthesis of intermediate 11-1

Figure pat00106
Figure pat00106

1,4-dibromobenzene(2.4 g, 0.010 mol)에 9,9-dimethyl-9H-fluoren-2-amine (2.9 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 11-1> 2.8 g (수율 77%)을 얻었다.(m/z=364)
2-amine (2.9 g, 0.010 mol) was added to 1,4-dibromobenzene (2.4 g, 0.010 mol) in the same manner as in Example 2 (1) To obtain 2.8 g (yield: 77%) of Intermediate 11-1 (m / z = 364)

(2) (2) 제조예Manufacturing example 2 : 중간체 11-2의 합성 2: Synthesis of intermediate 11-2

Figure pat00107
Figure pat00107

1-bromo-5-chloronaphthalene(2.4 g, 0.010 mol)에 phenyl boronic aicd(1.4 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 11-2> 1.7 g (수율 72%)을 얻었다.(m/z=238)
Intermediate 11-2 was synthesized by the same method as in Example 1 (5), except that phenyl boronic aicd (1.4 g, 0.012 mol) was added to 1-bromo-5-chloronaphthalene (2.4 g, 0.010 mol) 1.7 g (yield 72%) of the title compound was obtained (m / z = 238)

(3) (3) 제조예Manufacturing example 3 : 중간체 11-3의 합성 3: Synthesis of intermediate 11-3

Figure pat00108
Figure pat00108

중간체 11-1(3.6 g, 0.010 mol)에 중간체 11-2(2.5 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 11-3> 4.4 g (수율 77%)을 얻었다.(m/z=566)
Synthesis was conducted in the same manner as in Example 2 (1), except that Intermediate 11-1 (3.6 g, 0.010 mol) was added to Intermediate 11-2 (2.5 g, 0.010 mol) (Yield: 77%). (M / z = 566)

(4) (4) 제조예Manufacturing example 4 : 중간체 11-4의 합성 4: Synthesis of intermediate 11-4

Figure pat00109
Figure pat00109

중간체 11-3(5.7 g, 0.010 mol)에 bis(pinacolato)dibron(3.0 g, 0.012 mol) 를 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <중간체 11-4> 4.4 g (수율 72%)을 얻었다.(m/z=613)
Synthesis was conducted in the same manner as in Example 1 (4), except that bis (pinacolato) dibron (3.0 g, 0.012 mol) was added to Intermediate 11-3 (5.7 g, 0.010 mol) g (yield: 72%). (m / z = 613)

(5) (5) 제조예Manufacturing example 5 : 화합물 11의 합성 5: Synthesis of Compound 11

중간체 A-2(3.0 g, 0.010 mol)에 중간체 11-4(7.4 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 11> 5.5 g (수율 73%)을 얻었다.(m/z=000)Synthesis was conducted in the same manner as in Example 1 (5), except that Intermediate 11-4 (7.4 g, 0.012 mol) was added to Intermediate A-2 (3.0 g, 0.010 mol) 73%). (M / z = 000)

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.40/d, 8.04/d, 8.03/d, 7.90/d, 7.87/d, 7.69/d, 7.62/d, 7.61/m, 7.60/m, 7.55/d, 7.51/m, 7.28/m, 7.23/d, 6.98/d, 6.75/s, 6.58/d) 2H(7.79/d, 7.51/m, 7.38/m, 6.69/d, 1.61/s) 3H(7.54/d) 4H(1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.40 / d, 8.04 / d, 8.03 / d, 7.90 / d, 7.87 / d, 7.69 / d, 7.62 / d, 7.61 / m, 7.60 / m 7.51 / m, 7.28 / m, 7.23 / d, 6.98 / d, 6.75 / s, 6.58 / d) 2H (7.79 / d, 7.51 / m, 7.38 / ) 3H (7.54 / d) 4H (1.72 / s)

LC/MS: m/z=747 [(M+1)+]
LC / MS: m / z = 747 [(M + 1) &lt; + &

실시예Example 12 : 화합물 12 합성 12: Compound 12 Synthesis

(1) 제조예 1 : 중간체 C의 합성 (1) Production Example 1: Synthesis of Intermediate C

Figure pat00111
Figure pat00111

3-bromo-5-chloro-1,1-dimethyl-1H-isoindole(2.6 g, 0.010 mol)에 methyl 2-bromocyclohexanecarboxylate(2.7 g, 0.012 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 C> 1.3 g (수율 41%)을 얻었다.(m/z=319)
(2-bromo-5-chloro-1,1-dimethyl-1H-isoindole (2.6 g, (M / z = 319) (Intermediate C) (1.3 g, yield 41%).

(2) (2) 제조예Manufacturing example 2 : 중간체 C-1의 합성 2: Synthesis of intermediate C-1

Figure pat00112
Figure pat00112

중간체 C(3.2 g, 0.010 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 C-1> 2.0 g (수율 62%)을 얻었다.(m/z=319)
2.0 g (yield 62%) of Intermediate C-1 was obtained in the same manner as in Example 1 (2) except that Intermediate C (3.2 g, 0.010 mol) was added. M / z = 319 )

(3) (3) 제조예Manufacturing example 3 : 중간체 C-2의 합성 3: Synthesis of intermediate C-2

Figure pat00113
Figure pat00113

중간체 C-1(3.3 g, 0.010 mol)를 넣고 실시예 1-제조예 (3)에서 사용된 동일한 방법으로 합성하여 <중간체 C-2> 2.0 g (수율 66%)을 얻었다.(m/z=301)
2.0 g (yield 66%) of <Intermediate C-2> was obtained by the same method as in Example 1- (3), except that Intermediate C-1 (3.3 g, 0.010 mol) = 301)

(4) (4) 제조예Manufacturing example 4 : 화합물 12의 합성 4: Synthesis of Compound 12

Figure pat00114
Figure pat00114

중간체 C-2(3.0 g, 0.010 mol)에 중간체 1-1(6.8 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 12> 4.4 g (수율 62%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (5), except that Intermediate 1-1 (6.8 g, 0.012 mol) was added to Intermediate C-2 (3.0 g, 0.010 mol) 62%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.87/d, 7.69/d, 7.62/d, 7.55/d, 7.41/m, 7.38/m, 7.28/m, 7.21/m, 6.75/s, 6.58/d) 2H(7.52/d, 7.51/m, 1.72/s, 1.53/s, 1.50/s, 1.40/s, 1.30/s) 3H(7.54/d) 4H(6.69/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.87 / d, 7.69 / d, 7.62 / d, 7.55 / d, 7.41 / m, 7.38 / m, 7.28 / m, 7.21 / m, 6.75 / s D) 2H (7.52 / d, 7.51 / m, 1.72 / s, 1.53 / s, 1.50 / s, 1.40 / s, 1.30 / s)

LC/MS: m/z=703 [(M+1)+]
LC / MS: m / z = 703 [(M + 1) &lt; + &

실시예Example 13 : 화합물 13 합성 13: Compound 13 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 13-1의 합성 1: Synthesis of intermediate 13-1

Figure pat00115
Figure pat00115

중간체 6-3(4.2 g, 0.010 mol)에 4-bromobiphenyl(2.4 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 13-1> 3.9 g (수율 67%)을 얻었다.(m/z=578)
Intermediate 13-1 was synthesized in the same manner as in Example 2 (1) except that 4-bromobiphenyl (2.4 g, 0.010 mol) was added to Intermediate 6-3 (4.2 g, 0.010 mol) Yield: 67%). (M / z = 578)

(2) (2) 제조예Manufacturing example 2 : 화합물 13의 합성 2: Synthesis of Compound 13

Figure pat00116
Figure pat00116

중간체 A-2(3.0 g, 0.010 mol)에 중간체 4-2(6.9 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 13> 5.1 g (수율 72%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (5), except that Intermediate 4-2 (6.9 g, 0.012 mol) was added to Intermediate A-2 (3.0 g, 0.010 mol) 72%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.43/d, 7.90/d, 7.85/d, 7.69/d, 7.61/m, 7.51/m, 7.46/m, 7.41/m, 7.32/m, 7.23/d, 6.99/s, 6.76/s) 2H(7.79/d, 7.51/m, 1.72/s, 1.61/s) 4H(6.69/d) 5H(7.54/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.43 / d, 7.90 / d, 7.85 / d, 7.69 / d, 7.61 / m, 7.51 / m, 7.46 / m, 7.41 / m, 7.32 / m D, 7.53 / d, 6.99 / s, 6.76 / s) 2H (7.79 / d, 7.51 /

LC/MS: m/z=712 [(M+1)+]
LC / MS: m / z = 712 [(M + 1) &lt; + &

실시예Example 14 : 화합물 14 합성 14: Compound 14 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 D의 합성 1: Synthesis of intermediate D

Figure pat00117
Figure pat00117

3-methoxyisobenzofuran-1(3H)-one(1.6 g, 0.010 mol)에 (2-tert-butylphenyl)magnesium bromide(2.8 g, 0.012 mol)을 넣고 THF 50 mL에 녹이고, -78 ℃로 냉각시킨 후 2.5 M BuLi(0.01 mL, 0.0005 mol)을 dropping시킨 후, 1시간 동안 교반하였다. 이를 서서히 실온으로 올려 4시간 동안 더 교반하였다. 반응 완료 후 물 100 mL로 추출하여 유기층을 감압 건조하였다. 이를 EtOH : Acetone으로 재결정하여 중간체 D(1.0 g, 41%) 수득하였다.(m/z= 246)
(2-tert-butylphenyl) magnesium bromide (2.8 g, 0.012 mol) was added to 3-methoxyisobenzofuran-1 (3H) -one (1.6 g, 0.010 mol) and the resulting solution was dissolved in 50 mL of THF. M BuLi (0.01 mL, 0.0005 mol) was added dropwise and stirred for 1 hour. The mixture was slowly warmed to room temperature and stirred for 4 hours. After completion of the reaction, the reaction mixture was extracted with 100 mL of water, and the organic layer was dried under reduced pressure. This was recrystallized from EtOH: Acetone to give Intermediate D (1.0 g, 41%). (M / z = 246)

(2) (2) 제조예Manufacturing example 2 : 중간체 D-1의 합성 2: Synthesis of intermediate D-1

Figure pat00118
Figure pat00118

중간체 D(2.5 g, 0.010 mol)에 potassium fluoride(2.3 g, 0.040 mol)를 넣고, THF/H2O를 5 : 2 비율로 50 mL를 넣고 25 ℃에서 1시간 교반하여 반응시켰다..반응 종료 후 냉각하여 H20 : MC에 층분리 후 컬럼정제(n-Hexane : MC)하여 중간체D-1을 1.3 g(수율 51%) 수득하였다. (m/z=260)
Potassium fluoride (2.3 g, 0.040 mol) was added to Intermediate D (2.5 g, 0.010 mol), 50 mL of THF / H 2 O was added at a ratio of 5: 2 and the mixture was stirred at 25 ° C for 1 hour. After cooling, the mixture was separated into H 2 O: MC and column-purified (n-hexane: MC) to obtain 1.3 g (yield: 51%) of Intermediate D-1. (m / z = 260)

(3) (3) 제조예Manufacturing example 3 : 중간체 D-2의 합성 3: Synthesis of intermediate D-2

Figure pat00119
Figure pat00119

중간체 D-1(2.6 g, 0.010 mol)에 N-bromosuccinimide(1.8 g, 0.010 mol)에 DMF 100 mL를 넣고 20 ℃에서 8시간 교반하여 반응시켰다. 반응 종료 후 H20 : 아세트산에틸로 층분리 후 컬럼정제(n-Hexane :MC)하여 중간체 D-2을 1.6 g(48%)수득하였다.(m/z=339)
100 mL of DMF was added to N-bromosuccinimide (1.8 g, 0.010 mol) in Intermediate D-1 (2.6 g, 0.010 mol) and the mixture was reacted at 20 ° C for 8 hours with stirring. After completion of the reaction H 2 0: column purification after phase separation with ethyl acetate (n-Hexane: MC) to the intermediate D-2 to yield 1.6 g (48%) (m / z = 339).

(4) (4) 제조예Manufacturing example 4 : 화합물 14의 합성 4: Synthesis of Compound 14

Figure pat00120
Figure pat00120

중간체 D-2(3.4 g, 0.010 mol)에 중간체 1-1(6.8 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 14> 4.9 g (수율 70%)을 얻었다.Intermediate 1-1 (6.8 g, 0.012 mol) was added to Intermediate D-2 (3.4 g, 0.010 mol) and the compound was synthesized in the same manner as in Example 1- (5) 70%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.87/d, 7.62/d, 7.55/d, 7.42/d, 7.41/m, 7.38/m, 7.36/m, 7.30/d, 7.28/m, 7.27/m, 7.22/m, 6.75/s, 6.58/d) 2H(7.54/d, 7.52/d, 7.51/m, 7.25/d, 7.12/d, 6.69/d, 6.63/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.87 / d, 7.62 / d, 7.55 / d, 7.42 / d, 7.41 / m, 7.38 / m, 7.36 / m, 7.30 / d, 7.28 / m 7.52 / d, 7.51 / m, 7.25 / d, 7.12 / d, 6.69 / d, 6.63 / d), 7.27 /

LC/MS: m/z= 696[(M+1)+]
LC / MS: m / z = 696 [(M + 1) &lt; + &

실시예Example 15 : 화합물 15 합성 15: Compound 15 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 E의 합성 1: Synthesis of intermediate E

Figure pat00121
Figure pat00121

3-methoxyisobenzofuran-1(3H)-one(1.6 g, 0.010 mol)에 (2-tert-butyl-3-chlorophenyl)magnesium bromide(3.2 g, 0.012 mol)를 넣고 실시예 14-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 E> 1.1 g (수율 40%)을 얻었다.(m/z=280)
(2-tert-butyl-3-chlorophenyl) magnesium bromide (3.2 g, 0.012 mol) was added to 3-methoxyisobenzofuran-1 (3H) (M / z = 280) of Intermediate E < 1.1 g (yield 40%).

(2) (2) 제조예Manufacturing example 2 : 중간체 E-1의 합성 2: Synthesis of intermediate E-1

Figure pat00122
Figure pat00122

중간체 E(2.8 g, 0.010 mol)를 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 E-1> 2.1 g (수율 70%)을 얻었다.(m/z=294)
Intermediate E (2.8 g, 0.010 mol) was synthesized in the same manner as in Example 1- (5) to give 2.1 g (m / z = 294) of Intermediate E-1.

(3) (3) 제조예Manufacturing example 3 : 중간체 E-2의 합성 3: Synthesis of intermediate E-2

Figure pat00123
Figure pat00123

중간체 E-1(2.9 g, 0.010 mol)에 N-bromosuccinimide(1.8 g, 0.010 mol)를 넣고 실시예 14-제조예 (3)에서 사용된 동일한 방법으로 합성하여 <중간체 E-2> 1.5 g (수율 41%)수득하였다. m/z=373)
Intermediate E-2 was synthesized in the same manner as in Example 14 (3) except that N-bromosuccinimide (1.8 g, 0.010 mol) was added to Intermediate E-1 (2.9 g, 0.010 mol) Yield: 41%). m / z = 373)

(4) (4) 제조예Manufacturing example 4 : 중간체 15-1의 합성 4: Synthesis of intermediate 15-1

Figure pat00124
Figure pat00124

중간체 E-2(3.7 g, 0.010 mol)에 phenyl boronic acid (1.4 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 15-1> 2.7 g (수율 72%)을 얻었다.(m/z=370)
Intermediate 15-1 was synthesized in the same manner as in Example 1 (5), except that phenyl boronic acid (1.4 g, 0.012 mol) was added to Intermediate E-2 (3.7 g, 0.010 mol) Yield: 72%). (M / z = 370)

(5) (5) 제조예Manufacturing example 5 : 화합물 15의 합성 5: Synthesis of compound 15

Figure pat00125
Figure pat00125

중간체 15-1(3.7 g, 0.010 mol)에 중간체 1-1 (6.8 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 15> 5.5 g (수율 71%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (5) to obtain Intermediate 1-1 (6.8 g, 0.012 mol) and Intermediate 15-1 (3.7 g, 0.010 mol) 71%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.87/d, 7.62/s, 7.55/d, 7.48/d, 7.42/d, 7.41/m, 7.38/m, 7.30/d, 7.30/m, 7.28/m, 7.27/m, 7.22/m, 7.18/d, 6.75/s, 6.58/d) 2H(7.52/d, 7.51/m, 7.19/m, 6.95/d) 4H(7.54/d, 6.69/d) 6H(1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.87 / d, 7.62 / s, 7.55 / d, 7.48 / d, 7.42 / d, 7.41 / m, 7.38 / m, 7.30 / d, 7.30 / m D, 7.58 / d, 7.51 / m, 7.19 / m, 6.95 / d) 4H (7.54 / d, 6.69 / d, 7.28 / m, 7.27 / m, 7.22 / / d) 6H (1.72 / s)

LC/MS: m/z=773 [(M+1)+]
LC / MS: m / z = 773 [(M + 1) &lt; + &

실시예Example 16 : 화합물 16 합성 16: Compound 16 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 16-1의 합성 1: Synthesis of intermediate 16-1

Figure pat00126
Figure pat00126

dip-tolylamine(2.0 g, 0.010 mol)에 1,3,5-tribromobenzene(3.1 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 16-1> 4.8 g (수율 87%)을 얻었다.(m/z=547)
(3.1 g, 0.010 mol) was added to dip-tolylamine (2.0 g, 0.010 mol) in the same manner as in Example 2 (1) 16-1> 4.8 g (yield: 87%). (M / z = 547)

(2) (2) 제조예Manufacturing example 2 : 중간체 16-2의 합성 2: Synthesis of intermediate 16-2

Figure pat00127
Figure pat00127

중간체 16-1(5.5 g, 0.010 mol)에 bis(pinacolato)dibron(3.0 g, 0.012 mol) 를 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <중간체 16-2> 4.3g (수율 72%)을 얻었다.(m/z=594)
<Intermediate 16-2> 4.3 (5 g, 0.010 mol) was synthesized in the same manner as in Example 1 (4) except that bis (pinacolato) dibron (3.0 g, 0.012 mol) g (yield: 72%). (m / z = 594)

(3) (3) 제조예Manufacturing example 3 : 화합물 16의 합성 3: Synthesis of Compound 16

Figure pat00128
Figure pat00128

중간체 15-1(3.7 g, 0.010 mol)에 중간체 16-2(7.1 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 16> 5.4g (수율 67%)을 얻었다.(m/z=000)Synthesis was conducted in the same manner as in Example 1 (5) to give Intermediate 16-1 (7.1 g, 0.012 mol) and Intermediate 15-1 (3.7 g, 0.010 mol) 67%). (M / z = 000)

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.48/d, 7.42/d, 7.30/m, 7.30/d, 7.27/m, 7.22/m, 7.18/d, 5.73/s) 2H(7.19/m, 6.95/d, 6.25/s) 4H(2.34/s, 1.72/s) 8H(6.98/d, 6.51/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.48 / d, 7.42 / d, 7.30 / m, 7.30 / d, 7.27 / m, 7.22 / m, 7.18 / d, 5.73 / s) 2H (7.19 d, 6.25 / s) 4H (2.34 / s, 1.72 / s) 8H (6.98 / d, 6.51 / d)

LC/MS: m/z=804 [(M+1)+]
LC / MS: m / z = 804 [(M + 1) &lt; + &

실시예Example 17 : 화합물 17 합성 17: Compound 17 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 F의 합성 1: Synthesis of intermediate F

Figure pat00129
Figure pat00129

3-bromo-1,1-dimethyl-1H-pyrrolo[3,4-c]pyridine(2.3 g, 0.010 mol)에 methyl 2-bromo-6-chlorobenzoate(2.7 g, 0.012 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 F> 1.2 g (수율 37%)을 얻었다.(m/z=314)
Methyl 2-bromo-6-chlorobenzoate (2.7 g, 0.012 mol) was added to 3-bromo-1,1-dimethyl-1H- pyrrolo [ (M / z = 314) (1.2 g, yield 37%) was obtained by the same method as in Preparation Example (2)

(2) (2) 제조예Manufacturing example 2 : 중간체 F-1의 합성 2: Synthesis of intermediate F-1

Figure pat00130
Figure pat00130

중간체 F(3.1 g, 0.010 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 F-1> 1.8 g (수율 58%)을 얻었다.(m/z=314)
(M / z = 314 (M < + &gt;) was obtained by the procedure of Intermediate F (3.1 g, 0.010 mol) )

(3) (3) 제조예Manufacturing example 3 : 중간체 F-2의 합성 3: Synthesis of intermediate F-2

Figure pat00131
Figure pat00131

중간체 F-1(3.1 g, 0.010 mol)를 넣고 실시예 1-제조예 (3)에서 사용된 동일한 방법으로 합성하여 <중간체 F-2> 2.0 g (수율 66%)을 얻었다.(m/z=296)
2.0 g (yield 66%) of Intermediate F-2 was obtained in the same manner as in Example 1 (3), except that Intermediate F-1 (3.1 g, 0.010 mol) = 296)

(4) (4) 제조예Manufacturing example 4 : 중간체 17-1의 합성 4: Synthesis of intermediate 17-1

Figure pat00132
Figure pat00132

2-(4-bromophenyl)-4,6-diphenyl-1,3,5-triazine(3.9 g, 0.010 mol)에 bis(pinacolato)dibron(3.0 g, 0.012 mol)를 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <중간체 17-1> 3.1 g (수율 72%)을 얻었다.(m/z=435)
(Pinacolato) dibron (3.0 g, 0.012 mol) was added to 2- (4-bromophenyl) -4,6-diphenyl-1,3,5-triazine (3.9 g, 0.010 mol) (M / z = 435) was obtained (3.1 g, yield 72%).

(5) (5) 제조예Manufacturing example 5 : 화합물 17의 합성 5: Synthesis of Compound 17

Figure pat00133
Figure pat00133

중간체 F-2(3.0 g, 0.010 mol)에 중간체 17-1(5.2 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 17> 3.9g (수율 69%)을 얻었다.The compound 17-1 (5.2 g, 0.012 mol) was added to Intermediate F-2 (3.0 g, 0.010 mol) and the compound was obtained in the same manner as in Example 1- (5) 69%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.68/d, 7.77/d, 7.71/d, 7.49/d, 7.40/m) 2H(7.85/d, 7.41/m, 7.25/d) 4H(8.28/d, 7.51/m, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.68 / d, 7.77 / d, 7.71 / d, 7.49 / d, 7.40 / m) 2H (7.85 / d, 7.41 / m, 7.25 / d) 4H (8.28 / d, 7.51 / m, 1.72 / s)

LC/MS: m/z=570[(M+1)+]
LC / MS: m / z = 570 [(M + 1) &lt; + &

실시예Example 18 : 화합물 18 합성 18: Compound 18 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 G의 합성 1: Synthesis of intermediate G

Figure pat00134
Figure pat00134

3-bromo-1,1-dimethyl-1H-isoindole(2.2 g, 0.010 mol)에 methyl 2-bromo-6-chlorobenzoate(3.0 g, 0.012 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 G> 1.2 g (수율 37%)을 얻었다.(m/z=313)
(3.0 g, 0.012 mol) was added to 3-bromo-1,1-dimethyl-1H-isoindole (2.2 g, 0.010 mol) and methyl 2-bromo-6-chlorobenzoate Synthesis was conducted in the same manner to obtain 1.2 g (yield 37%) of Intermediate G (m / z = 313)

(2) (2) 제조예Manufacturing example 2 : 중간체 G-1의 합성 2: Synthesis of intermediate G-1

Figure pat00135
Figure pat00135

중간체 G(3.1 g, 0.010 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 G-1> 2.0 g (수율 66%)을 얻었다.(m/z=313)
2.0 g (yield 66%) of Intermediate G-1 was obtained by the same procedure as in Example 1 (2) except that Intermediate G (3.1 g, 0.010 mol) was added. M / z = 313 )

(3) (3) 제조예Manufacturing example 3 : 중간체 G-2의 합성 3: Synthesis of intermediate G-2

Figure pat00136
Figure pat00136

중간체 G-1(3.3 g, 0.010 mol)를 넣고 실시예 1-제조예 (3)에서 사용된 동일한 방법으로 합성하여 <중간체 G-2> 1.8 g (수율 60%)을 얻었다.(m/z=296)
Intermediate G-2 (1.8 g, yield 60%) was obtained by the same method as in Example 1 (3), except that Intermediate G-1 (3.3 g, 0.010 mol) = 296)

(4) (4) 제조예Manufacturing example 4 : 중간체 18-1의 합성 4: Synthesis of Intermediate 18-1

Figure pat00137
Figure pat00137

1,4-dibromo-2,5-dimethylbenzene(2.6 g, 0.010 mol)에 triphenylen-2-ylboronic acid (3.3 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 18-1> 3.0 g (수율 72%)을 얻었다.(m/z=411)
(3.3 g, 0.012 mol) of triphenylen-2-ylboronic acid was added to 1,4-dibromo-2,5-dimethylbenzene (2.6 g, 0.010 mol) in the same manner as in Example 1- 3.0 g (yield: 72%) of Intermediate 18-1 (m / z = 411) was obtained.

(5) (5) 제조예Manufacturing example 5 : 중간체 18-2의 합성 5: Synthesis of intermediate 18-2

Figure pat00138
Figure pat00138

중간체 18-1(4.1 g, 0.010 mol)에 bis(pinacolato)dibron(3.0 g, 0.012 mol) 를 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <중간체 18-2> 3.3 g (수율 72%)을 얻었다.(m/z=458)
Intermediate 18-2 was synthesized as in Intermediate 18-2 (4.1 g, 0.010 mol) by the same procedure as in Example 1 (4) except that bis (pinacolato) dibron (3.0 g, 0.012 mol) g (yield: 72%). (m / z = 458)

(6) (6) 제조예Manufacturing example 6 : 화합물 18의 합성 6: Synthesis of compound 18

Figure pat00139
Figure pat00139

중간체 G-2(3.0 g, 0.010 mol)에 중간체 18-2(5.5 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 18> 4.0 g (수율 67%)을 얻었다.(m/z=000)The compound 18 was synthesized in the same manner as in Example 1 (5), except that Intermediate 18-2 (5.5 g, 0.012 mol) was added to Intermediate G-2 (3.0 g, 0.010 mol) 67%). (M / z = 000)

H-NMR (200MHz, CDCl3):δ ppm, 1H(9.15/s, 8.18/d, 8.04/d, 7.95/d, 7.86/d, 7.57/m, 7.36/m) 2H(8.93/d, 8.12/d, 7.88/m, 7.82/m, 7.73/s, 7.17/d, 2.59/s) 4H(1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (9.15 / s, 8.18 / d, 8.04 / d, 7.95 / d, 7.86 / d, 7.57 / m, 7.36 / m) 2H (8.93 / d, 8.12 (dl / d, 7.88 / m, 7.82 / m, 7.73 / s, 7.17 / d, 2.59 / s)

LC/MS: m/z=592 [(M+1)+]
LC / MS: m / z = 592 [(M + 1) &lt; + &

실시예Example 19 : 화합물 19 합성 19: Compound 19 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 19-1의 합성 1: Synthesis of intermediate 19-1

Figure pat00140
Figure pat00140

9H-carbazol-3-ylboronic acid(2.1 g, 0.010 mol)에 중간체 17-1(3.1 g, 0.008 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 19-1> 3.2 g (수율 72%)을 얻었다.(m/z=442)
Intermediate 19-1 (3.1 g, 0.008 mol) was added to 9-carbazol-3-ylboronic acid (2.1 g, 0.010 mol) in the same manner as in Example 1- 1> 3.2 g (yield: 72%). (M / z = 442)

(2) (2) 제조예Manufacturing example 2 : 화합물 19의 합성 2: Synthesis of Compound 19

Figure pat00141
Figure pat00141

중간체 G-2(3.0 g, 0.010 mol)에 중간체 19-1(5.3 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 19> 4.9 g (수율 75%)을 얻었다.(m/z=000)Synthesis was conducted in the same manner as in Example 1 (5), except that Intermediate 19-1 (5.3 g, 0.012 mol) was added to Intermediate G-2 (3.0 g, 0.010 mol) 75%). (M / z = 000)

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.55/d, 7.95/d, 7.94/d, 7.87/d, 7.86/d, 7.77/d, 7.69/d, 7.57/m, 7.36/m, 7.33/m, 7.25/m) 2H(7.41/m, 7.17/d) 4H(8.28/d, 7.51/m, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.55 / d, 7.95 / d, 7.94 / d, 7.87 / d, 7.86 / d, 7.77 / d, 7.69 / d, 7.57 / m, 7.36 / m , 7.33 / m, 7.25 / m) 2H (7.41 / m, 7.17 / d) 4H (8.28 / d, 7.51 /

LC/MS: m/z=658[(M+1)+]
LC / MS: m / z = 658 [(M + 1) &lt; + &

실시예Example 20 : 화합물 20 합성 20: Compound 20 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 20-1의 합성 1: Synthesis of intermediate 20-1

Figure pat00142
Figure pat00142

2-bromo-2'-nitrobiphenyl(5.0 g, 0.017 mol)에 triphenylphosphine(4.5 g, 0.017 mol)에 1,2-dichlorobenzene 100 mL 넣고 180 ℃에서 24시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20 : MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 중간체 20-1을 4.2 g(수율 83%)수득하였다.(m/z=246)
100 mL of 1,2-dichlorobenzene was added to triphenylphosphine (4.5 g, 0.017 mol) in 2-bromo-2'-nitrobiphenyl (5.0 g, 0.017 mol) and reacted at 180 ° C for 24 hours with stirring. After completion of the reaction, the reaction mixture was cooled, and the product was separated into H 2 O: MC and subjected to column purification (n-hexane: MC) to obtain 4.2 g (m / z = 246)

(2) (2) 제조예Manufacturing example 2 : 중간체 20-2의 합성 2: Synthesis of intermediate 20-2

Figure pat00143
Figure pat00143

중간체 20-1(3.0 g, 0.012 mol)에 무수 THF 30 mL에 녹인 후, -78 ℃에서 n-BuLi(2.5M) 5.9 mL를 천천히 적가하였다. 1시간 동안 유지시킨 후, triisopropyl borate(3.4 g, 0.018 mol)을 첨가한 후, 상온에서 24시간 교반 하였다. 반응 종료 후 1N HCl을 넣고 1시간 교반한 뒤, EA : H2O에 층분리 후 n-Hexane 으로 재결정 하여 <중간체 20-2> 1.8 g (수율 70%)을 얻었다.(m/z=211)
The intermediate 20-1 (3.0 g, 0.012 mol) was dissolved in 30 mL of anhydrous THF, and then 5.9 mL of n-BuLi (2.5 M) was slowly added dropwise at -78 ° C. After maintaining for 1 hour, triisopropyl borate (3.4 g, 0.018 mol) was added and stirred at room temperature for 24 hours. After completion of the reaction, 1N HCl was added and the mixture was stirred for 1 hour. After separation into EA: H 2 O, the product was recrystallized with n-hexane to obtain 1.8 g (yield 70%) of Intermediate 20-2 )

(3) (3) 제조예Manufacturing example 3 : 중간체 20-3의 합성 3: Synthesis of intermediate 20-3

Figure pat00144
Figure pat00144

중간체 20-2(2.1 g, 0.010 mol)에 1,4-dibromobenzene(1.9 g, 0.008 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 20-3> 2.0g (수율 77%)을 얻었다.(m/z=322)
<Intermediate 20-3> 2.0 (0.19 g, 0.008 mol) was synthesized in the same manner as in Example 1 (5) except that 1,4-dibromobenzene (1.9 g, 0.008 mol) was added to Intermediate 20-2 g (yield: 77%). (m / z = 322)

(4) (4) 제조예Manufacturing example 4 : 중간체 20-4의 합성 4: Synthesis of intermediate 20-4

Figure pat00145
Figure pat00145

중간체 20-3(3.2 g, 0.010 mol)에 bis(pinacolato)dibron(3.0 g, 0.012 mol) 를 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <중간체 20-4> 2.9 g (수율 78%)을 얻었다.(m/z=369)
Intermediate 20-4 was synthesized by the same procedure as in Example 1 (4) (2.9 g, 0.012 mol) with bis (pinacolato) dibron (3.0 g, 0.012 mol) g (yield 78%). (m / z = 369)

(5) (5) 제조예Manufacturing example 5 : 중간체 20-5의 합성 5: Synthesis of intermediate 20-5

Figure pat00146
Figure pat00146

중간체 20-4(4.4 g, 0.012 mol)에 2-bromo-4,6-diphenyl-1,3,5-triazine (3.1 g, 0.010 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 20-5> 4.3 g (수율 72%)을 얻었다.(m/z=600)
To the intermediate 20-4 (4.4 g, 0.012 mol) was added 2-bromo-4,6-diphenyl-1,3,5-triazine (3.1 g, 0.010 mol) (M / z = 600) (yield: 72%) was obtained by the same method as Intermediate 20-5 (Intermediate 20-5)

(6) (6) 제조예Manufacturing example 6 : 화합물 20의 합성 6: Synthesis of Compound 20

Figure pat00147
Figure pat00147

중간체 G-2(3.0 g, 0.010 mol)에 중간체 20-5(7.2 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 20> 5.4 g (수율 73%)을 얻었다.The compound 20 was synthesized in the same manner as in Example 1 (5), except that Intermediate 20-5 (7.2 g, 0.012 mol) was added to Intermediate G-2 (3.0 g, 0.010 mol) 73%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.55/d, 7.95/d, 7.94/d, 7.86/d, 7.79/d, 7.59/d, 7.57/m, 7.43/m, 7.36/m, 7.33/m, 7.25/m) 2H(7.41/m, 7.17/d) 4H(8.28/d, 7.51/m, 7.25/d, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.55 / d, 7.95 / d, 7.94 / d, 7.86 / d, 7.79 / d, 7.59 / d, 7.57 / m, 7.43 / m, 7.36 / m , 7.33 / m, 7.25 / m) 2H (7.41 / m, 7.17 / d) 4H (8.28 / d, 7.51 / m, 7.25 / d, 1.72 /

LC/MS: m/z=734[(M+1)+]
LC / MS: m / z = 734 [(M + 1) &lt; + &

실시예Example 21 : 화합물 21 합성 21: Compound 21 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 21-1의 합성 1: Synthesis of intermediate 21-1

Figure pat00148
Figure pat00148

중간체 20-4(3.7 g, 0.010 mol)에 bromobenzene(1.3 g, 0.008 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 21-1> 2.7 g (수율 77%)을 얻었다.(m/z=445)
Intermediate 21-1 (2.7 g, Yield 77%) was synthesized in the same manner as in Example 2 (1) except that bromobenzene (1.3 g, 0.008 mol) was added to Intermediate 20-4 (3.7 g, 0.010 mol) %). (M / z = 445)

(2) (2) 제조예Manufacturing example 2 : 화합물 21의 합성 2: Synthesis of Compound 21

Figure pat00149
Figure pat00149

중간체 G-2(3.1 g, 0.010 mol)에 중간체 21-1(5.3 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 21> 4.3 g (수율 74%)을 얻었다.Intermediate 21-1 (5.3 g, 0.012 mol) was added to Intermediate G-2 (3.1 g, 0.010 mol) and the compound was synthesized in the same manner as in Example 1- 74%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.55/d, 7.95/d, 7.94/d, 7.86/d, 7.79/d, 7.59/d, 7.57/m, 7.45/m, 7.43/m, 7.36/m, 7.33/m, 7.25/m) 2H(7.58/m, 7.50/d, 7.17/d) 4H(7.25/d, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.55 / d, 7.95 / d, 7.94 / d, 7.86 / d, 7.79 / d, 7.59 / d, 7.57 / m, 7.45 / m, 7.43 / m , 7.36 / m, 7.33 / m, 7.25 / m) 2H (7.58 / m, 7.50 / d, 7.17 / d)

LC/MS: m/z=579[(M+1)+]
LC / MS: m / z = 579 [(M + 1) &lt; + &

실시예Example 22 : 화합물 22 합성 22: Compound 22 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 22-1의 합성 1: Synthesis of Intermediate 22-1

Figure pat00150
Figure pat00150

중간체 20-2(2.9 g, 0.010 mol)에 중간체 20-1(2.5 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 22-1> 3.5 g (수율 77%)을 얻었다.(m/z=458)
Intermediate 20-1 (2.5 g, 0.010 mol) was added to Intermediate 20-2 (2.9 g, 0.010 mol) and the same reaction procedure as in Preparation Example (1) (Yield: 77%). (M / z = 458)

(2) (2) 제조예Manufacturing example 2 : 중간체 22-2의 합성 2: Synthesis of Intermediate 22-2

Figure pat00151
Figure pat00151

중간체 22-1(4.6 g, 0.010 mol)에 bromobenzene(1.6 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 22-2> 4.1 g (수율 77%)을 얻었다.(m/z=534)
Intermediate 22-2 (4.1 g, Yield 77%) was obtained by synthesizing bromobenzene (1.6 g, 0.010 mol) in Intermediate 22-1 (4.6 g, 0.010 mol) %). (M / z = 534)

(3) (3) 제조예Manufacturing example 3 : 화합물 22의 합성 3: Synthesis of Compound 22

Figure pat00152
Figure pat00152

중간체 G-2(3.0 g, 0.010 mol)에 중간체 22-2(6.4 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 22> 4.8 g (수율 72%)을 얻었다.The compound 22-2 (6.4 g, 0.012 mol) was added to Intermediate G-2 (3.0 g, 0.010 mol) and the compound was obtained in the same manner as in Example 1- (5) 72%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.95/d, 7.86/d, 7.79/d, 7.63/d, 7.59/d, 7.57/m, 7.45/m, 7.43/m, 7.37/m, 7.36/m, 7.23/d) 2H(8.55/d, 7.94/d, 7.58/m, 7.50/d, 7.33/m, 7.25/m, 7.17/d) 4H(1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.95 / d, 7.86 / d, 7.79 / d, 7.63 / d, 7.59 / d, 7.57 / m, 7.45 / m, 7.43 / m, 7.37 / m D, 7,34 / d, 7.58 / m, 7.50 / d, 7.33 / m, 7.25 / m, 7.17 / d)

LC/MS: m/z=668[(M+1)+]
LC / MS: m / z = 668 [(M + 1) &lt; + &

실시예Example 23 : 화합물 23 합성 23: Compound 23 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 23-1의 합성 1: Synthesis of intermediate 23-1

Figure pat00153
Figure pat00153

3,6-dibromo-9-phenyl-9H-carbazole(4.0 g, 0.010 mol)에 bis(pinacolato) dibron(3.0 g, 0.012 mol)를 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <중간체 23-1> 3.5 g (수율 70%)을 얻었다.(m/z=495)
(Pinacolato) dibron (3.0 g, 0.012 mol) was added to 3,6-dibromo-9-phenyl-9H-carbazole (4.0 g, 0.010 mol) in the same manner as in Example 1- To obtain 3.5 g (yield 70%) of Intermediate 23-1 (m / z = 495)

(2) (2) 제조예Manufacturing example 2 : 화합물 23의 합성 2: Synthesis of Compound 23

Figure pat00154
Figure pat00154

중간체 G-2(3.0 g, 0.010 mol)에 중간체 4-2(5.9 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 23> 5.2 g (수율 68%)을 얻었다.(m/z=000)Synthesis was conducted in the same manner as in Example 1 (5), except that Intermediate 4-2 (5.9 g, 0.012 mol) was added to Intermediate G-2 (3.0 g, 0.010 mol) 68%). (M / z = 000)

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.18/d, 8.00/d, 7.87/d, 7.69/d, 7.45/m) 2H(7.95/d, 7.86/d, 7.77/s, 7.58/m, 7.57/m, 7.50/d, 7.36/m) 4H(7.17/d, 1.72/s, 1.61/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.18 / d, 8.00 / d, 7.87 / d, 7.69 / d, 7.45 / m) 2H (7.95 / d, 7.86 / d, 7.77 / s, 7.58 7.57 / m, 7.50 / d, 7.36 / m) 4H (7.17 / d, 1.72 / s, 1.61 / s)

LC/MS: m/z=762[(M+1)+]
LC / MS: m / z = 762 [(M + 1) &lt; + &

실시예Example 24 : 화합물 24 합성 24: Compound 24 Synthesis

(1) (One) 제조예Manufacturing example 1 : 화합물 24의 합성 1: Synthesis of Compound 24

Figure pat00155
Figure pat00155

중간체 G-2(3.0 g, 0.010 mol)에 4-(dibenzo[b,d]thiophen-4-yl)phenylboronic acid(3.6 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 24> 3.7 g (수율 72%)을 얻었다.To the intermediate G-2 (3.0 g, 0.010 mol) was added 4- (dibenzo [b, d] thiophen-4-yl) phenylboronic acid (3.6 g, 0.012 mol) Synthesis was conducted in the same manner to obtain 3.7 g (yield 72%) of <Compound 24>.

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.45/d, 8.41/d, 8.20/d, 7.98/d, 7.95/d, 7.86/d, 7.58/m, 7.57/m, 7.52/m, 7.50/m, 7.36/m) 2H(7.17/d, 1.72/s, 1.61/s) 4H(7.25/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.45 / d, 8.41 / d, 8.20 / d, 7.98 / d, 7.95 / d, 7.86 / d, 7.58 / m, 7.57 / m, 7.52 / m , 7.50 / m, 7.36 / m) 2H (7.17 / d, 1.72 / s, 1.61 / s)

LC/MS: m/z=520[(M+1)+]
LC / MS: m / z = 520 [(M + 1) &lt; + &

실시예Example 25 : 화합물 25 합성 25: Compound 25 Synthesis

(1) (One) 제조예Manufacturing example 1 : 화합물 25의 합성 1: Synthesis of Compound (25)

Figure pat00156
Figure pat00156

중간체 G-2(3.0 g, 0.010 mol)에 4-(2-phenyl-1H-benzo[d]imidazol-1-yl)phenylboronic acid(3.8 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 25> 3.9 g (수율 74%)을 얻었다.To the intermediate G-2 (3.0 g, 0.010 mol) was added 4- (2-phenyl-1H-benzo [d] imidazol-1-yl) phenylboronic acid (3.8 g, 0.012 mol) ) To obtain 3.9 g (yield 74%) of <Compound 25>.

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.56/d, 7.95/d, 7.86/d, 7.59/d, 7.57/m, 7.41/m, 7.36/m) 2H(8.28/d, 7.79/d, 7.68/d, 7.51/m, 7.22/m, 7.17/d, 1.72/s, 1.61/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.56 / d, 7.95 / d, 7.86 / d, 7.59 / d, 7.57 / m, 7.41 / m, 7.36 / m) 2H (8.28 / d, 7.79 / d, 7.68 / d, 7.51 / m, 7.22 / m, 7.17 / d, 1.72 / s, 1.61 / s)

LC/MS: m/z=530[(M+1)+]
LC / MS: m / z = 530 [(M + 1) &lt; + &

실시예Example 26 : 화합물 26 합성 26: Compound 26 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 26-1의 합성 1: Synthesis of intermediate 26-1

Figure pat00157
Figure pat00157

3-bromo-9H-carbazole(2.5 g, 0.010 mol)에 2-phenyl-1H-benzo[d]imidazole (1.9 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 26-1> 3.0 g (수율 84%)을 얻었다.(m/z=359)
2-phenyl-1H-benzo [d] imidazole (1.9 g, 0.010 mol) was added to 3-bromo-9H-carbazole (2.5 g, 0.010 mol) To obtain 3.0 g (yield 84%) of Intermediate 26-1 (m / z = 359)

(2) (2) 제조예Manufacturing example 2 : 화합물 26의 합성 2: Synthesis of Compound 26

Figure pat00158
Figure pat00158

중간체 G-2(3.0 g, 0.010 mol)에 중간체 26-1(3.6 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <화합물 26> 4.8 g (수율 77%)을 얻었다.Synthesis was conducted in the same manner as in Example 2 (1), except that Intermediate 26-1 (3.6 g, 0.010 mol) was added to Intermediate G-2 (3.0 g, 0.010 mol) 77%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.56/d, 8.55/d, 7.94/d, 7.63/s, 7.59/d, 7.50/d, 7.50/s, 7.41/m, 7.36/m, 7.33/m, 7.31/d, 7.25/m) 2H(8.28/d, 7.51/m, 7.90/d, 7.22/m, 7.17/d, 1.72/s, 1.61/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.56 / d, 8.55 / d, 7.94 / d, 7.63 / s, 7.59 / d, 7.50 / d, 7.50 / s, 7.41 / m, 7.36 / m D, 7.31 / d, 7.25 / m) 2H (8.28 / d, 7.51 / m, 7.90 / d, 7.22 / m, 7.17 / d, 1.72 / s, 1.61 / s)

LC/MS: m/z=619[(M+1)+]
LC / MS: m / z = 619 [(M + 1) &lt; + &

실시예Example 27 : 화합물 27 합성 27: Compound 27 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 27-1의 합성 1: Synthesis of intermediate 27-1

Figure pat00159
Figure pat00159

1,3,5-tribromobenzene(3.1 g, 0.010 mol)에 9H-carbazole(1.7 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 27-1> 4.1g (수율 85%)을 얻었다.(m/z=487)
Synthesis was conducted in the same manner as in Example 2 (1) except that 9H-carbazole (1.7 g, 0.010 mol) was added to 1,3,5-tribromobenzene (3.1 g, 0.010 mol) 27-1> (yield: 85%). (M / z = 487)

(2) (2) 제조예Manufacturing example 2 : 중간체 27-2의 합성 2: Synthesis of intermediate 27-2

Figure pat00160
Figure pat00160

중간체 27-1(4.9 g, 0.010 mol)에 bis(pinacolato)dibron(3.0 g, 0.012 mol)를 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <중간체 27-2> 4.0 g (수율 75%)을 얻었다.(m/z=534)
Intermediate 27-2 was synthesized by the same method as in Example 1 (4) except that bis (pinacolato) dibron (3.0 g, 0.012 mol) was added to Intermediate 27-1 (4.9 g, 0.010 mol) g (yield 75%). (m / z = 534)

(3) (3) 제조예Manufacturing example 3 : 화합물 27의 합성 3: Synthesis of Compound 27

Figure pat00161
Figure pat00161

중간체 G-2(3.0 g, 0.010 mol)에 중간체 27-2(6.4 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 27> 4.8 g (수율 72%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (5) to obtain Intermediate 27-2 (6.4 g, 0.012 mol) and Intermediate 27 (3.0 g, 0.010 mol) 72%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.95/d, 7.86/d, 7.57/m, 7.20/s) 2H(8.55/d, 8.12/d, 8.09/s, 7.94/d, 7.63/d, 7.50/m, 7.33/m, 7.29/m, 7.25/m, 7.17/d, 1.72/s, 1.61/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.95 / d, 7.86 / d, 7.57 / m, 7.20 / s) 2H (8.55 / d, 8.12 / d, 8.09 / s, 7.94 / d, 7.63 7.25 / m, 7.17 / d, 1.72 / s, 1.61 / s)

LC/MS: m/z=668[(M+1)+]
LC / MS: m / z = 668 [(M + 1) &lt; + &

실시예Example 28 : 화합물 28 합성 28: Compound 28 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 28-1의 합성 1: Synthesis of intermediate 28-1

Figure pat00162
Figure pat00162

중간체 20-4(3.7 g, 0.010 mol)에 4-bromodibenzo[b,d]thiophene(2.1 g, 0.008 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 28-1> 2.4 g (수율 72%)을 얻었다.(m/z=425)
Synthesis was carried out in the same manner as in Example 1 (5), except that 4-bromodibenzo [b, d] thiophene (2.1 g, 0.008 mol) was added to Intermediate 20-4 (3.7 g, 0.010 mol) -1> 2.4 g (yield 72%). (M / z = 425)

(2) (2) 제조예Manufacturing example 2 : 화합물 28의 합성 2: Synthesis of compound 28

Figure pat00163
Figure pat00163

중간체 G-2(3.0 g, 0.010 mol)에 중간체 28-1(4.3 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <화합물 28> 5.3 g (수율 77%)을 얻었다.Synthesis was conducted in the same manner as in Example 2 (1), except that Intermediate 28-1 (4.3 g, 0.010 mol) was added to Intermediate G-2 (3.0 g, 0.010 mol) 77%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.55/d, 8.45/d, 8.41/d, 8.20/d, 7.98/d, 7.94/d, 7.79/d, 7.59/d, 7.58/m, 7.52/m, 7.50/m, 7.50/d, 7.43/m, 7.33/m, 7.25/m) 2H(7.90/d, 7.17/d, 1.72/s, 1.61/s) 4H(7.25/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.55 / d, 8.45 / d, 8.41 / d, 8.20 / d, 7.98 / d, 7.94 / d, 7.79 / d, 7.59 / d, 7.58 / m D, 7.17 / d, 1.72 / s, 1.61 / s), 4H (7.25 / d), 7.52 / m, 7.50 / d, 7.50 / d, 7.43 / m, 7.33 /

LC/MS: m/z=685[(M+1)+]
LC / MS: m / z = 685 [(M + 1) &lt; + &

실시예Example 29 : 화합물 29 합성 29: Compound 29 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 29-1의 합성 1: Synthesis of intermediate 29-1

Figure pat00164
Figure pat00164

9-(4-bromophenyl)-9H-carbazole(3.2 g, 0.010 mol)에 9H-carbazol-2-ylboronic acid(2.5 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 29-1> 2.9 g (수율 72%)을 얻었다.(m/z=408)
2-ylboronic acid (2.5 g, 0.012 mol) was added to 9- (4-bromophenyl) -9H-carbazole (3.2 g, 0.010 mol) in the same manner as in Example 1- To obtain 2.9 g (yield 72%) of Intermediate 29-1 (m / z = 408)

(2) (2) 제조예Manufacturing example 2 : 화합물 29의 합성 2: Synthesis of Compound 29

Figure pat00165
Figure pat00165

중간체 G-2(3.0 g, 0.010 mol)에 중간체 29-1(4.1 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <화합물 29> 5.5 g (수율 82%)을 얻었다.The compound 29 was synthesized in the same manner as in Example 2 (1) except that Intermediate 29-1 (4.1 g, 0.010 mol) was added to Intermediate G-2 (3.0 g, 0.010 mol) 82%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.91/m) 2H(8.55/d, 8.12/d, 7.94/d, 7.63/d, 7.50/m, 7.33/m, 7.29/m, 7.25/m, 7.17/d, 1.72/s, 1.61/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.91 / m) 2H (8.55 / d, 8.12 / d, 7.94 / d, 7.63 / d, 7.50 / m, 7.33 / m, 7.29 / m, 7.25 / m, 7.17 / d, 1.72 / s, 1.61 / s)

LC/MS: m/z=668[(M+1)+]
LC / MS: m / z = 668 [(M + 1) &lt; + &

실시예Example 30 : 화합물 30 합성 30: Compound 30 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 30-1의 합성 1: Synthesis of intermediate 30-1

Figure pat00166
Figure pat00166

4,6-dibromo-2,5-dichloropyrimidine(3.1 g, 0.010 mol)에 phenyl boronic acid(1.4 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 30-1> 2.2 g (수율 72%)을 얻었다.(m/z=301)
Phenylboronic acid (1.4 g, 0.012 mol) was added to 4,6-dibromo-2,5-dichloropyrimidine (3.1 g, 0.010 mol) and the title compound was synthesized in the same manner as in Example 1- 30-1> 2.2 g (yield 72%). (M / z = 301)

(2) (2) 제조예Manufacturing example 2 : 중간체 30-2의 합성 2: Synthesis of intermediate 30-2

Figure pat00167
Figure pat00167

중간체 30-1(3.0 g, 0.010 mol)에 4,6-diphenyl-1,3,5-triazin-2-ylboronic acid(3.3 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 30-2> 3.6 g (수율 72%)을 얻었다.(m/z=498)
(3.3 g, 0.012 mol) of 4,6-diphenyl-1,3,5-triazin-2-ylboronic acid was added to Intermediate 30-1 (3.0 g, 0.010 mol) (M / z = 498) (3.6 g, yield: 72%). &Lt;

(3) (3) 제조예Manufacturing example 3 : 중간체 30-3의 합성 3: Synthesis of intermediate 30-3

Figure pat00168
Figure pat00168

중간체 30-2(5.0 g, 0.010 mol)에 bis(pinacolato)dibron(3.0 g, 0.012 mol)를 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <중간체 30-3> 4.2 g (수율 72%)을 얻었다.(m/z=589)
<Intermediate 30-3> 4.2 (0.2 g, 0.012 mol) was added to the intermediate 30-2 (5.0 g, 0.010 mol) and bis (pinacolato) dibron g (yield: 72%). (m / z = 589)

(4) (4) 제조예Manufacturing example 4 : 화합물 30의 합성 4: Synthesis of compound 30

Figure pat00169
Figure pat00169

중간체 G-2(3.0 g, 0.010 mol)에 중간체 30-3(7.1 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 30> 4.5 g (수율 62%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (5) to give Intermediate 30-3 (7.1 g, 0.012 mol) and Intermediate G-2 (3.0 g, 0.010 mol) 62%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.95/d, 7.86/d, 7.57/m, 7.36/m) 2H(7.17/d, 1.72/s, 1.61/s) 4H(8.28/d, 7.79/d, 7.41/m) 8H(7.51/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.95 / d, 7.86 / d, 7.57 / m, 7.36 / m) 2H (7.17 / d, 1.72 / s, 1.61 / s) 4H (8.28 / d , 7.79 / d, 7.41 / m) 8H (7.51 / m)

LC/MS: m/z=723[(M+1)+]
LC / MS: m / z = 723 [(M + 1) &lt; + &

실시예Example 31 : 화합물 31 합성 31: Compound 31 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 31-1의 합성 1: Synthesis of intermediate 31-1

Figure pat00170
Figure pat00170

2-(4-bromophenyl)-1H-benzo[d]imidazole(2.7 g, 0.010 mol)에 1,4-dibromobenzene(2.4 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 31-1> 3.3g (수율 77%)을 얻었다.(m/z=428)
The procedure of Example 2 was repeated except that 1,4-dibromobenzene (2.4 g, 0.010 mol) was added to 2- (4-bromophenyl) -1H-benzo [d] imidazole (2.7 g, 0.010 mol) (M / z = 428) of Intermediate 31-1 (yield: 77%).

(2) (2) 제조예Manufacturing example 2 : 중간체 31-2의 합성 2: Synthesis of intermediate 31-2

Figure pat00171
Figure pat00171

중간체 31-1(4.3 g, 0.010 mol)에 bis(pinacolato)dibron(3.0 g, 0.012 mol)를 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <중간체 31-2> 3.8 g (수율 72%)을 얻었다.(m/z=522)
<Intermediate 31-2> 3.8 (0.1 g, 0.012 mol) was synthesized in the same manner as in Example 1 (4) except that bis (pinacolato) dibron (3.0 g, 0.012 mol) was added to Intermediate 31-1 g (yield: 72%). (m / z = 522)

(3) (3) 제조예Manufacturing example 3 : 화합물 31의 합성 3: Synthesis of Compound 31

Figure pat00172
Figure pat00172

중간체 G-2(3.0 g, 0.010 mol)에 중간체 31-2(6.3 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 31> 5.2 g (수율 66%)을 얻었다.The compound 31 was synthesized in the same manner as in Example 1 (5), except that Intermediate 31-2 (6.3 g, 0.012 mol) was added to Intermediate G-2 (3.0 g, 0.010 mol) 66%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.56/d, 7.59/d) 2H(7.95/d, 7.86/d, 7.85/d, 7.79/d, 7.68/d, 7.57/m, 7.36/m, 7.25/d, 7.22/m) 4H(7.17/d, 1.72/s, 1.61/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.56 / d, 7.59 / d) 2H (7.95 / d, 7.86 / d, 7.85 / d, 7.79 / d, 7.68 / d, 7.57 / m, 7.36 / m, 7.25 / d, 7.22 / m) 4H (7.17 / d, 1.72 / s, 1.61 / s)

LC/MS: m/z=790[(M+1)+]
LC / MS: m / z = 790 [(M + 1) &lt; + &

실시예Example 32 : 화합물 32 합성 32: Compound 32 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 H의 합성 1: Synthesis of Intermediate H

Figure pat00173
Figure pat00173

3-bromo-1,1-dimethyl-1H-isoindole(2.2 g, 0.010 mol)에 methyl 4-bromo-2-chloronicotinate(3.0 g, 0.012 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 H> 1.2 g (수율 39%)을 얻었다.(m/z=314)
To a solution of methyl 4-bromo-2-chloronicotinate (3.0 g, 0.012 mol) in 3-bromo-1,1-dimethyl-1H-isoindole (2.2 g, 0.010 mol) (M / z = 314) (Intermediate H) (1.2 g, yield 39%).

(2) (2) 제조예Manufacturing example 2 : 중간체 H-1의 합성 2: Synthesis of Intermediate H-1

Figure pat00174
Figure pat00174

중간체 H(3.1 g, 0.010 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 H-1> 1.6 g (수율 51%)을 얻었다.(m/z=314)
Intermediate H-1 (1.6 g, yield 51%) was obtained by the same method as in Example 1- (2), except that Intermediate H (3.1 g, 0.010 mol) was added. M / z = 314 )

(3) (3) 제조예Manufacturing example 3 : 중간체 H-2의 합성 3: Synthesis of intermediate H-2

Figure pat00175
Figure pat00175

중간체 H-1(3.1 g, 0.010 mol)를 넣고 실시예 1-제조예 (3)에서 사용된 동일한 방법으로 합성하여 <중간체 H-2> 1.5 g (수율 52%)을 얻었다.(m/z=296)
Intermediate H-2 (1.5 g, yield 52%) was obtained by the same method as in Example 1 (3), except that Intermediate H-1 (3.1 g, 0.010 mol) = 296)

(4) (4) 제조예Manufacturing example 4 : 화합물 32의 합성 4: Synthesis of Compound 32

Figure pat00176
Figure pat00176

중간체 H-2(3.0 g, 0.010 mol)에 중간체 17-1(5.2 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 32> 3.7 g (수율 65%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (5), except that Intermediate 17-1 (5.2 g, 0.012 mol) was added to Intermediate H-2 (3.0 g, 0.010 mol) 65%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.60/d, 7.36/m, 7.21/d) 2H(8.81/d, 7.88/d, 7.41/m, 7.17/d, 1.72/s, 1.30/s) 4H(8.28/d, 7.51/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.60 / d, 7.36 / m, 7.21 / d) 2H (8.81 / d, 7.88 / d, 7.41 / m, 7.17 / d, 1.72 / s, 1.30 / s) 4H (8.28 / d, 7.51 / m)

LC/MS: m/z=570[(M+1)+]
LC / MS: m / z = 570 [(M + 1) &lt; + &

실시예Example 33 : 화합물 33 합성 33: Compound 33 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 I의 합성 1: Synthesis of intermediate I

Figure pat00177
Figure pat00177

3-methoxyisobenzofuran-1(3H)-one(1.6 g, 0.010 mol)에 (2-tert-butyl-3-chlorophenyl)magnesium bromide(3.2 g, 0.012 mol)를 넣고 실시예 14-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 I> 1.1 g (수율 40%)을 얻었다.(m/z=280)
(2-tert-butyl-3-chlorophenyl) magnesium bromide (3.2 g, 0.012 mol) was added to 3-methoxyisobenzofuran-1 (3H) (M / z = 280) (Intermediate I) (1.1 g, yield 40%).

(2) (2) 제조예Manufacturing example 2 : 중간체 I-1의 합성 2: Synthesis of Intermediate I-1

Figure pat00178
Figure pat00178

중간체 I(2.8 g, 0.010 mol)를 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 I-1> 1.9 g (수율 63%)을 얻었다.(m/z=294)
Intermediate I (2.8 g, 0.010 mol) was synthesized in the same manner as in Example 1- (5) to give 1.9 g (63% yield) of Intermediate I-1 (m / z = 294)

(3) (3) 제조예Manufacturing example 3 : 중간체 I-2의 합성 3: Synthesis of intermediate I-2

Figure pat00179
Figure pat00179

중간체 I-1(2.9 g, 0.010 mol)에 N-bromosuccinimide(1.8 g, 0.010 mol)를 넣고 실시예 14-제조예 (3)에서 사용된 동일한 방법으로 합성하여 <중간체 I-2> 1.3 g (수율 34%)수득하였다.(m/z=373)
Intermediate I-2 was synthesized in the same manner as in Example 14- (3) except that N-bromosuccinimide (1.8 g, 0.010 mol) was added to Intermediate I-1 (2.9 g, 0.010 mol) Yield: 34%). (M / z = 373)

(4) (4) 제조예Manufacturing example 4 : 중간체 33-1의 합성 4: Synthesis of intermediate 33-1

Figure pat00180
Figure pat00180

중간체 I-2(3.7 g, 0.010 mol)에 phenyl boronic acid (1.4 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 33-1> 2.2 g (수율 72%)을 얻었다.(m/z=370)
Intermediate 33-1 was prepared by the same method as in Example 1 (5), except that phenyl boronic acid (1.4 g, 0.012 mol) was added to Intermediate I-2 (3.7 g, 0.010 mol) Yield: 72%). (M / z = 370)

(5) (5) 제조예Manufacturing example 5 : 화합물 33의 합성 5: Synthesis of Compound 33

Figure pat00181
Figure pat00181

중간체 33-1(3.7 g, 0.010 mol)에 중간체 19-1(5.3 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 33> 4.8 g (수율 66%)을 얻었다.Intermediate 19-1 (5.3 g, 0.012 mol) was added to Intermediate 33-1 (3.7 g, 0.010 mol) and the compound was synthesized by the same method as in Example 1 (5) to give 4.8 g 66%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.55/d, 7.94/d, 7.87/d, 7.77/s, 7.69/d, 7.56/d, 7.38/d, 7.36/m, 7.30/m, 7.25/m) 2H(7.41/m, 7.33/m, 7.19/m, 7.12/d, 6.95/d, 1.72/s, 1.69/s) 4H(8.28/d, 7.51/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.55 / d, 7.94 / d, 7.87 / d, 7.77 / s, 7.69 / d, 7.56 / d, 7.38 / d, 7.36 / m, 7.30 / m , 7.25 / m) 2H (7.41 / m, 7.33 / m, 7.19 / m, 7.12 / d, 6.95 / d, 1.72 / s, 1.69 / s)

LC/MS: m/z=733[(M+1)+]
LC / MS: m / z = 733 [(M + 1) &lt; + &

실시예Example 34 : 화합물 34 합성 34: Compound 34 Synthesis

(1) (One) 제조예Manufacturing example 1 : 화합물 34의 합성 1: Synthesis of Compound 34

Figure pat00182
Figure pat00182

중간체 33-1(3.7 g, 0.010 mol)에 중간체 27-2(6.4 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 34> 5.2 g (수율 70%)을 얻었다.The compound 27-2 (6.4 g, 0.012 mol) was added to Intermediate 33-1 (3.7 g, 0.010 mol) and the compound was synthesized in the same manner as in Example 1 (5) 70%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.56/d, 7.38/d, 7.36/m, 7.34/m, 7.31/m, 7.20/s) 2H(8.55/d, 8.12/d, 8.09/s, 7.94/d, 7.63/d, 7.50/m, 7.33/m, 7.30/m, 7.29/m, 7.19/m, 7.12/d, 6.95/d, 1.72/s, 1.69/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.56 / d, 7.38 / d, 7.36 / m, 7.34 / m, 7.31 / m, 7.20 / s) 2H (8.55 / d, 8.12 / d, 8.09 7.9 / d, 7.63 / d, 7.50 / m, 7.33 / m, 7.30 / m, 7.29 / m, 7.19 / m, 7.12 / d, 6.95 / d, 1.72 / s,

LC/MS: m/z=743[(M+1)+]
LC / MS: m / z = 743 [(M + 1) &lt; + &

실시예Example 35 : 화합물 35 합성 35: Compound 35 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 35-1의 합성 1: Synthesis of intermediate 35-1

Figure pat00183
Figure pat00183

9H-carbazol-3-ylboronic acid(2.1 g, 0.010 mol)에 1,4-dibromobenzene(1.9 g, 0.008 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 35-1> 1.8 g (수율 71%)을 얻었다.(m/z=322)
Dibromobenzene (1.9 g, 0.008 mol) was added to 9-carbazol-3-ylboronic acid (2.1 g, 0.010 mol) -1> 1.8 g (yield: 71%). (M / z = 322)

(2) (2) 제조예Manufacturing example 2 : 중간체 35-2의 합성 2: Synthesis of intermediate 35-2

Figure pat00184
Figure pat00184

중간체 35-1(3.2 g, 0.010 mol)에 9,9-dimethyl-9H-fluoren-2-ylboronic acid(2.9 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 35-2> 3.1 g (수율 72%)을 얻었다.(m/z=435)
To the intermediate 35-1 (3.2 g, 0.010 mol) was added 9,9-dimethyl-9H-fluoren-2-ylboronic acid (2.9 g, 0.012 mol) To obtain 3.1 g (yield 72%) of Intermediate 35-2 (m / z = 435)

(3) (3) 제조예Manufacturing example 3 : 화합물 35의 합성 3: Synthesis of Compound 35

Figure pat00185
Figure pat00185

중간체 33-1(3.7 g, 0.010 mol)에 중간체 35-2(4.4 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <화합물 35> 6.0 g (수율 78%)을 얻었다.Synthesis was conducted in the same manner as in Example 2 (1) except that Intermediate 35-2 (4.4 g, 0.010 mol) was added to Intermediate 33-1 (3.7 g, 0.010 mol) 78%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.55/d, 7.94/d, 7.93/d, 7.69/d, 7.66/m, 7.63/d, 7.55/d, 7.42/d, 7.38/m, 7.36/m, 7.33/m, 7.30/m, 7.28/m, 7.25/m, 7.11/d) 2H(7.87/d, 7.77/s, 7.19/m, 7.12/d, 6.95/d, 1.69/s) 4H(7.25/d, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.55 / d, 7.94 / d, 7.93 / d, 7.69 / d, 7.66 / m, 7.63 / d, 7.55 / d, 7.42 / d, 7.38 / m , 7.36 / m, 7.33 / m, 7.30 / m, 7.28 / m, 7.25 / m, 7.11 / d) 2H (7.87 d, 7.77 s, 7.19 m, 7.12 d, 6.95 d, ) 4H (7.25 / d, 1.72 / s)

LC/MS: m/z=771[(M+1)+]
LC / MS: m / z = 771 [(M + 1) &lt; + &

실시예Example 36 : 화합물 36 합성 36: Compound 36 Synthesis

(1) (One) 제조예Manufacturing example 1 : 화합물 36의 합성 1: Synthesis of Compound 36

Figure pat00186
Figure pat00186

중간체 33-1(3.7 g, 0.010 mol)에 중간체 30-3 (6.4 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 36> 5.3 g (수율 67%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (5), except that Intermediate 30-3 (6.4 g, 0.012 mol) was added to Intermediate 33-1 (3.7 g, 0.010 mol) 67%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.56/d, 7.38/d, 7.36/m, 7.33/m, 7.30/m) 2H(7.19/m, 7.12/d, 6.95/d, 1.72/s, 1.69/s) 4H(8.28/d, 7.79/d, 7.41/m) 8H(7.51/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.56 / d, 7.38 / d, 7.36 / m, 7.33 / m, 7.30 / m) 2H (7.19 / m, 7.12 / d, 6.95 / d, 1.72 / s, 1.69 / s) 4H (8.28 / d, 7.79 / d, 7.41 / m) 8H (7.51 /

LC/MS: m/z=798[(M+1)+]
LC / MS: m / z = 798 [(M + 1) &lt; + &

실시예Example 37 : 화합물 37 합성 37: Compound 37 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 37-1의 합성 1: Synthesis of intermediate 37-1

Figure pat00187
Figure pat00187

2-bromo-3,10-dihydroimidazo[4,5-a]carbazole(2.9 g, 0.010 mol)에 bromobenzene(1.6 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 37-1> 2.8 g (수율 77%)을 얻었다.(m/z=362)
(1.6 g, 0.010 mol) was added to 2-bromo-3,10-dihydroimidazo [4,5-a] carbazole (2.9 g, 0.010 mol) in the same manner as in Example 2- To obtain 2.8 g (yield: 77%) of Intermediate 37-1 (m / z = 362)

(2) (2) 제조예Manufacturing example 2 : 중간체 37-2의 합성 2: Synthesis of intermediate 37-2

Figure pat00188
Figure pat00188

중간체 37-1(3.6 g, 0.010 mol)에 phenyl boronic acid(1.4 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 37-2> 2.6 g (수율 72%)을 얻었다.(m/z=359)
2.6 g (Intermediate 37-2) was synthesized in the same manner as in Example 1 (5) except that phenyl boronic acid (1.4 g, 0.012 mol) was added to Intermediate 37-1 (3.6 g, 0.010 mol) Yield: 72%). (M / z = 359)

(3) (3) 제조예Manufacturing example 3 : 중간체 37-3의 합성 3: Synthesis of intermediate 37-3

Figure pat00189
Figure pat00189

중간체 37-2(3.6 g, 0.010 mol)에 1,4-dibromobenzene(2.4 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 37-3> 4.1 g (수율 80%)을 얻었다.(m/z=514)
Intermediate 37-3> 4.1 (4-fluorobenzene) was synthesized in the same manner as in Example 2 (1) except that 1,4-dibromobenzene (2.4 g, 0.010 mol) g (yield: 80%). (m / z = 514)

(4) (4) 제조예Manufacturing example 4 : 중간체 37-4의 합성 4: Synthesis of intermediate 37-4

Figure pat00190
Figure pat00190

중간체 37-3(5.1 g, 0.010 mol)에 bis(pinacolato)dibron(3.0 g, 0.012 mol) 를 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <중간체 37-4> 4.0 g (수율 72%)을 얻었다.(m/z=561)
Intermediate 37-4 was synthesized in the same manner as in Example 1 (4) except that bis (pinacolato) dibron (3.0 g, 0.012 mol) was added to Intermediate 37-3 (5.1 g, 0.010 mol) g (yield: 72%). (m / z = 561)

(5) (5) 제조예Manufacturing example 5 : 화합물 37의 합성 5: Synthesis of Compound 37

Figure pat00191
Figure pat00191

중간체 33-1(3.7 g, 0.010 mol)에 중간체 37-4(6.7 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 37> 5.0 g (수율 65%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (5), except that Intermediate 37-4 (6.7 g, 0.012 mol) was added to Intermediate 33-1 (3.7 g, 0.010 mol) 65%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.55/d, 8.22/d, 7.94/d, 7.85/d, 7.58/m, 7.56/d, 7.45/m, 7.41/m, 7.38/d, 7.36/m, 7.30/m, 7.25/m) 2H(8.28/d, 7.79/d, 7.68/d, 7.51/m, 7.50/d, 7.33/m, 7.12/d, 6.95/d, 1.72/s, 1.69/s) 3H(7.19/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.55 / d, 8.22 / d, 7.94 / d, 7.85 / d, 7.58 / m, 7.56 / d, 7.45 / m, 7.41 / m, 7.38 / d D, 7.75 / d, 7.50 / d, 7.33 / m, 7.12 / d, 6.95 / d, 1.72 / , 1.69 / s) 3H (7.19 / m)

LC/MS: m/z=770[(M+1)+]
LC / MS: m / z = 770 [(M + 1) &lt; + &

실시예Example 38 : 화합물 38 합성 38: Compound 38 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 38-1의 합성 1: Synthesis of Intermediate 38-1

Figure pat00192
Figure pat00192

5-bromo-2-phenyl-1H-benzo[d]imidazole(2.7 g, 0.010 mol)에 2-(4-bromophenyl)triphenylene(3.8 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 38-1> 4.7 g (수율 81%)을 얻었다.(m/z=575)
2- (4-bromophenyl) triphenylene (3.8 g, 0.010 mol) was added to 5-bromo-2-phenyl-1H-benzo [d] imidazole (2.7 g, 0.010 mol) (M / z = 575) (yield: 81%) was obtained by the same method as in the synthesis of Intermediate 38-1 (Intermediate 38-1)

(2) (2) 제조예Manufacturing example 2 : 중간체 38-2의 합성 2: Synthesis of Intermediate 38-2

Figure pat00193
Figure pat00193

중간체 38-1(5.8 g, 0.010 mol)에 bis(pinacolato)dibron(3.0 g, 0.012 mol) 를 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <중간체 38-2> 4.5 g (수율 72%)을 얻었다.(m/z=622)
Intermediate 38-2 &gt; 4.5 (4.5 g, 0.010 mol) was synthesized in the same manner as in Example 1- (4) except that bis (pinacolato) dibron (3.0 g, 0.012 mol) g (yield: 72%). (m / z = 622)

(3) (3) 제조예Manufacturing example 3 : 화합물 38의 합성 3: Synthesis of Compound 38

Figure pat00194
Figure pat00194

중간체 33-1(3.7 g, 0.010 mol)에 중간체 38-2(7.5 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 38> 6.0 g (수율 72%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (5), except that Intermediate 38-1 (7.5 g, 0.012 mol) was added to Intermediate 33-1 (3.7 g, 0.010 mol) 72%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(9.15/s, 8.18/d, 8.07/d, 8.04/d, 7.92/s, 7.56/d, 7.41/m, 7.38/d, 7.36/m, 7.33/m, 7.30/m) 2H(8.93/d, 8.12/d, 7.88/m, 7.82/m, 7.79/d, 7.68/d, 7.51/m, 7.19/m, 7.12/d, 6.95/d, 1.72/s, 1.69/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (9.15 / s, 8.18 / d, 8.07 / d, 8.04 / d, 7.92 / s, 7.56 / d, 7.41 / m, 7.38 / d, 7.36 / m M, 7,30 / m, 7,12 / d, 8,12 / d, 7.88 / m, 7.82 / , 1.72 / s, 1.69 / s)

LC/MS: m/z=832[(M+1)+]
LC / MS: m / z = 832 [(M + 1) &lt; + &

실시예Example 39 : 화합물 39 합성 39: Compound 39 Synthesis

(1) (One) 제조예Manufacturing example 1 : 화합물 39의 합성 1: Synthesis of Compound 39

Figure pat00195
Figure pat00195

중간체 33-1(3.7 g, 0.010 mol)에 중간체 20-5(7.2 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 39> 5.0 g (수율 62%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (5), except that Intermediate 20-5 (7.2 g, 0.012 mol) was added to Intermediate 33-1 (3.7 g, 0.010 mol) 62%).

H-NMR (200MHz, CDCl3):δ ppm, 1h(8.55/d, 7.94/d, 7.79/d, 7.59/d, 7.56/d, 7.43/m, 7.38/d, 7.36/m, 7.30/m, 7.25/m) 2H(7.41/m, 7.33/m, 7.19/m, 7.12/d, 6.95/d, 1.72/s, 1.69/s) 4H(8.28/d, 7.51/m, 7.25/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1h (8.55 / d, 7.94 / d, 7.79 / d, 7.59 / d, 7.56 / d, 7.43 / m, 7.38 / d, 7.36 / m, 7.30 / m , 7.25 / m) 2H (7.41 / m, 7.33 / m, 7.19 / m, 7.12 / d, 6.95 / d, 1.72 / s,

LC/MS: m/z=810[(M+1)+]
LC / MS: m / z = 810 [(M + 1) &lt; + &

실시예Example 40 : 화합물 40 합성 40: Compound 40 Synthesis

(1) (One) 제조예Manufacturing example 1 : 화합물 40의 합성 1: Synthesis of Compound 40

Figure pat00196
Figure pat00196

중간체 33-1(3.7 g, 0.010 mol)에 중간체 28-1(4.3 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <화합물 40> 6.1 g (수율 80%)을 얻었다.Synthesis was conducted in the same manner as in Example 2 (1), except that Intermediate 28-1 (4.3 g, 0.010 mol) was added to Intermediate 33-1 (3.7 g, 0.010 mol) 80%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.55/d, 8.45/d, 8.41/d, 8.20/d, 7.98/d, 7.94/d, 7.79/d, 7.66/m, 7.59/d, 7.58/m, 7.52/m, 7.50/m, 7.43/m, 7.42/d, 7.36/m, 7.33/m, 7.30/m, 7.25/m, 7.11/d) 2H(7.19/m, 7.12/d, 6.95/d, 1.72/s, 1.69/s) 4H(7.25/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.55 / d, 8.45 / d, 8.41 / d, 8.20 / d, 7.98 / d, 7.94 / d, 7.79 / d, 7.66 / m, 7.59 / d M, 7,12 / m, 7.52 / m, 7.50 / m, 7.43 / m, 7.42 / d, 7.36 / m, 7.33 / , 6.95 / d, 1.72 / s, 1.69 / s) 4H (7.25 / d)

LC/MS: m/z=761[(M+1)+]
LC / MS: m / z = 761 [(M + 1) &lt; + &

실시예Example 41 : 화합물 41 합성 41: Compound 41 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 41-1의 합성 1: Synthesis of Intermediate 41-1

Figure pat00197
Figure pat00197

중간체 20-2(2.1 g, 0.010 mol)에 중간체 20-1(2.0 g, 0.008 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 41-1> 2.4 g (수율 72%)을 얻었다.(m/z=332)
Intermediate 20-1 (2.0 g, 0.008 mol) was added to Intermediate 20-2 (2.1 g, 0.010 mol), and 2.4 g of Intermediate 41-1 was synthesized in the same manner as in Example 1- (Yield: 72%). (M / z = 332)

(2) (2) 제조예Manufacturing example 2 : 중간체 41-2의 합성 2: Synthesis of intermediate 41-2

Figure pat00198
Figure pat00198

중간체 41-1(3.3 g, 0.010 mol)에 bromobenzene(1.6 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 41-2> 3.4 g (수율 83%)을 얻었다.(m/z=408)
Intermediate 41-2 (3.4 g, Yield 83%) was synthesized in the same manner as in Example 2 (1) except that bromobenzene (1.6 g, 0.010 mol) was added to Intermediate 41-1 (3.3 g, 0.010 mol) %). (M / z = 408)

(3) (3) 제조예Manufacturing example 3 : 화합물 41의 합성 3: Synthesis of Compound 41

Figure pat00199
Figure pat00199

중간체 33-1(3.7 g, 0.010 mol)에 중간체 41-2(4.1 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <화합물 41> 5.7 g (수율 77%)을 얻었다.Synthesis was conducted in the same manner as in Example 2 (1) except that Intermediate 41-2 (4.1 g, 0.010 mol) was added to Intermediate 33-1 (3.7 g, 0.010 mol) 77%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.55/d, 8.12/d, 8.10/d, 7.94/d, 7.90/d, 7.79/d, 7.66/m, 7.63/d, 7.59/d, 7.50/m, 7.45/m, 7.43/m, 7.42/d, 7.39/m, 7.36/m, 7.33/m, 7.30/m, 7.29/m, 7.25/m, 7.11/d) 2H(7.58/m, 7.50/d, 7.19/m, 7.12/d, 6.95/d, 1.72/s, 1.69/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.55 / d, 8.12 / d, 8.10 / d, 7.94 / d, 7.90 / d, 7.79 / d, 7.66 / m, 7.63 / d, 7.59 / d M, 7.46 / m, 7.42 / d, 7.39 / m, 7.36 / m, 7.33 / m, 7.30 / m, 7.29 / m, 7.25 / m, , 7.50 / d, 7.19 / m, 7.12 / d, 6.95 / d, 1.72 / s, 1.69 / s)

LC/MS: m/z=743[(M+1)+]
LC / MS: m / z = 743 [(M + 1) &lt; + &

실시예Example 42 : 화합물 42 합성 42: Compound 42 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 J의 합성 1: Synthesis of intermediate J

Figure pat00200
Figure pat00200

3-bromo-1,1-dimethyl-1H-isoindole(2.2 g, 0.010 mol)에 methyl 4-bromo-2-chloronicotinate(3.0 g, 0.012 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 J> 1.3 g (수율 40%)을 얻었다.(m/z=314)
To a solution of methyl 4-bromo-2-chloronicotinate (3.0 g, 0.012 mol) in 3-bromo-1,1-dimethyl-1H-isoindole (2.2 g, 0.010 mol) (M / z = 314) (Intermediate J) (1.3 g, yield 40%).

(2) (2) 제조예Manufacturing example 2 : 중간체 J-1의 합성 2: Synthesis of intermediate J-1

Figure pat00201
Figure pat00201

중간체 J(3.1 g, 0.010 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 J-1> 2.1 g (수율 66%)을 얻었다.(m/z=314)
2.1 g (yield 66%) of Intermediate J-1 was obtained in the same manner as in Example 1 (2) except that Intermediate J (3.1 g, 0.010 mol) was added. M / z = 314 )

(3) (3) 제조예Manufacturing example 3 : 중간체 J-2의 합성 3: Synthesis of intermediate J-2

Figure pat00202
Figure pat00202

중간체 J-1(3.1 g, 0.010 mol)를 넣고 실시예 1-제조예 (3)에서 사용된 동일한 방법으로 합성하여 <중간체 J-2> 2.0 g (수율 66%)을 얻었다.(m/z=297)
2.0 g (yield 66%) of <Intermediate J-2> was obtained by the same method as employed in the preparation example (3) of Example 1, with the intermediate J-1 (3.1 g, 0.010 mol) = 297)

(4) (4) 제조예Manufacturing example 4 : 화합물 42의 합성 4: Synthesis of Compound 42

Figure pat00203
Figure pat00203

중간체 J-2(3.0 g, 0.010 mol)에 중간체 17-1(5.2 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 42> 4.2 g (수율 74%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (5), except that Intermediate 17-1 (5.2 g, 0.012 mol) was added to Intermediate J-2 (3.0 g, 0.010 mol) 74%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.60/d, 7.36/m, 7.21/d) 2H(8.81/d, 7.88/d, 7.41/m, 7.17/d, 1.72/s, 1.30/s) 4H(8.28/d, 7.51/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.60 / d, 7.36 / m, 7.21 / d) 2H (8.81 / d, 7.88 / d, 7.41 / m, 7.17 / d, 1.72 / s, 1.30 / s) 4H (8.28 / d, 7.51 / m)

LC/MS: m/z=570[(M+1)+]
LC / MS: m / z = 570 [(M + 1) &lt; + &

실시예Example 43 : 화합물 43 합성 43: Compound 43 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 43-1의 합성 1: Synthesis of Intermediate 43-1

Figure pat00204
Figure pat00204

2-(4-bromophenyl)triphenylene(3.8 g, 0.010 mol)에 bis(pinacolato)dibron (3.0 g, 0.012 mol)를 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <중간체 43-1> 3.1 g (수율 72%)을 얻었다.(m/z=430)
Synthesis was conducted in the same manner as in Example 1 (4), except that bis (pinacolato) dibron (3.0 g, 0.012 mol) was added to 2- (4-bromophenyl) triphenylene (3.8 g, 0.010 mol) -1> 3.1 g (yield 72%). (M / z = 430)

(2) (2) 제조예Manufacturing example 2 : 화합물 43의 합성 2: Synthesis of Compound 43

Figure pat00205
Figure pat00205

중간체 J-2(3.0 g, 0.010 mol)에 중간체 43-1(5.2 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 43> 4.1 g (수율 72%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (5), except that Intermediate 43-1 (5.2 g, 0.012 mol) was added to Intermediate J-2 (3.0 g, 0.010 mol) 72%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(9.15/s, 8.60/d, 8.18/d, 8.04/d, 7.36/m, 7.21/d) 2H(8.93/d, 8.81/d, 8.12/d, 7.88/m, 7.88/d, 7.82/m, 7.17/d, 1.72/s, 1.30/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (9.15 / s, 8.60 / d, 8.18 / d, 8.04 / d, 7.36 / m, 7.21 / d) 2H (8.93 / d, 8.81 / d, 8.12 / d, 7.88 / m, 7.88 / d, 7.82 / m, 7.17 / d, 1.72 / s, 1.30 / s)

LC/MS: m/z=565[(M+1)+]
LC / MS: m / z = 565 [(M + 1) &lt; + &

실시예Example 44 : 화합물 44 합성 44: Compound 44 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 K의 합성 1: Synthesis of Intermediate K

Figure pat00206
Figure pat00206

3-bromo-7-chloro-1,1-dimethyl-1H-pyrrolo[3,4-c]pyridine(2.6 g, 0.010 mol)에 methyl 3-bromopicolinate(2.6 g, 0.012 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 K> 1.4 g (수율 43%)을 얻었다.(m/z=316)
Methyl 3-bromopicolinate (2.6 g, 0.012 mol) was added to 3-bromo-7-chloro-1,1-dimethyl-1H pyrrolo [3,4- (M / z = 316) (Intermediate K) (1.4 g, yield 43%) was synthesized in the same manner as in Preparation Example (2)

(2) (2) 제조예Manufacturing example 2 : 중간체 K-1의 합성 2: Synthesis of Intermediate K-1

Figure pat00207
Figure pat00207

중간체 K(3.2 g, 0.010 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 K-1> 2.1 g (수율 66%)을 얻었다.(m/z=316)
2.1 g (yield 66%) of Intermediate K-1 was obtained in the same manner as in Example 1 (2), except that Intermediate K (3.2 g, 0.010 mol) was added. M / z = 316 )

(3) (3) 제조예Manufacturing example 3 : 중간체 K-2의 합성 3: Synthesis of Intermediate K-2

Figure pat00208
Figure pat00208

중간체 K-1(3.2 g, 0.010 mol)를 넣고 실시예 1-제조예 (3)에서 사용된 동일한 방법으로 합성하여 <중간체 K-2> 1.4 g (수율 48%)을 얻었다.(m/z=297)
1.4 g (yield: 48%) of Intermediate K-2 was obtained by the same method as in Example 1 (3), except that Intermediate K-1 (3.2 g, 0.010 mol) = 297)

(4) (4) 제조예Manufacturing example 4 : 화합물 44의 합성 4: Synthesis of Compound 44

Figure pat00209
Figure pat00209

중간체 K-2(3.0 g, 0.010 mol)에 4-(dibenzo[b,d]thiophen-4-yl)phenylboronic acid(3.7 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 44> 3.6 g (수율 69%)을 얻었다.The same procedure as in Example 1 (5) was repeated except that 4- (dibenzo [b, d] thiophen-4-yl) phenylboronic acid (3.7 g, 0.012 mol) was added to Intermediate K-2 (3.0 g, 0.010 mol) Synthesis was conducted in the same manner to obtain 3.6 g (yield 69%) of <Compound 44>.

H-NMR (200MHz, CDCl3):δ ppm, 1H(9.09/s, 8.68/d, 8.41/d, 8.20/d, 8.17/d, 7.98/d, 7.58/m, 7.52/d, 7.50/m, 7.49/m) 2H(1.72/s, 1.30/s) 4H(7.25/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (9.09 / s, 8.68 / d, 8.41 / d, 8.20 / d, 8.17 / d, 7.98 / d, 7.58 / m, 7.52 / d, 7.50 / m , 7.49 / m) 2H (1.72 / s, 1.30 / s) 4H (7.25 / d)

LC/MS: m/z=522[(M+1)+]
LC / MS: m / z = 522 [(M + 1) &lt; + &

실시예Example 45 : 화합물 45 합성 45: Compound 45 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 45-1의 합성 1: Synthesis of intermediate 45-1

Figure pat00210
Figure pat00210

중간체 35-1(3.2 g, 0.010 mol)에 bromobenzene(1.6 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 45-1> 3.1 g (수율 77%)을 얻었다.(m/z=398)
3.1 g (yield: 77%) of Intermediate 45-1 was synthesized in the same manner as in Example 2 (1) except that bromobenzene (1.6 g, 0.010 mol) was added to Intermediate 35-1 (3.2 g, 0.010 mol) %). (M / z = 398)

(2) (2) 제조예Manufacturing example 2 : 중간체 45-2의 합성 2: Synthesis of intermediate 45-2

Figure pat00211
Figure pat00211

중간체 45-1(4.0 g, 0.010 mol)에 bis(pinacolato)dibron(3.0 g, 0.012 mol) 를 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <중간체 45-2> 3.3 g (수율 74%)을 얻었다.(m/z=445)
Intermediate 45-2> 3.3 g (0.012 mol) of bis (pinacolato) dibron was added to Intermediate 45-1 (4.0 g, 0.010 mol) g (yield: 74%). (m / z = 445)

(3) (3) 제조예Manufacturing example 3 : 화합물 45의 합성 3: Synthesis of Compound 45

Figure pat00212
Figure pat00212

중간체 K-2(3.0 g, 0.010 mol)에 중간체 45-2(5.3 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 45> 4.1 g (수율 71%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (5), except that Intermediate 45-2 (5.3 g, 0.012 mol) was added to Intermediate K-2 (3.0 g, 0.010 mol) 71%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(9.09/s, 8.68/d, 8.55/d, 8.17/d, 7.94/d, 7.87/d, 7.77/s, 7.69/d, 7.49/m, 7.45/m, 7.33/m, 7.25/m) 2H(7.58/m, 7.50/d, 1.72/s, 1.30/s) 4H(7.25/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (9.09 / s, 8.68 / d, 8.55 / d, 8.17 / d, 7.94 / d, 7.87 / d, 7.77 / s, 7.69 / d, 7.49 / m , 7.45 / m, 7.33 / m, 7.25 / m) 2H (7.58 / m, 7.50 /

LC/MS: m/z=581[(M+1)+]
LC / MS: m / z = 581 [(M + 1) &lt; + &

실시예Example 46 : 화합물 46 합성 46: Compound 46 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 L의 합성 1: Synthesis of Intermediate L

Figure pat00213
Figure pat00213

5-bromo-3-chloro-7,7-dimethyl-7H-pyrrolo[3,4-b]pyridine(2.6 g, 0.010 mol)에 methyl 3-bromopicolinate(2.6 g, 0.012 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 L> 1.3 g (수율 41%)을 얻었다.(m/z=316)
Methyl 3-bromopicolinate (2.6 g, 0.012 mol) was added to 5-bromo-3-chloro-7,7-dimethyl-7H-pyrrolo [3,4- (M / z = 316) (Intermediate L) was obtained (1.3 g, 41% yield) in the same manner as in Preparation Example (2)

(2) (2) 제조예Manufacturing example 2 : 중간체 L-1의 합성 2: Synthesis of intermediate L-1

Figure pat00214
Figure pat00214

중간체 L(3.2 g, 0.010 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 L-1> 1.6 g (수율 51%)을 얻었다.(m/z=316)
Intermediate L-1 (1.6 g, yield 51%) was obtained by introducing intermediate L (3.2 g, 0.010 mol) in the same manner as in Example 1- (2) to give m / z = 316 )

(3) (3) 제조예Manufacturing example 3 : 중간체 L-2의 합성 3: Synthesis of intermediate L-2

Figure pat00215
Figure pat00215

중간체 L-1(3.2 g, 0.010 mol)를 넣고 실시예 1-제조예 (3)에서 사용된 동일한 방법으로 합성하여 <중간체 L-2> 2.0 g (수율 66%)을 얻었다.(m/z=297)
2.0 g (yield 66%) of <Intermediate L-2> was obtained by the same method as in Example 1- (3), except that Intermediate L-1 (3.2 g, 0.010 mol) = 297)

(4) (4) 제조예Manufacturing example 4 : 화합물 46의 합성 4: Synthesis of Compound 46

Figure pat00216
Figure pat00216

중간체 L-2(3.0 g, 0.010 mol)에 중간체 17-1(5.2 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 46> 3.6 g (수율 63%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (5), except that Intermediate 17-1 (5.2 g, 0.012 mol) was added to Intermediate L-2 (3.0 g, 0.010 mol) 63%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(9.09/s, 8.68/d, 8.17/d, 7.49/m) 2H(7.85/d, 7.41/m, 7.25/d, 1.72/s, 1.30/s) 4H(8.28/d, 7.51/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (9.09 / s, 8.68 / d, 8.17 / d, 7.49 / m) 2H (7.85 / d, 7.41 / m, 7.25 / d, 1.72 / s, 1.30 / s) 4H (8.28 / d, 7.51 / m)

LC/MS: m/z=571[(M+1)+]
LC / MS: m / z = 571 [(M + 1) &lt; + &

실시예Example 47 : 화합물 47 합성 47: Compound 47 Synthesis

(1) (One) 제조예Manufacturing example 1 : 화합물 47의 합성 1: Synthesis of compound 47

Figure pat00217
Figure pat00217

중간체 L-2(3.0 g, 0.010 mol)에 중간체 43-1(5.2 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 47> 4.0 g (수율 71%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (5), except that Intermediate 43-1 (5.2 g, 0.012 mol) was added to Intermediate L-2 (3.0 g, 0.010 mol) 71%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(9.15/s, 9.09/s, 8.68/d, 8.18/d, 8.17/d, 8.04/d, 7.49/m) 2H(8.93/d, 8.12/d, 7.88/m, 7.82/m, 1.72/s, 1.30/s) 4H(7.25/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (9.15 / s, 9.09 / s, 8.68 / d, 8.18 / d, 8.17 / d, 8.04 / d, 7.49 / m) 2H (8.93 / d, 8.12 / d, 7.88 / m, 7.82 / m, 1.72 / s, 1.30 / s)

LC/MS: m/z=566[(M+1)+]
LC / MS: m / z = 566 [(M + 1) &lt; + &

실시예Example 48 : 화합물 48 합성 48: Compound 48 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 48-1의 합성 1: Synthesis of intermediate 48-1

Figure pat00218
Figure pat00218

3,4-dibromo-1,1-dimethyl-1H-isoindole(3.0 g, 0.010 mol)에 2-bromo-6-chlorophenol(2.5 g, 0.012 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 48-1> 1.1 g (수율 41%)을 얻었다.(m/z=269)
2-bromo-6-chlorophenol (2.5 g, 0.012 mol) was added to 3,4-dibromo-1,1-dimethyl-1H-isoindole (3.0 g, 0.010 mol) (M / z = 269) (yield: 41%). &Lt;

(2) (2) 제조예Manufacturing example 2 : 화합물 48의 합성 2: Synthesis of Compound 48

Figure pat00219
Figure pat00219

중간체 48-1(2.7 g, 0.010 mol)에 4-(dibenzo[b,d]thiophen-4-yl)phenylboronic acid(3.7 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 48> 3.6 g (수율 73%)을 얻었다.(Dibenzo [b, d] thiophen-4-yl) phenylboronic acid (3.7 g, 0.012 mol) was added to Intermediate 48-1 (2.7 g, 0.010 mol) Synthesis was conducted in the same manner to obtain 3.6 g (yield 73%) of <Compound 48>.

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.45/d, 8.41/d, 8.20/d, 7.99/d, 7.98/d, 7.90/d, 7.58/m, 7.52/m, 7.50/m, 7.47/m, 7.40/m, 7.21/d, 7.07/d) 2H(1.61/s) 4H(7.25/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.45 / d, 8.41 / d, 8.20 / d, 7.99 / d, 7.98 / d, 7.90 / d, 7.58 / m, 7.52 / m, 7.50 / m , 7.47 / m, 7.40 / m, 7.21 / d, 7.07 / d) 2H (1.61 / s)

LC/MS: m/z=494[(M+1)+]
LC / MS: m / z = 494 [(M + 1) &lt; + &

실시예Example 49 : 화합물 49 합성 49: Compound 49 Synthesis

(1) (One) 제조예Manufacturing example 1 : 화합물 49의 합성 1: Synthesis of Compound 49

Figure pat00220
Figure pat00220

중간체 48-1(2.7 g, 0.010 mol)에 중간체 45-2(5.3 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 49> 3.5 g (수율 64%)을 얻었다.(3.5 g, 0.012 mol) was added to Intermediate 48-1 (2.7 g, 0.010 mol) and the compound 45 was synthesized in the same manner as in Example 1 (5) 64%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.55/d, 7.99/d, 7.94/d, 7.90/d, 7.87/d, 7.77/s, 7.69/s, 7.47/m, 7.45/m, 7.40/m, 7.33/m, 7.26/d, 7.25/m, 7.07/d) 2H(7.58/m, 7.50/d, 1.61/s) 4H(7.25/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.55 / d, 7.99 / d, 7.94 / d, 7.90 / d, 7.87 / d, 7.77 / s, 7.69 / s, 7.47 / m, 7.45 / m M, 7.50 / d, 1.61 / s) 4H (7.25 / d)

LC/MS: m/z=553[(M+1)+]
LC / MS: m / z = 553 [(M + 1) &lt; + &

실시예Example 50 : 화합물 50 합성 50: Compound 50 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 N의 합성 1: Synthesis of intermediate N

Figure pat00221
Figure pat00221

2,3-dibromo-1H-indole(2.7 g, 0.010 mol)에 methyl 2-bromo-6-chlorobenzoate(3.0 g, 0.012 mol) 를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 N> 1.6 g (수율 41%)을 얻었다.(m/z=364)
(2-bromo-6-chlorobenzoate (3.0 g, 0.012 mol) was added to 2,3-dibromo-1H-indole (2.7 g, 0.010 mol) To obtain 1.6 g (yield 41%) of Intermediate N. (m / z = 364)

(2) (2) 제조예Manufacturing example 2 : 중간체 N-1의 합성 2: Synthesis of intermediate N-1

Figure pat00222
Figure pat00222

중간체 N(3.6 g, 0.010 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 N-1> 2.1 g (수율 658%)을 얻었다.(m/z=364)
2.1 g (yield 658%) of Intermediate N-1 was obtained in the same manner as in Example 1 (2) except that Intermediate N (3.6 g, 0.010 mol) )

(3) (3) 제조예Manufacturing example 3 : 중간체 N-2의 합성 3: Synthesis of intermediate N-2

Figure pat00223
Figure pat00223

중간체 N-1(3.6 g, 0.010 mol)를 넣고 실시예 1-제조예 (3)에서 사용된 동일한 방법으로 합성하여 <중간체 N-2> 2.1 g (수율 62%)을 얻었다.(m/z=346)
Intermediate N-2 (2.1 g, yield 62%) was obtained by the same method as in Example 1 (3), except that Intermediate N-1 (3.6 g, 0.010 mol) = 346)

(4) (4) 제조예Manufacturing example 4 : 중간체 50-1의 합성 4: Synthesis of intermediate 50-1

Figure pat00224
Figure pat00224

중간체 N-2(3.5 g, 0.010 mol)에 bromobenzene(1.6 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 50-1> 3.2 g (수율 77%)을 얻었다.(m/z=422)
Intermediate 50-1> 3.2 g (Yield 77%) was obtained by synthesizing the same method as that of Preparation Example (1) of Example 2, with the introduction of bromobenzene (1.6 g, 0.010 mol) into Intermediate N-2 (3.5 g, 0.010 mol) %). (M / z = 422)

(5) (5) 제조예Manufacturing example 5 : 중간체 50-2의 합성 5: Synthesis of intermediate 50-2

Figure pat00225
Figure pat00225

중간체 50-1(4.2 g, 0.010 mol)에 phenyl boronic acid(1.4 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 50-2> 3.0 g (수율 72%)을 얻었다.(m/z=419)
Intermediate 50-2 was synthesized in the same manner as in Example 1 (5), except that phenyl boronic acid (1.4 g, 0.012 mol) was added to Intermediate 50-1 (4.2 g, 0.010 mol) Yield: 72%). (M / z = 419)

(6) (6) 제조예Manufacturing example 6 : 화합물 50의 합성 6: Synthesis of Compound 50

Figure pat00226
Figure pat00226

중간체 50-2(4.2 g, 0.010 mol)에 중간체 17-1(5.2 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 50> 5.0 g (수율 72%)을 얻었다.5.0 g (yield: 5.0 g, 0.012 mol) was obtained from Intermediate 50-2 (4.2 g, 0.010 mol) by the same procedure as in Example 1- 72%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.53/d, 7.45/m, 7.39/m, 7.34/m, 7.00/d) 2H(7.85/d, 7.79/d, 7.67/d, 7.58/m, 7.50/d, 7.25/d, 1.72/s) 3H(7.41/m) 4H(8.28/d) 6H(7.51/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.53 / d, 7.45 / m, 7.39 / m, 7.34 / m, 7.00 / d) 2H (7.85 / d, 7.79 / d, 7.67 / d, 7.58 m, 7.50 / d, 7.25 / d, 1.72 / s) 3H (7.41 / m) 4H (8.28 / d)

LC/MS: m/z=693[(M+1)+]
LC / MS: m / z = 693 [(M + 1) &lt; + &

실시예Example 51 : 화합물 51 합성 51: Compound 51 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 51-1의 합성 1: Synthesis of Intermediate 51-1

Figure pat00227
Figure pat00227

2,3,4-tribromo-1H-indole(3.5 g, 0.010 mol)에 2-bromo-6-chlorophenol(2.1 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 51-1> 2.1g (수율 65%)을 얻었다.(m/z=320)
2-bromo-6-chlorophenol (2.1 g, 0.010 mol) was added to 2,3,4-tribromo-1H-indole (3.5 g, 0.010 mol) in the same manner as in Example 2- 2.1 g (yield 65%) of Intermediate 51-1 (m / z = 320)

(2) (2) 제조예Manufacturing example 2 : 중간체 51-2의 합성 2: Synthesis of intermediate 51-2

Figure pat00228
Figure pat00228

중간체 51-1(3.2 g, 0.010 mol)에 bromobenzene(1.6 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 51-2> 3.0g (수율 77%)을 얻었다.(m/z=396)
Intermediate 51-2 (3.0 g, yield 77%) was synthesized in the same manner as in Example 2 (1) except that bromobenzene (1.6 g, 0.010 mol) was added to Intermediate 51-1 (3.2 g, 0.010 mol) %). (M / z = 396)

(3) (3) 제조예Manufacturing example 3 : 중간체 51-3의 합성 3: Synthesis of Intermediate 51-3

Figure pat00229
Figure pat00229

중간체 51-2(4.0 g, 0.010 mol)에 phenyl boronic acid(1.4 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 51-3> 2.8 g (수율 72%)을 얻었다.(m/z=393)
Intermediate 51-3 was synthesized in the same manner as in Example 1 (5), except that phenyl boronic acid (1.4 g, 0.012 mol) was added to Intermediate 51-2 (4.0 g, 0.010 mol) Yield: 72%). (M / z = 393)

(4) (4) 제조예Manufacturing example 4 : 화합물 51의 합성 4: Synthesis of Compound 51

Figure pat00230
Figure pat00230

중간체 51-3(3.9 g, 0.010 mol)에 중간체 43-1(5.2 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 51> 4.9g (수율 74%)을 얻었다.(m/z=000)The compound 43-1 (5.2 g, 0.012 mol) was added to Intermediate 51-3 (3.9 g, 0.010 mol) and the compound was synthesized in the same manner as in Example 1 (5) 74%). (M / z = < RTI ID = 0.0 > 000)

H-NMR (200MHz, CDCl3):δ ppm, 1H(9.15/s, 8.18/d, 8.04/d, 7.45/m, 7.43/d, 7.41/m, 7.38/m, 7.29/m, 6.88/d) 2H(8.93/d, 8.12/d, 7.88/m, 7.82/m, 7.79/d, 7.71/d, 7.58/m, 7.51/m, 7.50/d) 4H(7.25/d)M, 7.38 / m, 7.29 / m, 6.88 / d (1 H-NMR (200 MHz, CDCl 3 ) ), 2H (8.93 d, 8.12 d, 7.88 m, 7.82 m, 7.79 d, 7.71 d, 7.58 m, 7.51 m, 7.50 d)

LC/MS: m/z=662[(M+1)+]
LC / MS: m / z = 662 [(M + 1) &lt; + &

실시예Example 52 : 화합물 52 합성 52: Synthesis of compound 52

(1) (One) 제조예Manufacturing example 1 : 중간체 52-1의 합성 1: Synthesis of Intermediate 52-1

Figure pat00231
Figure pat00231

2,3,4-tribromo-1H-indole(3.5 g, 0.010 mol)에 2-bromo-6-chlorobenzenethiol(2.2 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 52-1> 1.8 g (수율 55%)을 얻었다.(m/z=336)
2-bromo-6-chlorobenzenethiol (2.2 g, 0.010 mol) was added to 2,3,4-tribromo-1H-indole (3.5 g, 0.010 mol) in the same manner as in Example 2- To obtain 1.8 g (yield 55%) of Intermediate 52-1 (m / z = 336)

(2) (2) 제조예Manufacturing example 2 : 중간체 52-2의 합성 2: Synthesis of intermediate 52-2

Figure pat00232
Figure pat00232

중간체 52-1(3.4 g, 0.010 mol)에 bromobenzene(1.6 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 52-2> 3.2 g (수율 77%)을 얻었다.(m/z=412)
Intermediate 52-2 (3.2 g, Yield 77%) was synthesized by the same method as in Example 2 (1), except that bromobenzene (1.6 g, 0.010 mol) was added to Intermediate 52-1 (3.4 g, 0.010 mol) %). (M / z = 412)

(3) (3) 제조예Manufacturing example 3 : 중간체 52-3의 합성 3: Synthesis of intermediate 52-3

Figure pat00233
Figure pat00233

중간체 52-2(4.1 g, 0.010 mol)에 phenyl boronic acid(1.4 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 52-3> 2.9 g (수율 72%)을 얻었다.(m/z=409)
Intermediate 52-3 was synthesized in the same manner as in Example 1 (5), except that phenyl boronic acid (1.4 g, 0.012 mol) was added to Intermediate 52-2 (4.1 g, 0.010 mol) Yield: 72%). (M / z = 409)

(4) (4) 제조예Manufacturing example 4 : 화합물 52의 합성 4: Synthesis of Compound 52

Figure pat00234
Figure pat00234

중간체 52-3(4.1 g, 0.010 mol)에 중간체 17-1(5.2 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 52> 4.9 g (수율 72%)을 얻었다.(5.2 g, 0.012 mol) was added to Intermediate 52-3 (4.1 g, 0.010 mol) in the same manner as in Example 1-Preparation Example (5) 72%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.45/d, 7.45/m, 7.41/m, 7.31/m, 7.22/m, 7.10/d) 2H(7.85/d, 7.79/d, 7.58/m, 7.55/d, 7.51/m, 7.50/d, 7.41/m, 7.25/d) 4H(8.28/d, 7.51/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.45 / d, 7.45 / m, 7.41 / m, 7.31 / m, 7.22 / m, 7.10 / d) 2H (7.85 / d, 7.79 / d, 7.58 7.55 / d, 7.51 / m, 7.50 / d, 7.41 / m, 7.25 / d) 4H (8.28 / d, 7.51 /

LC/MS: m/z=683[(M+1)+]
LC / MS: m / z = 683 [(M + 1) &lt; + &

실시예Example 53 : 화합물 53 합성 53: Compound 53 Synthesis

(1) (One) 제조예Manufacturing example 1 : 화합물 53의 합성 1: Synthesis of Compound 53

Figure pat00235
Figure pat00235

중간체 52-3(4.1 g, 0.010 mol)에 중간체 43-1(5.2 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 53> 4.9 g (수율 73%)을 얻었다.The compound 43-1 (5.2 g, 0.012 mol) was added to Intermediate 52-3 (4.1 g, 0.010 mol) and the compound was synthesized in the same manner as in Example 1- (5) to give 4.9 g 73%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(9.15/s, 8.18/d, 8.04/d, 7.45/d, 7.45/m, 7.41/m, 7.31/m, 7.22/m, 7.10/d) 2H(8.93/d, 8.12/d, 7.88/m, 7.82/m, 7.79/d, 7.58/m, 7.55/d, 7.51/m, 7.50/d) 4H(7.25/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (9.15 / s, 8.18 / d, 8.04 / d, 7.45 / d, 7.45 / m, 7.41 / m, 7.31 / m, 7.22 / m, 7.10 / d ), 2H (8.93 / d, 8.12 / d, 7.88 / m, 7.82 / m, 7.79 / d, 7.58 / m, 7.55 / d, 7.51 / m, 7.50 /

LC/MS: m/z=678[(M+1)+]
LC / MS: m / z = 678 [(M + 1) &lt; + &

실시예Example 54 : 화합물 54 합성 54: Compound 54 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 54-1의 합성 1: Synthesis of intermediate 54-1

Figure pat00236
Figure pat00236

중간체 G-2(3.0 g, 0.010 mol)에 bromobenzene(3.2 g, 0.020 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 54-1> 2.4 g (수율 58%)을 얻었다.(m/z=419)
2.4 g (yield: 58%) of Intermediate 54-1 was synthesized in the same manner as in Example 2 (1) except that bromobenzene (3.2 g, 0.020 mol) was added to Intermediate G-2 (3.0 g, 0.010 mol) %). (M / z = 419)

(2) (2) 제조예Manufacturing example 2 : 화합물 54의 합성 2: Synthesis of compound 54

Figure pat00237
Figure pat00237

중간체 54-1(4.2 g, 0.010 mol)에 중간체 43-1(5.2 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 54> 4.8 g (수율 72%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (5) to give Intermediate 43-1 (5.2 g, 0.012 mol) and Intermediate 54-1 (4.2 g, 0.010 mol) 72%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(9.15/s, 8.18/d, 8.04/d, 7.95/d, 7.86/d, 7.57/m, 7.32/m, 7.16/d, 7.10/d) 2H(8.93/d, 8.12/d, 7.88/m, 7.82/m, 7.26/m, 1.72/s) 4H(7.33/m, 7.25/d, 7.23/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (9.15 / s, 8.18 / d, 8.04 / d, 7.95 / d, 7.86 / d, 7.57 / m, 7.32 / m, 7.16 / d, 7.10 / d 7H (7.33 / m, 7.25 / d, 7.23 / d) 2H (8.93 d, 8.12 d, 7.88 m, 7.82 m, 7.26 m,

LC/MS: m/z=688[(M+1)+]
LC / MS: m / z = 688 [(M + 1) &lt; + &

실시예Example 55 : 화합물 55 합성 55: Compound 55 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 O-1의 합성 1: Synthesis of intermediate O-1

Figure pat00238
Figure pat00238

3-bromo-1,1-dimethyl-1H-isoindolepyridine(2.2 g, 0.010 mol)에 methyl 2-bromo-5-chlorobenzoate(3.0 g, 0.012 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 O-1> 1.3 g (수율 41%)을 얻었다.(m/z=313)
(2-bromo-5-chlorobenzoate (3.0 g, 0.012 mol) was added to 3-bromo-1,1-dimethyl-1H- isoindolepyridine (2.2 g, 0.010 mol) (M / z = 313) (Intermediate O-1) (1.3 g, yield 41%).

(2) (2) 제조예Manufacturing example 2 : 중간체 O-2의 합성 2: Synthesis of Intermediate O-2

Figure pat00239
Figure pat00239

중간체 O-1(3.1 g, 0.010 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 O-2> 1.8 g (수율 56%)을 얻었다.(m/z=313)
Intermediate O-2 (1.8 g, yield: 56%) was obtained in the same manner as in Example 1 (2) except that Intermediate O-1 (3.1 g, 0.010 mol) = 313)

(3) (3) 제조예Manufacturing example 3 : 중간체 O-3의 합성 3: Synthesis of Intermediate O-3

Figure pat00240
Figure pat00240

중간체 O-2(3.1 g, 0.010 mol)를 넣고 실시예 1-제조예 (3)에서 사용된 동일한 방법으로 합성하여 <중간체 O-3> 1.9 g (수율 66%)을 얻었다.(m/z=295)
Intermediate O-3 (1.9 g, yield 66%) was obtained in the same manner as in Example 1- (3) except that Intermediate O-2 (3.1 g, 0.010 mol) = 295)

(4) (4) 제조예Manufacturing example 4 : 중간체 55-1의 합성 4: Synthesis of intermediate 55-1

Figure pat00241
Figure pat00241

중간체 O-3(3.0 g, 0.010 mol)에 bromobenzene(3.3 g, 0.020 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 55-1> 2.4 g (수율 57%)을 얻었다.(m/z=419)
2.4 g (yield: 57%) of Intermediate 55-1 was synthesized in the same manner as in Example 2 (1) except that bromobenzene (3.3 g, 0.020 mol) was added to Intermediate O-3 (3.0 g, 0.010 mol) %). (M / z = 419)

(5) (5) 제조예Manufacturing example 5 : 화합물 55의 합성 5: Synthesis of Compound 55

Figure pat00242
Figure pat00242

중간체 55-1(4.2 g, 0.010 mol)에 중간체 17-1(5.2 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 55> 5.0 g (수율 72%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (5), except that Intermediate 17-1 (5.2 g, 0.012 mol) was added to Intermediate 55-1 (4.2 g, 0.010 mol) 72%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.03/d, 7.92/d, 7.69/d, 7.32/d, 7.16/d) 2H(7.85/d, 7.41/m, 7.26/m, 7.25/d, 1.61/s) 4H(8.28/d, 7.51/m, 7.33/m, 7.11/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.03 / d, 7.92 / d, 7.69 / d, 7.32 / d, 7.16 / d) 2H (7.85 / d, 7.41 / m, 7.26 / m, 7.25 / d, 1.61 / s) 4H (8.28 / d, 7.51 / m, 7.33 / m, 7.11 / d)

LC/MS: m/z=693[(M+1)+]
LC / MS: m / z = 693 [(M + 1) &lt; + &

실시예Example 56 : 화합물 56 합성 56: Compound 56 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 56-1의 합성 1: Synthesis of intermediate 56-1

Figure pat00243
Figure pat00243

중간체 D-2(3.4 g, 0.010 mol)에 bromobenzene(3.5 g, 0.020 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 56-1> 2.4 g (수율 51%)을 얻었다.(m/z=463)
(2.4 g, 0.020 mol) was added to Intermediate D-2 (3.4 g, 0.010 mol) in the same manner as in Example 2-Preparation Example (1) %). (M / z = 463)

(2) (2) 제조예Manufacturing example 2 : 화합물 56의 합성 2: Synthesis of compound 56

Figure pat00244
Figure pat00244

중간체 56-3(4.6 g, 0.010 mol)에 중간체 43-1(5.2 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 56> 4.8 g (수율 70%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (5) to give Intermediate 43-1 (5.2 g, 0.012 mol) and Intermediate 56-3 (4.6 g, 0.010 mol) 70%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(9.15/s, 8.18/d, 8.04/d) 2H(8.93/d, 8.12/d, 7.88/m, 7.82/m, 7.64/d, 7.56/d, 1.69/s) 4H(7.26/m) 6H(7.33/m, 7.11/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (9.15 / s, 8.18 / d, 8.04 / d) 2H (8.93 / d, 8.12 / d, 7.88 / m, 7.82 / m, 7.64 / d, 7.56 / d, 1.69 / s) 4H (7.26 / m) 6H (7.33 / m, 7.11 / d)

LC/MS: m/z=687[(M+1)+]
LC / MS: m / z = 687 [(M + 1) &lt; + &

실시예Example 57 : 화합물 57 합성 57: Compound 57 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 M의 합성 1: Synthesis of intermediate M

Figure pat00245
Figure pat00245

methyl 2-benzyl-6-chlorobenzoate(2.6 g, 0.010 mol)에 MeLi을 dropping시킨 후 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 M> 0.8 g (수율 31%)을 얻었다.(m/z=260)
0.8 g (Yield: 31%) of Intermediate M was synthesized in the same manner as in Example 1-Preparation Example (2) after dropping MeLi into methyl 2-benzyl-6-chlorobenzoate (2.6 g, 0.010 mol) (M / z = 260).

(2) (2) 제조예Manufacturing example 2 : 중간체 M-1의 합성 2: Synthesis of intermediate M-1

Figure pat00246
Figure pat00246

중간체 M(2.6 g, 0.010 mol)를 넣고 실시예 1-제조예 (3)에서 사용된 동일한 방법으로 합성하여 <중간체 M-1> 1.5 g (수율 60%)을 얻었다.(m/z=242)
1.5 g (yield 60%) of <Intermediate M-1> was obtained by the same method as in Example 1-Preparation Example (3), except that Intermediate M (2.6 g, 0.010 mol) )

(3) (3) 제조예Manufacturing example 3 : 중간체 M-2의 합성 3: Synthesis of intermediate M-2

Figure pat00247
Figure pat00247

중간체 M-1(2.4 g, 0.010 mol)에 KMnO4(3.2 g, 0.0020 mol)에 MC 60 mL를 넣고 25 ℃에서 48시간 교반하여 반응시켰다.반응 종료 후 냉각하여 H20 : EA에 층분리 후 컬럼정제 (n-Hexane : EA)하여 중간체 M-2을 1.8 g(수율 71%) 수득하였다. (m/z=256)
Intermediate M-1 (2.4 g, 0.010 mol) in KMnO 4 (3.2 g, 0.0020 mol ) MC into the 60 mL was reacted by stirring at 25 ℃ 48 sigan H 2 0 cooled after the completion of the reaction to: separation layer EA Post-column purification (n-hexane: EA) gave 1.8 g (71% yield) of intermediate M-2. (m / z = 256)

(4) (4) 제조예Manufacturing example 4 : 중간체 M-3의 합성 4: Synthesis of intermediate M-3

Figure pat00248
Figure pat00248

중간체 M-2(2.6 g, 0.010 mol)에 bromoethane(1.1 g, 0.010 mol), Potassium carbonate(2.8 g, 0.020 mol), Copper(0.1 g, 0.0020 mol), iodine copper(1.1 g, 0.006 mol)에 n-butyl ether 70 mL에 녹인 후 질소하에서 48시간 교반하여 반응시켰다. 반응 종료 후 실온으로 냉각하여 H20 : MC 층분리 후 컬럼정제 (n-Hexane : EA)하여 중간체 M-3을 2.4 g(수율 68%)수득하였다.(m/z=349)
(1.1 g, 0.010 mol), Potassium carbonate (2.8 g, 0.020 mol), Copper (0.1 g, 0.0020 mol) and iodine copper (1.1 g, 0.006 mol) were added to Intermediate M-2 (2.6 g, 0.010 mol) dissolved in 70 mL of n-butyl ether, and reacted under nitrogen for 48 hours with stirring. After completion of the reaction, the reaction mixture was cooled to room temperature, and subjected to column purification (n-hexane: EA) after separation of H 2 O: MC layer to obtain 2.4 g (m / z = 349)

(5) (5) 제조예Manufacturing example 5 : 중간체 57-1의 합성 5: Synthesis of intermediate 57-1

Figure pat00249
Figure pat00249

중간체 M-3(3.5 g, 0.010 mol)에 phenyl boronic acid(1.4 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 57-1> 2.5 g (수율 74%)을 얻었다.(m/z=344)
Intermediate 57-1 was synthesized in the same manner as in Example 1 (5), except that phenyl boronic acid (1.4 g, 0.012 mol) was added to Intermediate M-3 (3.5 g, 0.010 mol) Yield: 74%). (M / z = 344)

(6) (6) 제조예Manufacturing example 6 : 화합물 57의 합성 6: Synthesis of Compound 57

Figure pat00250
Figure pat00250

중간체 57-1(3.4 g, 0.010 mol)에 12H-benzofuro[2,3-a]carbazole(2.6 g, 0.010 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 57> 4.6 g (수율 72%)을 얻었다.Benzofuro [2,3-a] carbazole (2.6 g, 0.010 mol) was added to Intermediate 57-1 (3.4 g, 0.010 mol) in the same manner as in Example 1- Compound 57> 4.6 g (yield: 72%) was obtained.

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.55/d, 8.09/d, 7.66/d, 7.53/d, 7.52/m, 7.51/m, 7.48/d, 7.46/d, 7.41/m, 7.39/m, 7.38/m, 7.33/m, 7.30/m, 7.25/m, 7.22/m, 7.00/d) 2H(8.10/d, 7.89/d, 7.67/d, 7.51/m, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.55 / d, 8.09 / d, 7.66 / d, 7.53 / d, 7.52 / m, 7.51 / m, 7.48 / d, 7.46 / d, 7.41 / m D, 7.89 / d, 7.67 / d, 7.51 / m, 1.72 / s (7.39 / m, 7.38 / m, 7.33 / m, 7.30 / m, 7.25 / m, 7.22 / )

LC/MS: m/z=642[(M+1)+]
LC / MS: m / z = 642 [(M + 1) &lt; + &

실시예Example 58 : 화합물 58 합성 58: Compound 58 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 58-1의 합성 1: Synthesis of intermediate 58-1

Figure pat00251
Figure pat00251

11,12-dihydroindolo[2,3-a]carbazole(2.6 g, 0.010 mol)에 bromobenzene(1.6 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 58-1> 2.6 g (수율 77%)을 얻었다.(m/z=332)
(1.6 g, 0.010 mol) was added to 11,12-dihydroindolo [2,3-a] carbazole (2.6 g, 0.010 mol) (M / z = 332) of 2.6 g (yield: 77%) was obtained.

(2) (2) 제조예Manufacturing example 2 : 화합물 58의 합성 2: Synthesis of compound 58

Figure pat00252
Figure pat00252

중간체 57-1(3.4 g, 0.010 mol)에 중간체 58-1(3.3 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <화합물 58> 5.6 g (수율 78%)을 얻었다.Synthesis was conducted in the same manner as in Example 2 (1), except that Intermediate 58-1 (3.3 g, 0.010 mol) was added to Intermediate 57-1 (3.4 g, 0.010 mol) 78%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.12/d, 8.09/d, 7.57/d, 7.52/d, 7.46/m, 7.45/m, 7.42/d, 7.41/m, 7.39/m, 7.30/m, 7.00/s) 2H(8.55/d, 8.10/d, 7.94/d, 7.67/d, 7.58/m, 7.51/m, 7.50/d, 7.33/m, 7.25/m, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.12 / d, 8.09 / d, 7.57 / d, 7.52 / d, 7.46 / m, 7.45 / m, 7.42 / d, 7.41 / m, 7.39 / m M, 7.00 / s) 2H (8.55 / d, 8.10 / d, 7.94 / d, 7.67 / d, 7.58 / m, 7.51 / m, 7.50 / d, 7.33 / m, 7.25 / )

LC/MS: m/z=717[(M+1)+]
LC / MS: m / z = 717 [(M + 1) &lt; + &

실시예Example 59 : 화합물 59 합성 59: Compound 59 Synthesis

(1) (One) 제조예Manufacturing example 1 : 화합물 59의 합성 1: Synthesis of compound 59

Figure pat00253
Figure pat00253

중간체 57-1(3.4 g, 0.010 mol)에 중간체 17-1(5.2 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 59> 4.7 g (수율 76%)을 얻었다.The compound 17-1 (5.2 g, 0.012 mol) was added to Intermediate 57-1 (3.4 g, 0.010 mol) and the compound was synthesized by the same method as in Example 1- (5) to give 4.7 g 76%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.48/d, 7.39/m, 7.30/m, 7.00/d) 2H(8.10/d, 7.85/d, 7.67/d, 7.51/m, 7.25/d, 1.72/s) 3H(7.41/m) 4H(8.28/d, 7.51/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.48 / d, 7.39 / m, 7.30 / m, 7.00 / d) 2H (8.10 / d, 7.85 / d, 7.67 / d, 7.51 / m, 7.25 / d, 1.72 / s) 3H (7.41 / m) 4H (8.28 / d, 7.51 /

LC/MS: m/z=618[(M+1)+]
LC / MS: m / z = 618 [(M + 1) &lt; + &

실시예Example 60 : 화합물 60 합성 60: Compound 60 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 60-1의 합성 1: Synthesis of intermediate 60-1

Figure pat00254
Figure pat00254

2,3,4-tribromobenzofuran(3.5 g, 0.010 mol)에 2-bromo-6-chlorophenol(2.1 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 60-1> 1.8g (수율 55%)을 얻었다.(m/z=321)
2-bromo-6-chlorophenol (2.1 g, 0.010 mol) was added to 2,3,4-tribromobenzofuran (3.5 g, 0.010 mol) in the same manner as in Example 2- 60-1> 1.8 g (yield: 55%). (M / z = 321)

(2) (2) 제조예Manufacturing example 2 : 중간체 60-2의 합성 2: Synthesis of intermediate 60-2

Figure pat00255
Figure pat00255

중간체 60-1(3.2 g, 0.010 mol)에 phenyl boronic acid(1.4 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 60-2> 2.4 g (수율 76%)을 얻었다.(m/z=318)
Synthesis was conducted in the same manner as in Example 1 (5), except that phenyl boronic acid (1.4 g, 0.012 mol) was added to Intermediate 60-1 (3.2 g, 0.010 mol) Yield: 76%). (M / z = 318)

(3) (3) 제조예Manufacturing example 3 : 화합물 60의 합성 3: Synthesis of Compound 60

Figure pat00256
Figure pat00256

중간체 60-2(3.2 g, 0.010 mol)에 중간체 43-1(5.2 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 60> 4.1 g (수율 69%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (5), except that Intermediate 43-1 (5.2 g, 0.012 mol) was added to Intermediate 60-2 (3.2 g, 0.010 mol) 69%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(9.15/s, 8.18/d, 8.04/d, 7.41/m, 7.38/d, 7.34/m, 7.29/m, 7.13/d) 2H(8.93/d, 8.12/d, 8.10/d, 7.88/m, 7.82/m, 7.71/d, 7.51/m) 4H(7.25/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (9.15 / s, 8.18 / d, 8.04 / d, 7.41 / m, 7.38 / d, 7.34 / m, 7.29 / m, 7.13 / d) 2H (8.93 d, 8.10 / d, 7.88 / m, 7.82 / m, 7.71 / d, 7.51 /

LC/MS: m/z=587[(M+1)+]
LC / MS: m / z = 587 [(M + 1) &lt; + &

실시예Example 61 : 화합물 61 합성 61: Compound 61 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 K의 합성 1: Synthesis of Intermediate K

Figure pat00257
Figure pat00257

methyl 2-chloro-6-(pyridin-3-ylmethyl)benzoate(5.2 g, 0.020 mol)에 MeLi을 dropping시킨 후 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 K> 1.5 g (수율 29%)을 얻었다.(m/z=261)
MeLi was dropped on methyl 2-chloro-6- (pyridin-3-ylmethyl) benzoate (5.2 g, 0.020 mol) and then synthesized in the same manner as in Example 1- g (yield: 29%). (m / z = 261)

(2) (2) 제조예Manufacturing example 2 : 중간체 K-1의 합성 2: Synthesis of Intermediate K-1

Figure pat00258
Figure pat00258

중간체 K(2.6 g, 0.010 mol)를 넣고 실시예 1-제조예 (3)에서 사용된 동일한 방법으로 합성하여 <중간체 K-1> 1.5 g (수율 60%)을 얻었다.(m/z=242)
1.5 g (yield 60%) of Intermediate K-1 was obtained in the same manner as in Example 1 (3), except that Intermediate K (2.6 g, 0.010 mol) )

(3) (3) 제조예Manufacturing example 3 : 중간체 K-2의 합성 3: Synthesis of Intermediate K-2

Figure pat00259
Figure pat00259

중간체 K-1(2.4 g, 0.010 mol)에 KMnO4(3.2 g, 0.0020 mol)에 MC 60 mL를 넣고 25 ℃에서 48시간 교반하여 반응시켰다.반응 종료 후 냉각하여 H20 : EA에 층분리 후 컬럼정제(n-Hexane : EA)하여 중간체 K-2을 1.7 g(수율 68%) 수득하였다. (m/z=256)
Intermediate K-1 (2.4 g, 0.010 mol) in KMnO 4 (3.2 g, 0.0020 mol ) MC into the 60 mL was reacted by stirring at 25 ℃ 48 sigan H 2 0 cooled after the completion of the reaction to: separation layer EA Post-column purification (n-hexane: EA) gave 1.7 g (yield 68%) of intermediate K-2. (m / z = 256)

(4) (4) 제조예Manufacturing example 4 : 중간체 K-3의 합성 4: Synthesis of intermediate K-3

Figure pat00260
Figure pat00260

중간체 K-2(2.6 g, 0.010 mol)에 bromoethane(1.1 g, 0.010 mol), Potassium carbonate(2.8 g, 0.020 mol), Copper(0.1 g, 0.0020 mol), iodine copper(1.1 g, 0.006 mol)에 n-butyl ether 70 mL에 녹인 후 질소하에서 48시간 교반하여 반응시켰다. 반응 종료 후 실온으로 냉각하여 H20 : MC 층분리 후 컬럼정제 (n-Hexane : EA)하여 중간체 K-3을 2.2 g(수율 62%)수득하였다.(m/z=351)
(1.1 g, 0.010 mol), Potassium carbonate (2.8 g, 0.020 mol), Copper (0.1 g, 0.0020 mol) and iodine copper (1.1 g, 0.006 mol) were added to Intermediate K-2 dissolved in 70 mL of n-butyl ether, and reacted under nitrogen for 48 hours with stirring. After completion of the reaction, the reaction mixture was cooled to room temperature, and subjected to column separation (n-hexane: EA) after separation of H 2 O: MC layer to obtain 2.2 g (m / z = 351)

(5) (5) 제조예Manufacturing example 5 : 중간체 61-1의 합성 5: Synthesis of intermediate 61-1

Figure pat00261
Figure pat00261

중간체 K-3(3.5 g, 0.010 mol)에 phenyl boronic acid(1.4 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 61-1> 2.4 g (수율 70%)을 얻었다.(m/z=345)
2.4 g of Intermediate 61-1 was synthesized in the same manner as in Example 1 (5) except that phenyl boronic acid (1.4 g, 0.012 mol) was added to Intermediate K-3 (3.5 g, 0.010 mol) Yield: 70%). (M / z = 345)

(6) (6) 제조예Manufacturing example 6 : 화합물 61의 합성 6: Synthesis of Compound 61

Figure pat00262
Figure pat00262

중간체 61-1(3.5 g, 0.010 mol)에 중간체 43-1(5.2 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 61> 4.4 g (수율 72%)을 얻었다.The compound 43-1 (5.2 g, 0.012 mol) was added to Intermediate 61-1 (3.5 g, 0.010 mol) and the compound was synthesized in the same manner as in Example 1 (5) 72%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(9.15/s, 8.43/d, 8.18/d, 8.04/d, 7.41/m, 7.39/m, 7.18/d) 2H(8.93/d, 8.12/d, 8.10/d, 7.88/m, 7.82/m, 7.67/d, 7.51/m, 1.72/s) 4H(7.25/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (9.15 / s, 8.43 / d, 8.18 / d, 8.04 / d, 7.41 / m, 7.39 / m, 7.18 / d) 2H (8.93 / d, 8.12 d, 7.88 / m, 7.82 / m, 7.67 / d, 7.51 / m, 1.72 / s)

LC/MS: m/z=614[(M+1)+]
LC / MS: m / z = 614 [(M + 1) &lt; + &

실시예Example 62 : 화합물 62 합성 62: Compound 62 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 K-4의 합성 1: Synthesis of intermediate K-4

Figure pat00263
Figure pat00263

중간체 K-2(2.6 g, 0.010 mol)에 bromoethane(1.1 g, 0.010 mol), Potassium carbonate(2.8 g, 0.020 mol), Copper(0.1 g, 0.0020 mol), iodine copper(1.1 g, 0.006 mol)에 n-butyl ether 70 mL에 녹인 후 질소하에서 48시간 교반하여 반응시켰다. 반응 종료 후 실온으로 냉각하여 H20 : MC 층분리 후 컬럼정제 (n-Hexane : EA)하여 중간체 K-4을 2.1 g(수율 60%)수득하였다.(m/z=351)
(1.1 g, 0.010 mol), Potassium carbonate (2.8 g, 0.020 mol), Copper (0.1 g, 0.0020 mol) and iodine copper (1.1 g, 0.006 mol) were added to Intermediate K-2 dissolved in 70 mL of n-butyl ether, and reacted under nitrogen for 48 hours with stirring. After completion of the reaction, the reaction mixture was cooled to room temperature, and subjected to column purification (n-hexane: EA) after separation of H 2 O: MC layer to obtain 2.1 g (m / z = 351)

(2) (2) 제조예Manufacturing example 2 : 중간체 62-1의 합성 2: Synthesis of intermediate 62-1

Figure pat00264
Figure pat00264

중간체 K-4(3.5 g, 0.010 mol)에 phenyl boronic acid(1.4 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 62-1> 2.5 g (수율 72%)을 얻었다.(m/z=345)
Intermediate 62-1 was synthesized in the same manner as in Example 1 (5), except that phenyl boronic acid (1.4 g, 0.012 mol) was added to Intermediate K-4 (3.5 g, 0.010 mol) Yield: 72%). (M / z = 345)

(3) (3) 제조예Manufacturing example 3 : 화합물 62의 합성 3: Synthesis of Compound 62

Figure pat00265
Figure pat00265

중간체 K-4(3.5 g, 0.010 mol)에 중간체 43-1(5.2 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 62> 4.6 g (수율 75%)을 얻었다.Intermediate 43-1 (5.2 g, 0.012 mol) was added to Intermediate K-4 (3.5 g, 0.010 mol) and the compound was synthesized in the same manner as in Example 1- 75%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(9.15/s, 8.39/d, 8.18/d, 8.04/d, 7.89/d, 7.73/d, 7.54/d, 7.41/m) 2H(8.93/d, 8.12/d, 8.10/d, 7.88/m, 7.82/m, 7.51/m, 1.72/s) 4H(7.25/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (9.15 / s, 8.39 / d, 8.18 / d, 8.04 / d, 7.89 / d, 7.73 / d, 7.54 / d, 7.41 / m) 2H (8.93 m), 7.41 / m, 1.72 / s), 4H (7.25 / d)

LC/MS: m/z=614 [(M+1)+]
LC / MS: m / z = 614 [(M + 1) &lt; + &

실시예Example 63 : 화합물 63 합성 63: Compound 63 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 63-1의 합성 1: Synthesis of intermediate 63-1

Figure pat00266
Figure pat00266

중간체 20-2(2.1 g, 0.010 mol)에 2-bromo-4,6-diphenyl-1,3,5-triazine(2.6 g, 0.008 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 63-1> 4.0g (수율 77%)을 얻었다.(m/z=524)
2-bromo-4,6-diphenyl-1,3,5-triazine (2.6 g, 0.008 mol) was added to Intermediate 20-2 (2.1 g, 0.010 mol) (M / z = 524) (Intermediate 63-1) was obtained (yield: 77%).

(2) (2) 제조예Manufacturing example 2 : 화합물 63의 합성 2: Synthesis of Compound 63

Figure pat00267
Figure pat00267

중간체 57-1(3.4 g, 0.010 mol)에 중간체 63-1(6.3 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 63> 4.4 g (수율 62%)을 얻었다.The compound 63-1 (6.3 g, 0.012 mol) was added to Intermediate 57-1 (3.4 g, 0.010 mol) and the compound was used in the same manner as in Example 1 (5) 62%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.55/d, 7.94/d, 7.79/d, 7.59/d, 7.48/d, 7.43/m, 7.39/m, 7.33/m, 7.30/m, 7.25/m, 7.00/d) 2H(8.10/d, 7.67/d, 1.72/s) 3H(7.41/m) 4H(8.28/d) 6H(7.51/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.55 / d, 7.94 / d, 7.79 / d, 7.59 / d, 7.48 / d, 7.43 / m, 7.39 / m, 7.33 / m, 7.30 / m (7.21 / m, 7.00 / d) 2H (8.10 / d, 7.67 / d, 1.72 / s)

LC/MS: m/z=707[(M+1)+]
LC / MS: m / z = 707 [(M + 1) &lt; + &

실시예Example 64 : 화합물 64 합성 64: Compound 64 Synthesis

(1) (One) 제조예Manufacturing example 1 : 화합물 64의 합성 1: Synthesis of Compound 64

Figure pat00268
Figure pat00268

중간체 57-1(3.4 g, 0.010 mol)에 중간체 20-5(7.2 g, 0.010 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 64> 5.9 g (수율 76%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (5) to give Intermediate 20-5 (7.2 g, 0.010 mol) and Intermediate 57-1 (3.4 g, 0.010 mol) 76%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.55/d, 7.94/d, 7.59/d, 7.48/d, 7.43/m, 7.39/m, 7.33/m, 7.30/m, 7.25/m, 7.00/d) 2H(8.28/d, 8.10/d, 7.67/d, 1.72/s) 3H(7.79/d, 7.41/m) 4H(7.25/d) 6H(7.51/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.55 / d, 7.94 / d, 7.59 / d, 7.48 / d, 7.43 / m, 7.39 / m, 7.33 / m, 7.30 / m, 7.25 / m M) 2H (8.28 / d, 8.10 / d, 7.67 / d, 1.72 / s) 3H (7.79 / d, 7.41 /

LC/MS: m/z=782[(M+1)+]
LC / MS: m / z = 782 [(M + 1) &lt; + &

실시예Example 65 : 화합물 65 합성 65: Synthesis of compound 65

(1) (One) 제조예Manufacturing example 1 : 화합물 65의 합성 1: Synthesis of Compound 65

Figure pat00269
Figure pat00269

중간체 57-1(3.4 g, 0.010 mol)에 중간체 22-2(6.4 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 65> 5.2 g (수율 72%)을 얻었다.Intermediate 22-2 (6.4 g, 0.012 mol) was added to Intermediate 57-1 (3.4 g, 0.010 mol) and the compound was synthesized in the same manner as in Example 1- 72%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.79/d, 7.63/d, 7.59/d, 7.48/d, 7.43/m, 7.39/m, 7.37/m, 7.30/m, 7.23/d, 7.00/d) 2H(8.55/d, 8.10/d, 7.94/d, 7.67/d, 7.58/m, 7.51/m, 7.50/d, 7.41/m, 7.33/m, 7.25/m, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.79 / d, 7.63 / d, 7.59 / d, 7.48 / d, 7.43 / m, 7.39 / m, 7.37 / m, 7.30 / m, 7.23 / d M, 7.50 / d, 7.00 / d) 2H (8.55 / d, 8.10 d, 7.94 d, 7.67 d, 7.58 m, 7.51 m, 7.50 d, 7.41 m, 7.33 m, 7.25 m, )

LC/MS: m/z=717[(M+1)+]
LC / MS: m / z = 717 [(M + 1) &lt; + &

실시예Example 66 : 화합물 66 합성 66: Compound 66 Synthesis

(1) (One) 제조예Manufacturing example 1 : 화합물 66의 합성 1: Synthesis of Compound 66

Figure pat00270
Figure pat00270

중간체 57-1(3.4 g, 0.010 mol)에 중간체 49-2(2.6 g, 0.010 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 66> 4.1 g (수율 72%)을 얻었다.Intermediate 49-2 (2.6 g, 0.010 mol) was added to Intermediate 57-1 (3.4 g, 0.010 mol) and the compound obtained in Synthesis Example (5) 72%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.55/d, 7.94/d, 7.87/d, 7.77/s, 7.69/d, 7.48/d, 7.45/m, 7.41/m, 7.39/m, 7.30/m, 7.29/m, 7.25/m, 7.00/d) 2H(8.10/d, 7.67/d, 7.58/m, 7.51/m, 7.50/d, 1.72/s) 4H(7.25/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.55 / d, 7.94 / d, 7.87 / d, 7.77 / s, 7.69 / d, 7.48 / d, 7.45 / m, 7.41 / m, 7.39 / m D, 7.50 / d, 7.50 / d, 1.72 / s) 4H (7.25 / d)

LC/MS: m/z=628[(M+1)+]
LC / MS: m / z = 628 [(M + 1) &lt; + &

실시예Example 67 : 화합물 67 합성 67: Compound 67 Synthesis

(1) (One) 제조예Manufacturing example 1 : 화합물 67의 합성 1: Synthesis of Compound 67

Figure pat00271
Figure pat00271

중간체 57-1(3.4 g, 0.010 mol)에 4-(dibenzo[b,d]thiophen-4-yl)phenylboronic acid(3.6 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 67> 3.3g (수율 58%)을 얻었다.(Dibenzo [b, d] thiophen-4-yl) phenylboronic acid (3.6 g, 0.012 mol) was added to Intermediate 57-1 (3.4 g, 0.010 mol) Synthesis was conducted in the same manner to obtain 3.3 g (yield 58%) of Compound 67.

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.45/d, 8.41/d, 8.20/d, 7.98/d, 7.58/m, 7.52/m, 7.50/m, 7.48/d, 7.41/m, 7.39/m, 7.30/m, 7.00/d) 2H(8.10/d, 7.67/d, 7.51/m, 1.72/s) 4H(7.25/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.45 / d, 8.41 / d, 8.20 / d, 7.98 / d, 7.58 / m, 7.52 / m, 7.50 / m, 7.48 / d, 7.41 / m M), 7.30 / m, 7.00 / d) 2H (8.10 / d, 7.67 / d, 7.51 /

LC/MS: m/z=569[(M+1)+]
LC / MS: m / z = 569 [(M + 1) &lt; + &

실시예Example 68 : 화합물 68 합성 68: Compound 68 Synthesis

(1) (One) 제조예Manufacturing example 1 : 화합물 68의 합성 1: Synthesis of Compound 68

Figure pat00272
Figure pat00272

중간체 57-1(3.4 g, 0.010 mol)에 중간체 17-1(5.2 g, 0.010 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 68> 3.8 g (수율 61%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (5), except that Intermediate 17-1 (5.2 g, 0.010 mol) was added to Intermediate 57-1 (3.4 g, 0.010 mol) 61%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.48/d, 7.39/m, 7.30/m, 7.00/d) 2H(8.10/d, 7.85/d, 7.67/d, 7.25/d, 1.72/s) 3H(7.41/m) 4H(8.28/d) 6H(7.51/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.48 / d, 7.39 / m, 7.30 / m, 7.00 / d) 2H (8.10 / d, 7.85 / d, 7.67 / d, 7.25 / d, 1.72 / s) 3H (7.41 / m) 4H (8.28 / d) 6H (7.51 / m)

LC/MS: m/z=618[(M+1)+]
LC / MS: m / z = 618 [(M + 1) &lt; + &

실시예Example 69 : 화합물 69 합성 69: Compound 69 Synthesis

(1) (One) 제조예Manufacturing example 1 : 화합물 69의 합성 1: Synthesis of Compound 69

Figure pat00273
Figure pat00273

중간체 57-1(3.4 g, 0.010 mol)에 중간체 26-1(3.6 g, 0.010 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 69> 4.3 g (수율 65%)을 얻었다.Intermediate 26-1 (3.6 g, 0.010 mol) was added to Intermediate 57-1 (3.4 g, 0.010 mol) and the compound obtained in Preparation Example (5) 65%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.56/d, 8.55/d, 7.94/d, 7.71/d, 7.63/d, 7.59/d, 7.50/s, 7.48/d, 7.31/d, 7.30/m, 7.25/m, 7.22/d, 7.00/d) 2H(8.28/d, 8.10/d, 7.41/m, 7.33/m, 7.22/m, 1.72/s) 4H(7.51/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.56 / d, 8.55 / d, 7.94 / d, 7.71 / d, 7.63 / d, 7.59 / d, 7.50 / s, 7.48 / d, 7.31 / d M, 7,30 / m, 7.25 / m, 7.22 / d, 7.00 / d) 2H (8.28 / d, 8.10 / d, 7.41 / m, 7.33 /

LC/MS: m/z=668[(M+1)+]
LC / MS: m / z = 668 [(M + 1) &lt; + &

실시예Example 70 : 화합물 70 합성 70: Compound 70 Synthesis

(1) (One) 제조예Manufacturing example 1 : 화합물 70의 합성 1: Synthesis of Compound 70

Figure pat00274
Figure pat00274

중간체 57-1(3.4 g, 0.010 mol)에 중간체 27-2(6.4 g, 0.011 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 70> 4.4g (수율 62%)을 얻었다.Synthesis was conducted in the same manner as in Example 1-Preparation Example (5), except that Intermediate 27-2 (6.4 g, 0.011 mol) was added to Intermediate 57-1 (3.4 g, 0.010 mol) 62%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.48/d, 7.41/m, 7.39/m, 7.30/m, 7.20/s, 7.00/d) 2H(8.55/d, 8.12/d, 8.10/d, 8.09/s, 7.94/d, 7.67/d, 7.63/d, 7.51/m, 7.50/m, 7.33/m, 7.29/m, 7.25/m, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.48 / d, 7.41 / m, 7.39 / m, 7.30 / m, 7.20 / s, 7.00 / d) 2H (8.55 / d, 8.12 / d, 8.10 7.51 / m, 7.50 / m, 7.33 / m, 7.29 / m, 7.25 / m, 1.72 / s)

LC/MS: m/z=717[(M+1)+]
LC / MS: m / z = 717 [(M + 1) &lt; + &

실시예Example 71 : 화합물 71 합성 71: Compound 71 Synthesis

(1) (One) 제조예Manufacturing example 1 : 화합물 71의 합성 1: Synthesis of Compound 71

Figure pat00275
Figure pat00275

중간체 57-1(3.4 g, 0.010 mol)에 중간체 28-1(4.3 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <화합물 71> 5.6 g (수율 76%)을 얻었다.Synthesis was conducted in the same manner as in Example 2 (1), except that Intermediate 28-1 (4.3 g, 0.010 mol) was added to Intermediate 57-1 (3.4 g, 0.010 mol) 76%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.55/d, 8.45/d, 8.41/d, 8.20/d, 7.98/d, 7.94/d, 7.79/d, 7.71/d, 7.59/d, 7.52/m, 7.51/m, 7.50/m, 7.48/d, 7.43/m, 7.41/m, 7.30/m, 7.25/m, 7.22/d, 7.00/d) 2H(8.10/d, 7.51/m, 7.33/m, 1.72/s) 4H(7.25/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.55 / d, 8.45 / d, 8.41 / d, 8.20 / d, 7.98 / d, 7.94 / d, 7.79 / d, 7.71 / d, 7.59 / d 7.51 / m, 7.50 / m, 7.48 / d, 7.43 / m, 7.41 / m, 7.30 / m, 7.25 / m, 7.22 / d, 7.00 / , 7.33 / m, 1.72 / s) 4H (7.25 / d)

LC/MS: m/z=734[(M+1)+]
LC / MS: m / z = 734 [(M + 1) &lt; + &

실시예Example 72 : 화합물 72 합성 72: Compound 72 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 72-1의 합성 1: Synthesis of intermediate 72-1

Figure pat00276
Figure pat00276

1,3-dibromo-2,5-dichlorobenzene(3.0 g, 0.010 mol)에 pyridin-3-ylboronic acid(2.8 g, 0.024 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 72-1> 2.2g (수율 72%)을 얻었다.(m/z=301)
3-ylboronic acid (2.8 g, 0.024 mol) was added to 1,3-dibromo-2,5-dichlorobenzene (3.0 g, 0.010 mol) 2.2 g (yield 72%) of Intermediate 72-1 (m / z = 301) was obtained.

(2) (2) 제조예Manufacturing example 2 : 중간체 72-2의 합성 2: Synthesis of intermediate 72-2

Figure pat00277
Figure pat00277

중간체 72-1(3.0 g, 0.010 mol)에 4,6-diphenyl-1,3,5-triazin-2-ylboronic acid(3.2 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 72-2> 3.0g (수율 61%)을 얻었다.(m/z=498)
(4.2 g, 0.012 mol) of 4,6-diphenyl-1,3,5-triazin-2-ylboronic acid was added to the intermediate 72-1 (3.0 g, 0.010 mol) (M / z = 498) (Intermediate 72-2) in an amount of 3.0 g (yield: 61%).

(3) (3) 제조예Manufacturing example 3 : 중간체 72-3의 합성 3: Synthesis of intermediate 72-3

Figure pat00278
Figure pat00278

중간체 72-2(5.0 g, 0.010 mol)에 bis(pinacolato)dibron(3.0 g, 0.012 mol) 를 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <중간체 2-2> 3.5g (수율 60%)을 얻었다.(m/z=590)
Intermediate 2-2> 3.5 g (0.012 mol) of bis (pinacolato) dibron was added to Intermediate 72-2 (5.0 g, 0.010 mol) g (yield: 60%). (m / z = 590)

(4) (4) 제조예Manufacturing example 4 : 화합물 72의 합성 4: Synthesis of Compound 72

Figure pat00279
Figure pat00279

중간체 57-1(3.4 g, 0.010 mol)에 중간체 72-3(7.1 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 72> 4.5 g (수율 57%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (5) to give Intermediate 72-3 (7.1 g, 0.012 mol) and Intermediate 57-1 (3.4 g, 0.010 mol) 57%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.48/d, 7.39/m, 7.30/m, 7.00/d) 2H(9.24/s, 8.70/d, 8.42/d, 8.10/d, 7.72/s, 7.67/d, 7.57/m, 1.72/s) 3H(7.41/m) 4H(8.28/d) 6H(7.51/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.48 / d, 7.39 / m, 7.30 / m, 7.00 / d) 2H (9.24 / s, 8.70 / d, 8.42 / d, 8.10 / d, 7.72 / s, 7.67 / d, 7.57 / m, 1.72 / s) 3H (7.41 / m) 4H (8.28 / d)

LC/MS: m/z=785[(M+1)+]
LC / MS: m / z = 785 [(M + 1) &lt; + &

실시예Example 73 : 화합물 73 합성 73: Compound 73 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 73-1의 합성 1: Synthesis of intermediate 73-1

Figure pat00280
Figure pat00280

2-bromo-3,10-dihydroimidazo[4,5-a]carbazole(2.5 g, 0.010 mol)에 2-bromo-4,6-diphenyl-1,3,5-triazine(3.1 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 73-1> 3.7g (수율 71%)을 얻었다.(m/z=517)
2-bromo-4,6-diphenyl-1,3,5-triazine (3.1 g, 0.010 mol) was added to 2-bromo-3,10-dihydroimidazo [4,5- (M / z = 517) was obtained in the same manner as in Example 2 (1), and 3.7 g (yield: 71%) of Intermediate 73-1 was obtained.

(2) (2) 제조예Manufacturing example 2 : 중간체 73-2의 합성 2: Synthesis of Intermediate 73-2

Figure pat00281
Figure pat00281

중간체 73-1(5.2 g, 0.010 mol)에 phenyl boronic acid(1.4 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 73-2> 3.7g (수율 72%)을 얻었다.(m/z=514)
Synthesis was conducted in the same manner as in Example 1 (5), except that phenyl boronic acid (1.4 g, 0.012 mol) was added to Intermediate 73-1 (5.2 g, 0.010 mol) Yield: 72%). (M / z = 514)

(3) (3) 제조예Manufacturing example 3 : 중간체 73-3의 합성 3: Synthesis of Intermediate 73-3

Figure pat00282
Figure pat00282

중간체 73-2(5.1 g, 0.010 mol)에 1,4-dibromobenzene(2.4 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 73-3> 5.2g (수율 77%)을 얻었다.(m/z=670)
Intermediate 73-3> 5.2 (4-fluorobenzyl) was synthesized in the same manner as in Example 2 (1) except that 1,4-dibromobenzene (2.4 g, 0.010 mol) g (yield: 77%). (m / z = 670)

(4) (4) 제조예Manufacturing example 4 : 중간체 73-4의 합성 4: Synthesis of Intermediate 73-4

Figure pat00283
Figure pat00283

중간체 73-3(6.7 g, 0.010 mol)에 bis(pinacolato)dibron(3.0 g, 0.012 mol)를 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <중간체 73-4> 4.5g (수율 63%)을 얻었다.(m/z=716)
<Intermediate 73-4> 4.5 (4-aminophenoxy)] was synthesized in the same manner as in Example 1 (4) except that bis (pinacolato) dibron (3.0 g, 0.012 mol) was added to Intermediate 73-3 g (yield: 63%). (m / z = 716)

(5) (5) 제조예Manufacturing example 5 : 화합물 73의 합성 5: Synthesis of Compound 73

Figure pat00284
Figure pat00284

중간체 57-1(3.4 g, 0.010 mol)에 중간체 73-4(8.6 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 73> 6.7 g (수율 74%)을 얻었다.Intermediate 73-4 (8.6 g, 0.012 mol) was added to intermediate 57-1 (3.4 g, 0.010 mol) and 6.7 g (yield: 74%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.55/d, 8.22/d, 7.94/d, 7.85/d, 7.48/d, 7.39/m, 7.33/m, 7.30/m, 7.25/m, 7.00/d) 2H(8.10/d, 7.79/d, 7.68/d, 7.67/d, 1.72/s) 4H(7.41/m) 6H(8.28/d) 8H(7.51/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.55 / d, 8.22 / d, 7.94 / d, 7.85 / d, 7.48 / d, 7.39 / m, 7.33 / m, 7.30 / m, 7.25 / m M) 2H (8.10 / d, 7.79 / d, 7.68 / d, 7.67 / d, 1.72 / s)

LC/MS: m/z=900[(M+1)+]
LC / MS: m / z = 900 [(M + 1) &lt; + &

실시예Example 74 : 화합물 74 합성 74: Compound 74 Synthesis

(1) (One) 제조예Manufacturing example 1 : 화합물 74의 합성 1: Synthesis of Compound 74

Figure pat00285
Figure pat00285

중간체 57-1(3.4 g, 0.010 mol)에 중간체 38-2(7.5 g, 0.010 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 74> 5.4g (수율 67%)을 얻었다.(7.5 g, 0.010 mol) was added to Intermediate 57-1 (3.4 g, 0.010 mol) in the same manner as in Example 1- (5) 67%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(9.15/s, 8.18/d, 8.07/d, 8.04/d, 7.92/d, 7.48/d, 7.39/m, 7.30/m, 7.00/d) 2H(8.93/d, 8.12/d, 8.10/d, 7.88/m, 7.82/m, 7.79/d, 7.68/d, 7.67/d, 7.41/m, 1.72/s) 3H(8.28/d) 4H(7.51/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (9.15 / s, 8.18 / d, 8.07 / d, 8.04 / d, 7.92 / d, 7.48 / d, 7.39 / m, 7.30 / m, 7.00 / d ) 2H (8.93 d, 8.12 d, 8.10 d, 7.88 m, 7.82 m, 7.79 d, 7.68 d, 7.67 d, 7.41 m, 1.72 s) (7.51 / m)

LC/MS: m/z=805[(M+1)+]
LC / MS: m / z = 805 [(M + 1) &lt; + &

실시예Example 75 : 화합물 75 합성 75: Compound 75 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 75-1의 합성 1: Synthesis of intermediate 75-1

Figure pat00286
Figure pat00286

9H-carbazol-3-ylboronic acid(2.1 g, 0.010 mol)에 9-(3-bromophenyl)-9H-carbazole(2.6 g, 0.008 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 75-1> 3.5g (수율 77%)을 얻었다.(m/z=452)
(3-bromophenyl) -9H-carbazole (2.6 g, 0.008 mol) was added to 9H-carbazol-3-ylboronic acid (2.1 g, 0.010 mol) To obtain 3.5 g (yield 77%) of Intermediate 75-1 (m / z = 452).

(2) (2) 제조예Manufacturing example 2 : 화합물 75의 합성 2: Synthesis of Compound 75

Figure pat00287
Figure pat00287

중간체 57-1(3.4 g, 0.010 mol)에 중간체 75-1(4.5 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 75> 4.1g (수율 72%)을 얻었다.Intermediate 75-1 (4.5 g, 0.012 mol) was added to Intermediate 57-1 (3.4 g, 0.010 mol) and the compound was synthesized in the same manner as in Example 1- (5) 72%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.87/d, 7.77/s, 7.69/d, 7.39/m, 7.30/m, 7.00/d) 2H(8.55/d, 8.12/d, 8.10/d, 7.94/d, 7.67/d, 7.63/d, 7.51/m, 7.50/d, 7.50/m, 7.33/m, 7.29/m, 7.25/m, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.87 / d, 7.77 / s, 7.69 / d, 7.39 / m, 7.30 / m, 7.00 / d) 2H (8.55 / d, 8.12 / d, 8.10 7.50 / d, 7.50 / m, 7.33 / m, 7.29 / m, 7.25 / m, 1.72 / s)

LC/MS: m/z=717[(M+1)+]
LC / MS: m / z = 717 [(M + 1) &lt; + &

실시예Example 76 : 화합물 76 합성 76: Compound 76 Synthesis

(1) (One) 제조예Manufacturing example 1 : 화합물 76의 합성 1: Synthesis of Compound 76

Figure pat00288
Figure pat00288

중간체 57-1(3.4 g, 0.010 mol)에 중간체 77-1(5.2 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 76> 4.8 g (수율 77%)을 얻었다.The compound 77-1 (5.2 g, 0.012 mol) was added to Intermediate 57-1 (3.4 g, 0.010 mol) and the compound was synthesized in the same manner as in Example 1- (5) 77%).

LC/MS: m/z=618[(M+1)+]
LC / MS: m / z = 618 [(M + 1) &lt; + &

실시예Example 77 : 화합물 77 합성 77: Compound 77 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 77-1의 합성 1: Synthesis of intermediate 77-1

Figure pat00289
Figure pat00289

중간체 20-4(3.7 g, 0.010 mol)에 bromobenzene(1.6 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 77-1> 3.1g (수율 71%)을 얻었다.(m/z=445)
3.1 g (yield: 71%) of Intermediate 77-1 was synthesized in the same manner as in Example 2 (1) except that bromobenzene (1.6 g, 0.010 mol) was added to Intermediate 20-4 (3.7 g, 0.010 mol) %). (M / z = 445)

(2) (2) 제조예Manufacturing example 2 : 화합물 77의 합성 2: Synthesis of Compound 77

Figure pat00290
Figure pat00290

중간체 57-1(3.4 g, 0.010 mol)에 중간체 77-1(5.3 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 77> 4.5g (수율 71%)을 얻었다.Intermediate 77-1 (5.3 g, 0.012 mol) was added to Intermediate 57-1 (3.4 g, 0.010 mol) and the compound obtained in Synthesis Example (5) 71%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.55/d, 7.94/d, 7.79/d, 7.59/d, 7.48/d, 7.45/m, 7.43/m, 7.41/m, 7.39/m, 7.33/m, 7.30/m, 7.25/m, 7.00/d) 2H(8.10/d, 7.67/d, 7.58/m, 7.51/m, 7.50/d, 1.72/s) 4H(7.25/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.55 / d, 7.94 / d, 7.79 / d, 7.59 / d, 7.48 / d, 7.45 / m, 7.43 / m, 7.41 / m, 7.39 / m (7.10 / d, 7.67 / d, 7.58 / m, 7.51 / m, 7.50 / d, 1.72 / s)

LC/MS: m/z=628[(M+1)+]
LC / MS: m / z = 628 [(M + 1) &lt; + &

실시예Example 78 : 화합물 78 합성 78: Compound 78 Synthesis

(1) (One) 제조예Manufacturing example 1 : 화합물 78의 합성 1: Synthesis of Compound 78

Figure pat00291
Figure pat00291

중간체 57-1(3.4 g, 0.010 mol)에 중간체 43-1(5.2 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 78> 4.1g (수율 66%)을 얻었다.Intermediate 43-1 (5.2 g, 0.012 mol) was added to Intermediate 57-1 (3.4 g, 0.010 mol) and the compound was synthesized in the same manner as in Example 1- (5) 66%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(9.15/s, 8.18/d, 8.04/d, 7.48/d, 7.41/m, 7.39/m, 7.30/m, 7.00/d) 2H(8.93/d, 8.12/d, 8.10/d, 7.88/m, 7.82/m, 7.67/d, 7.51/m, 1.72/s) 4H(7.25/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (9.15 / s, 8.18 / d, 8.04 / d, 7.48 / d, 7.41 / m, 7.39 / m, 7.30 / m, 7.00 / d) 2H (8.93 d, 8.10 / d, 7.88 / m, 7.82 / m, 7.67 / d, 7.51 / m, 1.72 / s)

LC/MS: m/z=626[(M+1)+]
LC / MS: m / z = 626 [(M + 1) &lt; + &

실시예Example 79 : 화합물 79 합성 79: Compound 79 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 79-1의 합성 1: Synthesis of intermediate 79-1

Figure pat00292
Figure pat00292

9H-carbazol-2-ylboronic acid(2.1 g, 0.010 mol)에 2-bromo-4,6-diphenyl-1,3,5-triazine(3.1 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 79-1> 3.4g (수율 77%)을 얻었다.(m/z=442)
2-bromo-4,6-diphenyl-1,3,5-triazine (3.1 g, 0.010 mol) was added to 9H-carbazol-2-ylboronic acid (2.1 g, 0.010 mol) ) (3.4 g, Yield: 77%) (m / z = 442).

(2) (2) 제조예Manufacturing example 2 : 중간체 79-2의 합성 2: Synthesis of intermediate 79-2

Figure pat00293
Figure pat00293

중간체 79-1(4.4 g, 0.010 mol)에 1,4-dibromobenzene(1.9 g, 0.008 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 79-2> 3.2g (수율 72%)을 얻었다.(m/z=553)
Intermediate 79-2> 3.2 (4-aminopyridine) was synthesized by the same method as in Example 1 (5), except that 1,4-dibromobenzene (1.9 g, 0.008 mol) g (yield: 72%). (m / z = 553)

(3) (3) 제조예Manufacturing example 3 : 중간체 79-3의 합성 3: Synthesis of intermediate 79-3

Figure pat00294
Figure pat00294

중간체 79-2(5.5 g, 0.010 mol)에 bis(pinacolato)dibron(3.0 g, 0.012 mol) 를 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <중간체 79-3> 4.3g (수율 72%)을 얻었다.(m/z=600)
Intermediate 79-3 was synthesized by the same method as in Example 1 (4) except that bis (pinacolato) dibron (3.0 g, 0.012 mol) was added to Intermediate 79-2 (5.5 g, 0.010 mol) g (yield: 72%). (m / z = 600)

(4) (4) 제조예Manufacturing example 4 : 화합물 79의 합성 4: Synthesis of Compound 79

Figure pat00295
Figure pat00295

중간체 57-1(3.4 g, 0.010 mol)에 중간체 79-3(7.2 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 79> 5.5g (수율 70%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (5), except that Intermediate 79-3 (7.2 g, 0.012 mol) was added to Intermediate 57-1 (3.4 g, 0.010 mol) 70%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.55/d, 8.18/d, 7.94/d, 7.79/d, 7.62/d, 7.48/d, 7.39/m, 7.33/m, 7.30/m, 7.25/m, 7.00/d) 2H(8.10/d, 7.67/d, 1.72/s) 3H(7.41/m) 4H(8.28/d, 7.25/d) 6H(7.51/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.55 / d, 8.18 / d, 7.94 / d, 7.79 / d, 7.62 / d, 7.48 / d, 7.39 / m, 7.33 / m, 7.30 / m (7.21 / m, 7.00 / d) 2H (8.10 / d, 7.67 / d, 1.72 / s)

LC/MS: m/z=783[(M+1)+]
LC / MS: m / z = 783 [(M + 1) &lt; + &

실시예Example 80 : 화합물 80 합성 80: Compound 80 Synthesis

(1) (One) 제조예Manufacturing example 1 : 화합물 80의 합성 1: Synthesis of Compound 80

Figure pat00296
Figure pat00296

중간체 57-1(3.4 g, 0.010 mol)에 중간체 20-5(7.2 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <화합물 80> 5.7g (수율 72%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (5), except that Intermediate 20-5 (7.2 g, 0.012 mol) was added to Intermediate 57-1 (3.4 g, 0.010 mol) 72%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.55/d, 7.94/d, 7.79/d, 7.59/d, 7.48/d, 7.43/m, 7.39/m, 7.33/m, 7.30/m, 7.25/m, 7.00/d) 2H(8.10/d, 7.67/d, 1.72/s) 3H(7.41/m) 4H(8.28/d, 7.25/d) 6H(7.51/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.55 / d, 7.94 / d, 7.79 / d, 7.59 / d, 7.48 / d, 7.43 / m, 7.39 / m, 7.33 / m, 7.30 / m (7.21 / m, 7.00 / d) 2H (8.10 / d, 7.67 / d, 1.72 / s)

LC/MS: m/z=796[(M+1)+]
LC / MS: m / z = 796 [(M + 1) &lt; + &

실시예Example 81 : 화합물 81 합성 81: Synthesis of compound 81

(1) (One) 제조예Manufacturing example 1 : 화합물 81의 합성 1: Synthesis of Compound 81

Figure pat00297
Figure pat00297

중간체 57-1(3.4 g, 0.010 mol)에 중간체 28-1(4.3 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <화합물 81> 5.7 g (수율 77%)을 얻었다.Synthesis was conducted in the same manner as in Example 2 (1), except that Intermediate 28-1 (4.3 g, 0.010 mol) was added to Intermediate 57-1 (3.4 g, 0.010 mol) 77%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.55/d, 8.45/d, 8.41/d, 8.20/d, 7.98/d, 7.94/d, 7.79/d, 7.71/d, 7.59/d, 7.58/m, 7.52/m, 7.50/m, 7.48/d, 7.43/m, 7.41/m, 7.30/m, 7.25/m, 7.22/m) 2H(8.10/d, 7.51/m, 7.33/m, 1.72/s) 4H(7.25/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.55 / d, 8.45 / d, 8.41 / d, 8.20 / d, 7.98 / d, 7.94 / d, 7.79 / d, 7.71 / d, 7.59 / d 7.51 / m, 7.50 / m, 7.48 / d, 7.43 / m, 7.41 / m, 7.30 / m, 7.25 / m, 7.22 / , 1.72 / s) 4H (7.25 / d)

LC/MS: m/z=734[(M+1)+]
LC / MS: m / z = 734 [(M + 1) &lt; + &

실시예Example 82 : 화합물 82 합성 82: Compound 82 Synthesis

(1) (One) 제조예Manufacturing example 1 : 화합물 82의 합성 1: Synthesis of Compound (82)

Figure pat00298
Figure pat00298

중간체 57-1(3.4 g, 0.010 mol)에 중간체 41-2(4.1 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <화합물 82> 5.7g (수율 80%)을 얻었다.Synthesis was conducted in the same manner as in Example 2 (1) except that Intermediate 41-2 (4.1 g, 0.010 mol) was added to Intermediate 57-1 (3.4 g, 0.010 mol) 80%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.55/d, 8.12/d, 8.10/d, 7.94/d, 7.90/d, 7.79/d, 7.71/d, 7.63/d, 7.59/d, 7.50/m, 7.45/m, 7.43/m, 7.41/m, 7.39/m, 7.29/m, 7.22/d) 2H(8.10/d, 7.58/m, 7.51/m, 7.50/d, 7.33/m, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.55 / d, 8.12 / d, 8.10 / d, 7.94 / d, 7.90 / d, 7.79 / d, 7.71 / d, 7.63 / d, 7.59 / d 7.50 / m, 7.43 / m, 7.41 / m, 7.39 / m, 7.29 / m, 7.22 / d) 2H (8.10 / d, 7.58 / m, 7.51 / , 1.72 / s)

LC/MS: m/z=717[(M+1)+]
LC / MS: m / z = 717 [(M + 1) &lt; + &

실시예Example 83 : 화합물 83 합성 83: Synthesis of compound 83

(1) (One) 제조예Manufacturing example 1 : 화합물 83의 합성 1: Synthesis of Compound 83

Figure pat00299
Figure pat00299

중간체 57-1(3.4 g, 0.010 mol)에 중간체 26-1(3.6 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <화합물 83> 4.9g (수율 73%)을 얻었다.Synthesis was conducted in the same manner as in Example 2 (1), except that Intermediate 26-1 (3.6 g, 0.010 mol) was added to Intermediate 57-1 (3.4 g, 0.010 mol) 73%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.56/d, 8.55/d, 7.94/d, 7.71/d, 7.63/d, 7.59/d, 7.50/s, 7.48/d, 7.31/d, 7.30/m, 7.25/m, 7.22/d, 7.00/d) 2H(8.28/d, 8.10/d, 7.41/m, 7.33/m, 7.22/m, 1.72/s) 4H(7.51/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.56 / d, 8.55 / d, 7.94 / d, 7.71 / d, 7.63 / d, 7.59 / d, 7.50 / s, 7.48 / d, 7.31 / d M, 7,30 / m, 7.25 / m, 7.22 / d, 7.00 / d) 2H (8.28 / d, 8.10 / d, 7.41 / m, 7.33 /

LC/MS: m/z=668[(M+1)+]
LC / MS: m / z = 668 [(M + 1) &lt; + &

실시예Example 84 : 화합물 84 합성 84: Compound 84 Synthesis

(1) (One) 제조예Manufacturing example 1 : 중간체 84-1의 합성 1: Synthesis of intermediate 84-1

9H-carbazol-3-ylboronic acid(2.1 g, 0.010 mol)에 2-bromotriphenylene(3.1 g, 0.010 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 84-1> 3.1 g (수율 72%)을 얻었다.(m/z=437)
2-bromotriphenylene (3.1 g, 0.010 mol) was added to 9-carbazol-3-ylboronic acid (2.1 g, 0.010 mol) > 3.1 g (yield: 72%). (M / z = 437)

(2) (2) 제조예Manufacturing example 2 : 화합물 84의 합성 2: Synthesis of Compound 84

Figure pat00301
Figure pat00301

중간체 57-1(3.4 g, 0.010 mol)에 중간체 84-1(5.2 g, 0.012 mol)를 넣고 실시예 2-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <화합물 84> 4.4g (수율 63%)을 얻었다.Synthesis was conducted in the same manner as in Example 2 (1), except that Intermediate 84-1 (5.2 g, 0.012 mol) was added to Intermediate 57-1 (3.4 g, 0.010 mol) 63%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(9.15/s, 8.55/d, 8.18/d, 8.04/d, 7.94/d, 7.87/d, 7.77/s, 7.69/d, 7.48/d, 7.41/m, 7.39/m, 7.33/m, 7.30/m, 7.25/m, 7.00/d) 2H(8.93/d, 8.12/d, 8.10/d, 7.88/m, 7.82/m, 7.67/d, 7.51/m, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (9.15 / s, 8.55 / d, 8.18 / d, 8.04 / d, 7.94 / d, 7.87 / d, 7.77 / s, 7.69 / d, 7.48 / d D, 8.10 / d, 7.88 / m, 7.82 / m, 7.67 / d, 7.31 / , 7.51 / m, 1.72 / s)

LC/MS: m/z=702[(M+1)+]
LC / MS: m / z = 702 [(M + 1) &lt; + &

소자 device 실시예Example 1 : 화합물 1을  1: Compound 1 정공수송재료로With hole transport material 하여  So 유기전계발광소자Organic electroluminescent device 제조 Produce

ITO로 코팅된 유리기판 위에 <화합물 1>을 증착하여 120 nm의 정공수송층을 형성하였으며, 이어서 도펀트로 Ir(ppy)3을 사용하여 증착속도를 0.009 nm/sec로 증착하고, 호스트로 CBP를 사용하여 증착속도를 0.1 nm/sec로 증착하고, 증착속도 비율이 9%가 되도록 Ir(ppy)3을 도핑하여 정공수송층 상에 발광층을 30 nm 두께로 형성하였다.<Compound 1> was deposited on ITO-coated glass substrate to form a hole transporting layer of 120 nm, followed by deposition of Ir (ppy) 3 as a dopant at a deposition rate of 0.009 nm / sec and using CBP as a host The deposition rate was 0.1 nm / sec, and Ir (ppy) 3 was doped to a deposition rate ratio of 9% to form a light emitting layer with a thickness of 30 nm on the hole transport layer.

그 위에 Balq를 10 nm 두께로 증착하여 정공이 발광층을 지나 전자수송층으로 이동하는 것을 방지하는 정공차단층을 형성하고, 그 위에 Alq3를 증착하여 40 nm의 전자수송층을 형성하였으며, 그 위에 불화리튬을 증착하여 1 nm의 전자주입층을 형성하였다. 전자주입층 상에 알루미늄을 증착하여 120 nm의 음극을 형성하여 유기전계발광소자를 제조하였다.Balq was deposited thereon to a thickness of 10 nm to form a hole blocking layer for preventing holes from moving to the electron transporting layer through the light emitting layer, and Alq 3 was deposited thereon to form an electron transporting layer of 40 nm. Lithium fluoride To form a 1 nm electron injection layer. Aluminum was deposited on the electron injection layer to form a 120 nm negative electrode, thereby fabricating an organic electroluminescent device.

이때, 각 물질의 증착속도는 유기물질인, CBP, 화합물 1, Alq3, Balq는 0.1 nm/sec, 불화리튬은 0.01 nm/sec, 알루미늄은 0.5 nm/sec로 하였다.
At this time, the deposition rate of each material was set to 0.1 nm / sec for CBP, compound 1, Alq 3 , Balq, 0.01 nm / sec for lithium fluoride, and 0.5 nm / sec for aluminum, which are organic materials.

소자 device 실시예Example 2 내지 15 2 to 15

상기 화합물 1 대신 하기 [표 1]에 기재된 화합물을 사용한 것을 제외하고는 소자실시예 1과 동일한 방법으로 소자 실시예 2 내지 15의 유기전계발광소자를 제조하였다.
An organic electroluminescent device of each of the device embodiments 2 to 15 was fabricated in the same manner as in the device example 1, except that the compound described in [Table 1] was used in place of the compound 1 described above.

소자 device 비교예Comparative Example 1 One

비교예1을 위한 유기발광다이오드 소자는 상기 실시예의 소자구조에서 발명에 의해 제조된 화합물 1 대신 일반적으로 정공수송물질로 많이 사용되고 있는 NPB를 사용한 점을 제외하고 동일하게 제작하였다.
The organic light emitting diode device for Comparative Example 1 was fabricated in the same manner except that NPB, which is generally used as a hole transport material, was used instead of the compound 1 produced by the invention in the device structure of the above embodiment.

소자 device 실시예Example 16: 화합물 16을  16: Compound 16 발광층의The light- 호스트 재료로 하여  As a host material 유기전계발광소Organic electroluminescence 자 제조Manufacturing

ITO로 코팅된 유리기판 위에 NPB를 증착하여 120 nm의 정공수송층을 형성하였으며, 이어서 도펀트로 Ir(ppy)3을 사용하여 증착속도를 0.009 nm/sec로 증착하고, 호스트로 <화합물 16>을 사용하여 증착속도를 0.1 nm/sec로 증착하고, 증착속도 비율이 9%가 되도록 Ir(ppy)3을 도핑하여 정공수송층 상에 발광층을 30 nm 두께로 형성하였다.NPB was deposited on a glass substrate coated with ITO to form a hole transport layer having a thickness of 120 nm, followed by deposition of Ir (ppy) 3 as a dopant at a deposition rate of 0.009 nm / sec. The deposition rate was 0.1 nm / sec, and Ir (ppy) 3 was doped to a deposition rate ratio of 9% to form a light emitting layer with a thickness of 30 nm on the hole transport layer.

그 위에 Balq를 10 nm 두께로 증착하여 정공이 발광층을 지나 전자수송층으로 이동하는 것을 방지하는 정공차단층을 형성하고, 그 위에 Alq3를 증착하여 40 nm의 전자수송층을 형성하였으며, 그 위에 불화리튬을 증착하여 1 nm의 전자주입층을 형성하였다. 전자주입층 상에 알루미늄을 증착하여 120 nm의 음극을 형성하여 유기전계발광소자를 제조하였다.Balq was deposited thereon to a thickness of 10 nm to form a hole blocking layer for preventing holes from moving to the electron transporting layer through the light emitting layer, and Alq 3 was deposited thereon to form an electron transporting layer of 40 nm. Lithium fluoride To form a 1 nm electron injection layer. Aluminum was deposited on the electron injection layer to form a 120 nm negative electrode, thereby fabricating an organic electroluminescent device.

이때, 각 물질의 증착속도는 유기물질인, 화합물 16, NPB, Alq3, Balq는 0.1 nm/sec, 불화리튬은 0.01 nm/sec, 알루미늄은 0.5 nm/sec로 하였다.
At this time, the deposition rate of each material was set to 0.1 nm / sec for compound 16, NPB, Alq 3 , Balq, 0.01 nm / sec for lithium fluoride, and 0.5 nm / sec for aluminum.

소자 device 실시예Example 17 내지 84 17 to 84

상기 화합물 16 대신 하기 [표 2]에 기재된 화합물을 사용한 것을 제외하고는 소자 실시예 16과 동일한 방법으로 소자 실시예 17 내지 84의 유기전계발광소자를 제조하였다.
An organic electroluminescent device of each of the device embodiments 17 to 84 was fabricated in the same manner as in the device example 16, except that the compound described in [Table 2] was used instead of the compound 16.

소자 device 비교예Comparative Example 2 2

비교예 2를 위한 유기발광다이오드 소자는 상기 실시예의 소자구조에서 발명에 의해 제조된 화합물 16 대신 일반적으로 인광호스트 물질로 많이 사용되고 있는 CBP를 사용한 점을 제외하고 동일하게 제작하였다.The organic light emitting diode device for Comparative Example 2 was fabricated in the same manner except that CBP, which is generally used as a phosphorescent host material, was used instead of the compound 16 produced by the invention in the device structure of the embodiment.

상기에서 사용된 Ir(ppy)3, CBP, NPB의 구조는 다음과 같다.The structures of Ir (ppy) 3 , CBP and NPB used in the above are as follows.

Figure pat00302
Figure pat00302

이하, 상기 소자 실시예 1 내지 84과 소자 비교예 1,2에 따라 제조된 유기전계발광소자의 특성을 비교한 결과를 하기 [표 1], [표 2]에 나타내었다. Hereinafter, the characteristics of the organic electroluminescent device manufactured according to the device embodiments 1 to 84 and the device comparison examples 1 and 2 are compared, and the results are shown in Table 1 and Table 2, respectively.

[표 1][Table 1]

Figure pat00303
Figure pat00303

[표 2][Table 2]

Figure pat00304
Figure pat00304

Figure pat00305
Figure pat00305

Figure pat00306

Figure pat00306

구동전압 및 발광효율 측정Measurement of driving voltage and luminous efficiency

위에서 만든 유기발광소자(기판크기 : 25×25 ㎟ / 증착면적: 2×2 ㎟)를 IVL 측정셋트(CS-2000+지그+IVL프로그램)에 고정한 후 전류를 1 mA/㎡씩 상승시키며 증착면의 발광 휘도(cd/㎡), 구동전압(V), 전류밀도(A/㎡), 발광효율(cd/A)을 측정하여 휘도가 1000 cd/㎡일 때 구동전압과 발광효율을 상기 [표 1], [표 2]에 나타내었다.After fixing the organic light emitting device (substrate size: 25 × 25 mm 2 / deposition area: 2 × 2 mm 2) made in the above to the IVL measurement set (CS-2000 + jig + IVL program), the current was increased by 1 mA / (Cd / m 2), a driving voltage (V), a current density (A / m 2) and a luminous efficiency (cd / A) 1] and [Table 2].

상기 [표 1]과 [표 2]에서 보는 바와 같이, 본 발명에 따른 유기전계발광소자용 화합물이 유기전계발광소자의 발광층의 호스트 물질, 정공수송물질로 사용될 때 종래의 CBP(호스트재료), NPB(정공수송재료)를 사용할 때보다 구동전압은 낮아지고, 발광효율은 증가됨을 볼 수 있다.As shown in the above Tables 1 and 2, when the compound for an organic electroluminescence device according to the present invention is used as a host material and a hole transporting material of the light emitting layer of an organic electroluminescence device, the conventional CBP (host material) The driving voltage is lowered and the luminous efficiency is increased as compared with the case of using NPB (hole transporting material).

Claims (10)

하기 [화학식 1] 또는 [화학식 2]로 표시되는 유기발광 화합물:
[화학식 1] [화학식 2]
Figure pat00307

상기 [화학식 1] 또는 [화학식 2]에서,
X1 내지 X11은 서로 동일하거나 상이하고, 각각 독립적으로 N, O, S, Te, CR1, NR2, CR3R4, SiR5R6, GeR7R8, PR9 및 BR10 중에서 선택되고, 상기 R3와 R4, R5와 R6, R7와 R8은 각각 서로 연결되어 고리를 형성할 수 있으며,
상기 R1 내지 R10은 서로 동일하거나 상이하고, 각각 독립적으로 수소, 중수소, 치환 또는 비치환된 탄소수 1 내지 30의 알킬기, 치환 또는 비치환된 탄소수 2 내지 30의 알케닐기, 치환 또는 비치환된 탄소수 2 내지 30의 알키닐기, 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬기, 치환 또는 비치환된 탄소수 2 내지 30의 헤테로시클로알킬기, 치환 또는 비치환된 탄소수 5 내지 30의 시클로알케닐기, 치환 또는 비치환된 탄소수 1 내지 30의 알콕시기, 치환 또는 비치환된 탄소수 6 내지 30의 아릴옥시기, 치환 또는 비치환된 탄소수 1 내지 30의 알킬티옥시기, 치환 또는 비치환된 탄소수 5 내지 30의 아릴티옥시기, 치환 또는 비치환된 탄소수 1 내지 30의 알킬아민기, 치환 또는 비치환된 탄소수 5 내지 30의 아릴아민기, 치환 또는 비치환된 탄소수 5 내지 50의 아릴기, 치환 또는 비치환된 탄소수 3 내지 50의 헤테로아릴기, 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬이 하나 이상 융합된 치환 또는 비치환된 탄소수 5 내지 50의 아릴기, 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬이 하나 이상 융합된 치환 또는 비치환된 탄소수 2 내지 50의 헤테로아릴기, 치환 또는 비치환된 실릴기, 치환 또는 비치환된 게르마늄기, 치환 또는 비치환된 붕소기, 카르보닐기, 포스포릴기, 아미노기, 싸이올기, 시아노기, 히드록시기, 니트로기, 할로겐기 및 아미드기 중에서 선택되며,
상기 R1 내지 R10 및 이들의 치환기는 서로 결합하거나 인접한 치환기와 연결되어 지환족, 방향족의 단일환 또는 다환 고리를 형성할 수 있으며, 상기 형성된 지환족, 방향족의 단일환 또는 다환 고리의 탄소원자는 N, S 및 O 중에서 선택되는 어느 하나 이상의 헤테로원자로 치환될 수 있다.
An organic light-emitting compound represented by the following Chemical Formula 1 or Chemical Formula 2:
[Chemical Formula 1] &lt; EMI ID =
Figure pat00307

In the above Chemical Formula 1 or Chemical Formula 2,
X 1 to X 11 are the same or different from each other, each independently from N, O, S, Te, CR 1, NR 2, CR 3 R 4, SiR 5 R 6, GeR 7 R 8, PR 9 and BR 10 R 3 and R 4 , R 5 and R 6 , R 7 and R 8 may be linked to each other to form a ring,
Wherein R 1 to R 10 are the same or different from each other and each independently represents hydrogen, deuterium, a substituted or unsubstituted alkyl group having 1 to 30 carbon atoms, a substituted or unsubstituted alkenyl group having 2 to 30 carbon atoms, A substituted or unsubstituted cycloalkyl group having 3 to 30 carbon atoms, a substituted or unsubstituted heterocycloalkyl group having 2 to 30 carbon atoms, a substituted or unsubstituted cycloalkenyl group having 5 to 30 carbon atoms, a substituted or unsubstituted cycloalkyl group having 3 to 30 carbon atoms, Or an unsubstituted or substituted C 1 -C 30 alkoxy group, a substituted or unsubstituted C 6 -C 30 aryloxy group, a substituted or unsubstituted C 1 -C 30 alkylthio group, a substituted or unsubstituted C 5 -C 30 A substituted or unsubstituted alkylamine group having 1 to 30 carbon atoms, a substituted or unsubstituted arylamine group having 5 to 30 carbon atoms, a substituted or unsubstituted aliphatic hydrocarbon group having 5 to 50 carbon atoms A substituted or unsubstituted aryl group having 5 to 50 carbon atoms, a substituted or unsubstituted aryl group having 3 to 50 carbon atoms, a substituted or unsubstituted heteroaryl group having 3 to 50 carbon atoms, a substituted or unsubstituted aryl group having 5 to 50 carbon atoms, A substituted or unsubstituted C 2 -C 50 heteroaryl group, a substituted or unsubstituted silyl group, a substituted or unsubstituted germanium group, a substituted or unsubstituted boron group , A carbonyl group, a phosphoryl group, an amino group, a thiol group, a cyano group, a hydroxy group, a nitro group, a halogen group and an amide group,
The R 1 to R 10 and substituents thereof may be bonded to each other or may be connected with adjacent substituents to form a monocyclic or polycyclic ring of an alicyclic or aromatic group and the carbon atom of the formed alicyclic or aromatic monocyclic or polycyclic ring may be a N, S and O. The term &quot; heteroaryl &quot;
제1항에 있어서,
상기 R1 내지 R10은 각각 독립적으로 하기 [구조식 1] 또는 [구조식 2]인 것을 특징으로 하는 유기발광 화합물:
[구조식 1] [구조식 2]
Figure pat00308

상기 [구조식 1] 또는 [구조식 2]에서,
L은 단일결합이거나, 치환 또는 비치환된 탄소수 1 내지 30의 알킬렌기, 치환 또는 비치환된 탄소수 2 내지 30의 알케닐렌기, 치환 또는 비치환된 탄소수 2 내지 30의 알키닐렌기, 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬렌기, 치환 또는 비치환된 탄소수 5 내지 50의 아릴렌기, 치환 또는 비치환된 탄소수 2 내지 50의 헤테로아릴렌기, 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬이 하나 이상 융합된 치환 또는 비치환된 탄소수 5 내지 50의 아릴렌기 및 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬이 하나 이상 융합된 치환 또는 비치환된 탄소수 2 내지 50의 헤테로아릴렌기 중에서 선택되고,
n은 0 내지 4의 정수이며, 상기 n이 2 이상인 경우 복수의 L은 서로 동일하거나 상이하고,
A1 내지 A3는 서로 동일하거나 상이하고, 각각 독립적으로 치환 또는 비치환된 탄소수 1 내지 30의 알킬기, 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬기, 치환 또는 비치환된 탄소수 5 내지 50의 아릴기, 치환 또는 비치환된 탄소수 2 내지 50의 헤테로아릴기, 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬이 하나 이상 융합된 치환 또는 비치환된 탄소수 5 내지 50의 아릴기 및 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬이 하나 이상 융합된 치환 또는 비치환된 탄소수 2 내지 50의 헤테로아릴기 중에서 선택되며,
상기 L, A1 내지 A3 및 이들의 치환기는 서로 결합하거나 인접한 치환기와 연결되어 지환족, 방향족의 단일환 또는 다환 고리를 형성할 수 있으며, 상기 형성된 지환족, 방향족의 단일환 또는 다환 고리의 탄소원자는 N, S 및 O 중에서 선택되는 어느 하나 이상의 헤테로원자로 치환될 수 있다.
The method according to claim 1,
Wherein each of R 1 to R 10 independently represents an organic luminescent compound represented by the following formula 1 or 2:
[Structural formula 1] [Structural formula 2]
Figure pat00308

In the structural formula 1 or the structural formula 2,
L is a single bond, a substituted or unsubstituted alkylene group having 1 to 30 carbon atoms, a substituted or unsubstituted aliphatic hydrocarbon group having 2 to 30 carbon atoms A substituted or unsubstituted C2-C30 alkynylene group, a substituted or unsubstituted C3-C30 A substituted or unsubstituted C2 to C30 heteroarylene group, a substituted or unsubstituted C3 to C30 cycloalkyl, a substituted or unsubstituted C1 to C50 arylene group, a substituted or unsubstituted C2 to C30 heteroarylene group, A substituted or unsubstituted C2 to C50 heteroarylene group in which at least one unsubstituted or substituted unsubstituted arylene group having 5 to 50 carbon atoms and a substituted or unsubstituted C3 to C30 cycloalkyl is fused,
n is an integer of 0 to 4, and when n is 2 or more, plural Ls are the same or different from each other,
A 1 to A 3 are the same or different and each independently represents a substituted or unsubstituted alkyl group having 1 to 30 carbon atoms, a substituted or unsubstituted cycloalkyl group having 3 to 30 carbon atoms, a substituted or unsubstituted group having 5 to 50 carbon atoms A substituted or unsubstituted aryl group, a substituted or unsubstituted C2 to C50 heteroaryl group, a substituted or unsubstituted C3 to C30 cycloalkyl substituted or unsubstituted aryl group having 5 to 50 carbon atoms, A substituted or unsubstituted C2 to C50 heteroaryl group in which one or more ring-opened cycloalkyls having 3 to 30 carbon atoms is fused,
Wherein L, A 1 to A 3, and these substituents may be coupled or the adjacent connection with substituents each cycloaliphatic, may form a monocyclic or polycyclic ring of the aromatic group, the monocyclic or polycyclic ring of an alicyclic, aromatic so formed The carbon atom may be substituted with any one or more heteroatoms selected from N, S and O.
제2항에 있어서,
상기 L 및 A1 내지 A3는 각각 독립적으로 하기 [구조식 3] 중에서 선택되는 것을 특징으로 하는 유기발광 화합물:
[구조식 3]
Figure pat00309

상기 [구조식 3]에서,
Z는 CR1, NR2, CR3R4, SiR5R6, GeR7R8, PR9, BR10, Te, O 및 S 중에서 선택되고, 상기 R1 내지 R10은 상기 [화학식 1] 또는 [화학식 2]에서의 정의와 동일하다.
3. The method of claim 2,
Wherein L and A 1 to A 3 are each independently selected from the following structural formula 3:
[Structural Formula 3]
Figure pat00309

In the above formula 3,
Z is CR 1, NR 2, CR 3 R 4, SiR 5 R 6, GeR 7 R 8, PR 9, BR 10, Te, O , and is selected from S, wherein R 1 to R 10 are the Formula 1 Or the formula (2).
제1항에 있어서,
상기 [화학식 1] 또는 [화학식 2]는 하기 [화합물 1] 내지 [화합물 752] 중에서 선택되는 것을 특징으로 하는 유기발광 화합물:
Figure pat00310

Figure pat00311

Figure pat00312

Figure pat00313

Figure pat00314

Figure pat00315

Figure pat00316

Figure pat00317

Figure pat00318

Figure pat00319

Figure pat00320

Figure pat00321

Figure pat00322

Figure pat00323

Figure pat00324

Figure pat00325

Figure pat00326

Figure pat00327

Figure pat00328

Figure pat00329

Figure pat00330

Figure pat00331

Figure pat00332

Figure pat00333

Figure pat00334

Figure pat00335

Figure pat00336

Figure pat00337

Figure pat00338

Figure pat00339

Figure pat00340

Figure pat00341

Figure pat00342

Figure pat00343

Figure pat00344

Figure pat00345

Figure pat00346

Figure pat00347

Figure pat00348

Figure pat00349

Figure pat00350

Figure pat00351

Figure pat00352

Figure pat00353

Figure pat00354

Figure pat00355

Figure pat00356

Figure pat00357

Figure pat00358

Figure pat00359

Figure pat00360

Figure pat00361
The method according to claim 1,
[Formula 1] or [Formula 2] is selected from the following [Compound 1] to [Compound 752]:
Figure pat00310

Figure pat00311

Figure pat00312

Figure pat00313

Figure pat00314

Figure pat00315

Figure pat00316

Figure pat00317

Figure pat00318

Figure pat00319

Figure pat00320

Figure pat00321

Figure pat00322

Figure pat00323

Figure pat00324

Figure pat00325

Figure pat00326

Figure pat00327

Figure pat00328

Figure pat00329

Figure pat00330

Figure pat00331

Figure pat00332

Figure pat00333

Figure pat00334

Figure pat00335

Figure pat00336

Figure pat00337

Figure pat00338

Figure pat00339

Figure pat00340

Figure pat00341

Figure pat00342

Figure pat00343

Figure pat00344

Figure pat00345

Figure pat00346

Figure pat00347

Figure pat00348

Figure pat00349

Figure pat00350

Figure pat00351

Figure pat00352

Figure pat00353

Figure pat00354

Figure pat00355

Figure pat00356

Figure pat00357

Figure pat00358

Figure pat00359

Figure pat00360

Figure pat00361
제1 전극, 제2 전극, 및 상기 제1 전극과 제2 전극 사이에 배치된 1층 이상의 유기물층을 포함하는 유기전계발광소자로서,
상기 유기물층 중 1 층 이상은 제1항에 따른 [화학식 1] 또는 [화학식 2]의 유기발광 화합물을 포함하는 것을 특징으로 하는 유기전계발광소자.
1. An organic electroluminescent device comprising a first electrode, a second electrode, and at least one organic material layer disposed between the first electrode and the second electrode,
Wherein at least one of the organic material layers comprises an organic light emitting compound represented by Formula 1 or Formula 2 according to Claim 1.
제5항에 있어서,
상기 유기물층은 정공 주입층, 정공 수송층, 정공 주입 및 정공 수송을 동시에 하는 층, 전자 수송층, 전자 주입층, 전자 수송 및 전자 주입을 동시에 하는 층 및 발광층 중 1층 이상을 포함하고, 상기 층들 중 1층 이상이 상기 [화학식 1] 또는 [화학식 2]로 표시되는 유기발광 화합물을 포함하는 것을 특징으로 하는 유기전계발광소자.
6. The method of claim 5,
Wherein the organic material layer includes at least one of a hole injecting layer, a hole transporting layer, a hole injecting and transporting layer, an electron transporting layer, an electron injecting layer, a layer simultaneously performing electron transport and electron injection, and a light emitting layer, Wherein at least one layer comprises an organic light-emitting compound represented by the above Chemical Formula (1) or (2).
제6항에 있어서,
상기 발광층이 상기 [화학식 1] 또는 [화학식 2]로 표시되는 유기발광 화합물을 포함하는 것을 특징으로 하는 유기전계발광소자.
The method according to claim 6,
Wherein the light emitting layer comprises an organic light emitting compound represented by the formula (1) or (2).
제7항에 있어서,
상기 [화학식 1] 또는 [화학식 2]로 표시되는 유기발광 화합물은 상기 발광층 내의 호스트 화합물로 사용되고, 상기 발광층은 도판트 화합물을 1종 이상 더 포함하는 것을 특징으로 하는 유기전계발광소자.
8. The method of claim 7,
The organic electroluminescent compound represented by Formula 1 or Formula 2 is used as a host compound in the light emitting layer, and the light emitting layer further includes at least one dopant compound.
제6항에 있어서,
상기 정공수송층 또는 정공 주입 및 정공 수송을 동시에 하는 층이 상기 [화학식 1] 또는 [화학식 2]로 표시되는 유기발광 화합물을 포함하는 것을 특징으로 하는 유기전계발광소자.
The method according to claim 6,
Wherein the hole transporting layer or the layer simultaneously injecting holes and transporting holes comprises an organic light emitting compound represented by the formula (1) or (2).
제5항에 있어서,
상기 유기물층에 적색, 녹색 또는 청색 발광을 하는 유기 발광층을 하나 이상을 더 포함하여 백색 발광을 하는 것을 특징으로 하는 유기전계발광소자.
6. The method of claim 5,
Wherein at least one of the organic light emitting layers emitting red, green or blue light is further included in the organic material layer to emit white light.
KR1020140085277A 2014-07-08 2014-07-08 An electroluminescent compound and an electroluminescent device comprising the same KR101913628B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020140085277A KR101913628B1 (en) 2014-07-08 2014-07-08 An electroluminescent compound and an electroluminescent device comprising the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020140085277A KR101913628B1 (en) 2014-07-08 2014-07-08 An electroluminescent compound and an electroluminescent device comprising the same

Publications (3)

Publication Number Publication Date
KR20160006007A true KR20160006007A (en) 2016-01-18
KR101913628B1 KR101913628B1 (en) 2018-10-31
KR101913628B9 KR101913628B9 (en) 2022-04-11

Family

ID=55305705

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020140085277A KR101913628B1 (en) 2014-07-08 2014-07-08 An electroluminescent compound and an electroluminescent device comprising the same

Country Status (1)

Country Link
KR (1) KR101913628B1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016021923A3 (en) * 2014-08-04 2016-09-15 주식회사 동진쎄미켐 Novel compound and orgarnic light emitting device containing same
KR20190021129A (en) * 2017-08-22 2019-03-05 (주)피엔에이치테크 An electroluminescent compound and an electroluminescent device comprising the same
CN109749735A (en) * 2017-11-08 2019-05-14 Sfc株式会社 The naphthalene derivatives that amine replaces and the Organic Light Emitting Diode comprising it
KR20190112083A (en) * 2018-03-23 2019-10-02 에스케이머티리얼즈 주식회사 Compounds, Organic Light-Emitting Devices and Display Devices
CN111793000A (en) * 2019-04-02 2020-10-20 材料科学有限公司 Organic compound and organic electroluminescent element comprising same
CN111825558A (en) * 2019-04-17 2020-10-27 乐金显示有限公司 Novel compound and organic light-emitting device
CN115260138A (en) * 2022-08-08 2022-11-01 吉林奥来德光电材料股份有限公司 Hole organic electroluminescent compound and preparation method and application thereof

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016021923A3 (en) * 2014-08-04 2016-09-15 주식회사 동진쎄미켐 Novel compound and orgarnic light emitting device containing same
KR20190021129A (en) * 2017-08-22 2019-03-05 (주)피엔에이치테크 An electroluminescent compound and an electroluminescent device comprising the same
CN109749735A (en) * 2017-11-08 2019-05-14 Sfc株式会社 The naphthalene derivatives that amine replaces and the Organic Light Emitting Diode comprising it
KR20190112083A (en) * 2018-03-23 2019-10-02 에스케이머티리얼즈 주식회사 Compounds, Organic Light-Emitting Devices and Display Devices
CN111793000A (en) * 2019-04-02 2020-10-20 材料科学有限公司 Organic compound and organic electroluminescent element comprising same
CN111825558A (en) * 2019-04-17 2020-10-27 乐金显示有限公司 Novel compound and organic light-emitting device
US11844270B2 (en) 2019-04-17 2023-12-12 Lg Display Co., Ltd. Compound and organic light emitting device including the same
CN111825558B (en) * 2019-04-17 2024-05-03 乐金显示有限公司 Novel compound and organic light-emitting device
CN115260138A (en) * 2022-08-08 2022-11-01 吉林奥来德光电材料股份有限公司 Hole organic electroluminescent compound and preparation method and application thereof

Also Published As

Publication number Publication date
KR101913628B1 (en) 2018-10-31
KR101913628B9 (en) 2022-04-11

Similar Documents

Publication Publication Date Title
KR101825405B1 (en) An electroluminescent compound and an electroluminescent device comprising the same
KR101530266B1 (en) An electroluminescent compound and an electroluminescent device comprising the same
KR101627691B1 (en) An electroluminescent compound and an electroluminescent device comprising the same
KR101852926B1 (en) An electroluminescent compound and an electroluminescent device comprising the same
KR101790550B1 (en) An electroluminescent compound and an electroluminescent device comprising the same
KR101913628B1 (en) An electroluminescent compound and an electroluminescent device comprising the same
KR20170082459A (en) An electroluminescent compound and an electroluminescent device comprising the same
KR20160066308A (en) An electroluminescent compound and an electroluminescent device comprising the same
KR101842013B1 (en) An electroluminescent compound and an electroluminescent device comprising the same
KR101626524B1 (en) An electroluminescent compound and an electroluminescent device comprising the same
KR20160127429A (en) An electroluminescent compound and an electroluminescent device comprising the same
KR101666826B1 (en) An electroluminescent compound and an electroluminescent device comprising the same
KR101837048B1 (en) An electroluminescent compound and an electroluminescent device comprising the same
KR20150110101A (en) An electroluminescent compound and an electroluminescent device comprising the same
KR20160054870A (en) An electroluminescent compound and an electroluminescent device comprising the same
KR101713530B1 (en) An electroluminescent compound and an electroluminescent device comprising the same
KR20150133097A (en) An electroluminescent compound and an electroluminescent device comprising the same
KR101627695B1 (en) An electroluminescent compound and an electroluminescent device comprising the same
JP6766303B2 (en) Nitrogen-containing polycyclic compound and organic light emitting device using it
KR101838504B1 (en) An electroluminescent compound and an electroluminescent device comprising the same
KR20180042944A (en) An electroluminescent compound and an electroluminescent device comprising the same
KR101638073B1 (en) An electroluminescent compound and an electroluminescent device comprising the same
KR101640478B1 (en) Novel compound for organic electroluminescent device and organic electroluminescent device comprising the same
KR101891714B1 (en) An electroluminescent compound and an electroluminescent device comprising the same
KR101837049B1 (en) An electroluminescent compound and an electroluminescent device comprising the same

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
G170 Re-publication after modification of scope of protection [patent]